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Background: Based on our laboratory work and clinical trials we hypothesised that radiotherapy after
lumpectomy for breast cancer could be restricted to the tumour bed. In collaboration with the industry we
developed a new radiotherapy device and a new surgical operation for delivering single-dose radiation to
the tumour bed – the tissues at highest risk of local recurrence. We named it TARGeted Intraoperative
radioTherapy (TARGIT). From 1998 we confirmed its feasibility and safety in pilot studies.
Objective: To compare TARGIT within a risk-adapted approach with whole-breast external beam
radiotherapy (EBRT) over several weeks.
Design: The TARGeted Intraoperative radioTherapy Alone (TARGIT-A) trial was a pragmatic, prospective,
international, multicentre, non-inferiority, non-blinded, randomised (1 : 1 ratio) clinical trial. Originally,
randomisation occurred before initial lumpectomy (prepathology) and, if allocated TARGIT, the patient
received it during the lumpectomy. Subsequently, the postpathology stratum was added in which
randomisation occurred after initial lumpectomy, allowing potentially easier logistics and a more stringent
case selection, but which needed a reoperation to reopen the wound to give TARGIT as a delayed
procedure. The risk-adapted approach meant that, in the experimental arm, if pre-specified unsuspected
adverse factors were found postoperatively after receiving TARGIT, EBRT was recommended. Pragmatically,
this reflected how TARGIT would be practised in the real world.
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Setting: Thirty-three centres in 11 countries.
Participants: Women who were aged ≥ 45 years with unifocal invasive ductal carcinoma preferably
≤ 3.5 cm in size.
Interventions: TARGIT within a risk-adapted approach and whole-breast EBRT.
Main outcome measures: The primary outcome measure was absolute difference in local recurrence,
with a non-inferiority margin of 2.5%. Secondary outcome measures included toxicity and breast
cancer-specific and non-breast-cancer mortality.
Results: In total, 3451 patients were recruited between March 2000 and June 2012. The following values
are 5-year Kaplan–Meier rates for TARGIT compared with EBRT. There was no statistically significant
difference in local recurrence between TARGIT and EBRT. TARGIT was non-inferior to EBRT overall [TARGIT
3.3%, 95% confidence interval (CI) 2.1% to 5.1% vs. EBRT 1.3%, 95% CI 0.7% to 2.5%; p = 0.04;
Pnon-inferiority = 0.00000012] and in the prepathology stratum (n = 2298) when TARGIT was given concurrently
with lumpectomy (TARGIT 2.1%, 95% CI 1.1% to 4.2% vs. EBRT 1.1%, 95% CI 0.5% to 2.5%; p = 0.31;
Pnon-inferiority = 0.0000000013). With delayed TARGIT postpathology (n = 1153), the between-group
difference was larger than 2.5% and non-inferiority was not established for this stratum (TARGIT 5.4%,
95% CI 3.0% to 9.7% vs. EBRT 1.7%, 95% CI 0.6% to 4.9%; p = 0.069; Pnon-inferiority = 0.06640]. The local
recurrence-free survival was 93.9% (95% CI 90.9% to 95.9%) when TARGIT was given with lumpectomy
compared with 92.5% (95% CI 89.7% to 94.6%) for EBRT (p = 0.35). In a planned subgroup analysis,
progesterone receptor (PgR) status was found to be the only predictor of outcome: hormone-responsive
patients (PgR positive) had similar 5-year local recurrence with TARGIT during lumpectomy (1.4%, 95% CI
0.5% to 3.9%) as with EBRT (1.2%, 95% CI 0.5% to 2.9%; p = 0.77). Grade 3 or 4 radiotherapy toxicity
was significantly reduced with TARGIT. Overall, breast cancer mortality was much the same between
groups (TARGIT 2.6%, 95% CI 1.5% to 4.3% vs. EBRT 1.9%, 95% CI 1.1% to 3.2%; p = 0.56) but there
were significantly fewer non-breast-cancer deaths with TARGIT (1.4%, 95% CI 0.8% to 2.5% vs. 3.5%,
95% CI 2.3% to 5.2%; p = 0.0086), attributable to fewer deaths from cardiovascular causes and other
cancers, leading to a trend in reduced overall mortality in the TARGIT arm (3.9%, 95% CI 2.7% to 5.8%
vs. 5.3%, 95% CI 3.9% to 7.3%; p = 0.099]. Health economic analyses suggest that TARGIT was
statistically significantly less costly than EBRT, produced similar quality-adjusted life-years, had a positive
incremental net monetary benefit that was borderline statistically significantly different from zero and had
a probability of > 90% of being cost-effective. There appears to be little uncertainty in the point estimates,
based on deterministic and probabilistic sensitivity analyses. If TARGIT were given instead of EBRT in
suitable patients, it might potentially reduce costs to the health-care providers in the UK by £8–9.1 million
each year. This does not include environmental, patient and societal costs.
Limitations: The number of local recurrences is small but the number of events for local recurrence-free
survival is not as small (TARGIT 57 vs. EBRT 59); occurrence of so few events (< 3.5%) also implies that
both treatments are effective and any difference is unlikely to be large. Not all 3451 patients were
followed up for 5 years; however, more than the number of patients required to answer the main trial
question (n = 585) were followed up for > 5 years.
Conclusions: For patients with breast cancer (women who are aged ≥ 45 years with hormone-sensitive
invasive ductal carcinoma that is up to 3.5 cm in size), TARGIT concurrent with lumpectomy within a
risk-adapted approach is as effective as, safer than and less expensive than postoperative EBRT.
Future work: The analyses will be repeated with longer follow-up. Although this may not change the
primary result, the larger number of events may confirm the effect on overall mortality and allow
more detailed subgroup analyses. The TARGeted Intraoperative radioTherapy Boost (TARGIT-B) trial is
testing whether or not a tumour bed boost given intraoperatively (TARGIT) boost is superior to a tumour
bed boost given as part of postoperative EBRT.
Trial registration: Current Controlled Trials ISRCTN34086741 and ClinicalTrials.gov NCT00983684.
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Highlights
Rationale based on biology and natural history An academic insight led to the development of the
new radiotherapy device and surgical operation and scientific and academic enthusiasm enabled
recruitment of 3451 patients in 33 centres in 11 countries.
Non-inferiority For patients with breast cancer carefully selected based on the TARGIT-A trial results,
TARGIT within a risk-adapted approach, particularly when given concurrent with lumpectomy, is as
effective as and safer than several weeks of postoperative EBRT.
Non-breast-cancer mortality In the randomised TARGIT-A trial, there were fewer deaths from causes
other than breast cancer in patients allocated to TARGIT.
Evidence to support new trials The trial provides several new findings that support future trials (e.g. the
TARGIT-B trial and at least seven other work packages).
Wide dissemination The trial results have been published in a high-impact journal that is open access
and the results have been widely disseminated through many publications and media attention.
Worldwide acceptance The St Gallen panel of experts, which meets every 2 years to recommend breast
cancer treatment, has broadly accepted the new treatment. About 20,000 women have been treated with
the TARGIT technique worldwide. The technique is currently being assessed by the National Institute for
Health and Care Excellence for adoption in the UK.
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Plain English summary
About 70% of patients with breast cancer are eligible for breast-conserving surgery (a lumpectomy),after which the remaining breast is treated with radiotherapy; this avoids a full mastectomy.
Traditionally, external beam radiotherapy (EBRT) is delivered to the entire breast in small doses every day
for 3–6 weeks, necessitating patients to travel to and from the radiotherapy centre every working day.
This can be impractical and strenuous.
The TARGIT (TARGeted Intraoperative radioTherapy) procedure precisely delivers radiation in a single dose
during the lumpectomy operation over 15–35 minutes, using a ball-shaped device that is placed in the
space where the tumour was. This way, unnecessary potentially harmful radiation to healthy tissues (skin,
heart, lungs, etc.) is avoided and the areas nearest to the tumour site receive the most radiation. In this
way, four-fifths of patients avoid EBRT altogether.
The TARGIT-A (TARGeted Intraoperative radioTherapy Alone) trial compared TARGIT with EBRT in
3451 patients who were aged ≥ 45 years and found that, when TARGIT is given with lumpectomy, the
control of breast cancer is much the same as with EBRT. The chances of being alive without return of cancer
in the breast at 5 years were 93.9% with TARGIT during lumpectomy and 92.5% with EBRT. Compared with
EBRT, TARGIT had fewer side effects and fewer deaths from heart attacks or other cancers. TARGIT would be
less expensive than EBRT, potentially saving the NHS up to £9.1 million a year, without considering the cost
savings to patients.
Targeted intraoperative radiotherapy during lumpectomy is an effective, safer and less expensive option for
eligible patients.
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Scientific summary
Background
Early local recurrence of breast cancer most commonly (> 90%) occurs at the site of the primary tumour.
Whole-organ analysis of mastectomy specimens, on the other hand, reveals that 63% of breasts harbour
occult cancer foci and 80% of these are situated remote from the index quadrant. Therefore, these occult
cancer foci may not be clinically relevant and it may not be necessary to treat the whole breast with
radiotherapy, which is normally given as a 6-week long course of external beam radiotherapy (EBRT).
EBRT is effective but can be inconvenient and costly and may cause many women from geographically
remote areas to choose mastectomy. In 1995 we suggested that restriction of radiation therapy to the
peritumoural area alone might provide adequate local control for selected patients within a risk-adapted
design. In collaboration with the industry we developed a device (INTRABEAM®) and a surgical procedure
to enable us to give TARGeted Intraoperative radioTherapy (TARGIT) at a dose of about 20 Gy to the
surface of the applicator in 20–30 minutes during surgery in a standard operating theatre environment.
We then proceeded to test its feasibility and safety in pilot studies between 1998 and 2000 followed by
the TARGeted Intraoperative radioTherapy Alone (TARGIT-A) randomised trial.
Methods
The TARGIT-A trial recruited 3451 patients between 24 March 2000 and June 2012. In this prospective,
randomised, non-inferiority trial, women aged ≥ 45 years with invasive ductal breast carcinoma
undergoing breast-conserving surgery were enrolled from 33 centres in 11 countries. Patients were
randomly assigned in a 1 : 1 ratio to receive TARGIT or whole-breast EBRT, with blocks stratified by centre
and by timing of delivery of TARGIT. Randomisation occurred either before lumpectomy (prepathology
stratum – TARGIT concurrent with lumpectomy) or after lumpectomy (postpathology stratum – TARGIT
given subsequently by reopening the wound). Such stratification allowed easier operating theatre logistics
and more stringent case selection, but needed a reoperation to reopen the wound to give TARGIT as a
delayed procedure. Neither patients nor investigators or their teams were masked to treatment
assignment. Postoperative discovery of predefined factors (e.g. lobular carcinoma) could trigger the
addition of EBRT (excluding tumour bed boost) to TARGIT (in an expected 15% of patients), making the
experimental arm a risk-adapted radiotherapy approach vis-à-vis the control arm, which followed a
one-size-fits-all policy of giving whole-breast radiotherapy to all patients. The primary outcome was
absolute difference in local recurrence in the conserved breast, with a pre-specified non-inferiority margin
of 2.5% at 5 years; pre-specified analyses included outcome according to the timing of randomisation in
relation to lumpectomy. Secondary outcomes included complications and mortality. The planned analyses
were performed in 2010 after the initial accrual of 2232 patients and again in 2012 after closure of the
trial with an accrual of 3451 patients. For the second analysis, standard tests for non-inferiority were
performed and at this time for a log-rank test for difference in survival the significance level was set at a
p-value of 0.01 for local recurrence as this was a second analysis and at a p-value of 0.05 for mortality.
In 2010 it was calculated that the number of participants needed to prove non-inferiority was 585.
For subgroup analysis, before the data were unblinded for the 2012 analysis, we hypothesised that
hormone sensitivity might be predictive of response to TARGIT and therefore analysed whether or not the
response to radiotherapy in the TARGIT-A trial was dependent on hormone receptor responsiveness using
progesterone receptor (PgR) status as a marker. We assessed the effect of hormone sensitivity using PgR
status, timing of randomisation/delivery of TARGIT, age, tumour grade, oestrogen receptor status, human
epidermal growth factor receptor-2 (HER2) status, presence of ductal carcinoma in situ (DCIS), margin
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status, whether screen detected or not, lymphovascular invasion and node status, on the outcome in a Cox
proportional hazard model.
We performed the main analyses on patients in the prepathology stratum who were randomised in the
first 8 years of the TARGIT-A trial. We also analysed (1) the effect of omission of EBRT on recurrence of
breast cancer in quadrants of the breast other than the index quadrant (the original hypothesis), (2) the
effect of omission of EBRT on axillary recurrence, (3) whether or not a beneficial effect of irradiation of the
tumour bed on the patient’s microenvironment could contribute to the difference in non-breast-cancer
mortality, (4) whether or not the higher threshold for margin positivity in the German cohort with regard
to adding EBRT improved outcomes and (5) health economics.
Findings
Main findings
In total, 1721 patients were randomised to TARGIT and 1730 to EBRT. Supplemental EBRT after TARGIT
was necessary in 15.2% (239/1571) of patients who received TARGIT (21.6% prepathology, 3.6%
postpathology). With regard to follow-up, 3451 patients had a median follow-up of 2 years and 5 months
(interquartile range 12–52 months), 2020 patients had a median follow-up of 4 years and the first 1222
randomised patients (the earliest cohort) had a median follow-up of 5 years.
First analysis of local recurrence
The first analysis, after completion of the original accrual of 2232 patients (the mature cohort), described
the results at 4 years when there were six local recurrences in the intraoperative radiotherapy group and five
in the EBRT group. The Kaplan–Meier estimate of local recurrence in the conserved breast at 4 years was
1.20% [95% confidence interval (CI) 0.53% to 2.71%] in the TARGIT group and 0.95% (95% CI 0.39% to
2.31%) in the EBRT group [difference between groups 0.25% (95% CI –1.04% to 1.54%); p = 0.41].
Five-year analysis of local recurrence and survival
The test of non-inferiority in terms of control of local recurrence in the conserved breast found that TARGIT
was non-inferior to EBRT for the whole trial (Pnon-inferiority = 0.00000012) and for the prepathology stratum
(Pnon-inferiority = 0.0000000013), but not for the postpathology stratum (Pnon-inferiority = 0.06640).
For the first 1222 patients randomised in the trial the median follow-up was 5 years and the test for
non-inferiority found that TARGIT was non-inferior to EBRT in terms of local recurrence in the conserved
breast when both strata were taken together (Pnon-inferiority = 0.040) and for the prepathology stratum
(Pnon-inferiority = 0.00914), but not for the postpathology stratum (Pnon-inferiority = 0.35108).
The 5-year estimated risk for local recurrence in the conserved breast was 3.3% (95% CI 2.1% to 5.1%)
for TARGIT and 1.3% (95% CI 0.7% to 2.5%) for EBRT. TARGIT concurrently with lumpectomy
(prepathology, n = 2298) had much the same rate of local recurrence in the conserved breast as EBRT
(2.1%, 95% CI 1.1% to 4.2% vs. 1.1%, 95% CI 0.5% to 2.5%; p = 0.31). With delayed TARGIT
(postpathology, n = 1153) the between-group difference in local recurrence was larger than 2.5%
(TARGIT 5.4%, 95% CI 3.0% to 9.7% vs. EBRT 1.7%, 95% CI 0.6% to 4.9%; p = 0.069).
There was no difference in the 5-year estimated local recurrence-free survival between TARGIT and EBRT
[all patients: 93.1% (95% CI 90.8% to 94.9%) vs. 93.8% (95% CI 91.7% to 95.4%); p = 0.81;
prepathology: 93.9% (95% CI 90.9% to 95.9%) vs. 92.5% (95% CI 89.7% to 94.6%); p = 0.35].
Overall, breast cancer mortality was similar between the groups (TARGIT 2.6%, 95% CI 1.5% to 4.3% vs.
EBRT 1.9%, 95% CI 1.1% to 3.2%; p = 0.56) but there were significantly fewer non-breast-cancer deaths
with TARGIT (1.4%, 95% CI 0.8% to 2.5% vs. 3.5%, 95% CI 2.3% to 5.2%; p = 0.0086), attributable to
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fewer deaths from cardiovascular causes and other cancers. Overall mortality was 3.9% (95% CI 2.7%
to 5.8%) for TARGIT compared with 5.3% (95% CI 3.9% to 7.3%) for EBRT (p = 0.099).
For the preferred option of using TARGIT during initial lumpectomy, breast cancer mortality was similar
between the groups (TARGIT 17 deaths vs. EBRT 15 deaths; 5-year rates 3.3%, 95% CI 1.9% to 5.8% vs.
2.7%, 95% CI 1.5% to 4.6%; p = 0.72). Non-breast-cancer mortality was 12 patients for TARGIT and
27 patients for EBRT (1.3%, 95% CI 0.7% to 2.8% vs. 4.4%, 95% CI 2.8% to 6.9%; p = 0.016). Overall
mortality was numerically lower by 2.3% in the TARGIT group (4.6%, 95% CI 1.8% to 6.0% vs. 6.9%,
95% CI 4.3% to 9.6%; p = 0.12).
In total, 817 patients were randomised in the first 8 years of the trial in the prepathology stratum. The
median follow-up was 5.01 years. For local recurrence in the conserved breast, TARGIT was non-inferior to
EBRT (Pnon-inferiority = 0.00914). The 5-year Kaplan–Meier estimated risk was not statistically different between
the groups for local recurrence (TARGIT 1.8%, 95% CI 0.84% to 4.2% vs. EBRT 0.84%, 95% CI 0.3% to
2.6%; p = 0.32) and death from breast cancer (TARGIT 3.9%, 95% CI 2.3% to 6.7% vs. EBRT 3.0%,
95% CI 1.7% to 5.4%; p = 0.34). There were significantly fewer deaths from causes other than breast
cancer with TARGIT (1.9%, 95% CI 0.9% to 3.9% vs. 5.1%, 95% CI 3.2% to 8.0%; p = 0.04). It should
be noted that the number needed to prove non-inferiority was calculated to be 585 and therefore this
earliest cohort of 817 patients had enough power to draw reliable conclusions.
Local toxicity
The frequency of any complications and major toxicity was similar in the two groups [major toxicity:
TARGIT 37/1113 (3.3%) vs. EBRT 44/1119 (3.9%); p = 0.44]. Radiotherapy toxicity (Radiation Therapy
Oncology Group grade 3) was lower in the TARGIT group (six patients, 0.5%) than in the EBRT group
(23 patients, 2.1%; p = 0.002). In the second analysis in 2012, among complications 6 months after
surgery, wound-related complications were much the same between groups but grade 3 or 4 skin
complications were significantly reduced with TARGIT (4/1720 vs. 13/1731; p = 0.029).
Subgroup analysis
In PgR-positive cases (n = 2462) there was no significant difference between the two arms (TARGIT vs.
EBRT) in terms of the 5-year risk of local recurrence (2.3%, 95% CI 1.3% to 4.3% vs. 1.49%, 95% CI
0.75% to 3.0%; p = 0.51), whereas in PgR-negative cases local recurrence was higher in the TARGIT arm
(7.0%, 95% CI 3.5% to 13.6% vs. 0.5%, 95% CI 0.1% to 3.7%; p = 0.017). In the large group of
1625 PgR-positive cases in the prepathology stratum, breast cancer control with TARGIT was similar to that
with EBRT (5-year risk of local recurrence 1.4%, 95% CI 0.5% to 3.9% vs. 1.2%, 95% CI 0.5% to 2.9%;
p = 0.77); this was also the case for breast cancer mortality (1.78%, 95% CI 0.7% to 4.4% vs. 1.98%,
95% CI 0.94% to 4.2%; p = 0.9) whereas mortality from other causes was reduced with TARGIT (1.59%,
95% CI 0.7% to 3.4% vs. 4.51%, 95% CI 2.8% to 7.3%; p = 0.04), leading to a 3.1% reduction in
overall mortality (3.3%, 95% CI 1.83% to 6.04% vs. 6.4%, 95% CI 4.3% to 9.6%; p = 0.08). Margin
status was a predictive factor only in the EBRT arm. Other factors did not influence the outcomes.
Other analyses
1. Other quadrant recurrences. In total, 94.4% of cases in the TARGIT-A trial did not have a preoperative
magnetic resonance imaging (MRI) scan. A total of 793 patients in the prepathology stratum
randomised to TARGIT had only TARGIT as their radiotherapy. With 2098 women-years of follow-up,
there were nine recurrences in the conserved breast. The 5-year local recurrence rate in those who
received TARGIT alone was 2.7% (95% CI 1.3% to 5.5%), which was not different from the rate in the
whole prepathology cohort randomised to TARGIT (2.1%, 95% CI 1.1% to 4.2%). In these 793
patients, one would expect 63% of patients (i.e. n = 500) to have additional foci of cancer in their
breasts and 80% of these (i.e. n = 400) should be in quadrants other than the index quadrant. In
reality, seven patients had recurrence in the scar, six had new contralateral cancers and two had
cancers growing in other quadrants, implying that the remaining 398 foci had remained dormant.
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Among 935 patients who received whole-breast radiotherapy, the same number of cancers (n = 2)
grew in other quadrants and there were five new contralateral cancers. Therefore, cancer foci in the
breast that were away from the site of the primary tumour remained dormant and behaved no
differently from those in the contralateral breast. They also appeared to be unaffected by whole-breast
radiotherapy. This analysis from the randomised TARGIT-A trial provides further evidence supporting
partial breast irradiation.
2. Axillary recurrence. We found that omission of EBRT did not increase axillary recurrence when analysed
according to treatment received: the number of axillary recurrences was 5 out of 1613 when EBRT was
not given compared with 6 out of 1762 when EBRT was given (5-year risk 0.68%, 95% CI 0.28% to
1.6% vs. 0.82%, 95% CI 0.34% to 2.02%; hazard ratio 0.84, 95% CI 0.26 to 2.74; p = 0.8).
3. Reduction in non-breast-cancer mortality: could this be a beneficial effect of TARGIT? We found that,
among the 1730 patients randomised to receive EBRT, eight cardiac deaths were seen in contrast
to the 12 estimated based on age, sex and follow-up period. Most interestingly, there were no deaths
from non-breast-cancer causes in the TARGIT + EBRT group compared with 24 in the EBRT group
(0/218 vs. 24/892; log-rank p = 0.012). Although the numbers are small, these data suggest that EBRT
toxicity may not be the only possible explanation for the excess of non-breast-cancer deaths; they lead
to the hypothesis that the local effect of TARGIT on the tumour bed by inhibiting cancer-stimulating
cytokines may spill over to reduce the systemic inflammatory response to trauma and have significant
long-term systemic beneficial effects that might be protective against cardiac and cancer mortality.
4. Adequacy of 1 mm as a threshold for negative margins. Additional EBRT was given in nearly twice the
number of patients in the TARGIT arm in the German centres (prompted by the higher limit of a 10-mm
tumour-free margin) compared with the TARGIT arm in the rest of the trial population [31.4% (96/306)
vs. 17.4% (123/706)]. However, the 5-year local recurrence rate in the German cohort was not lower
than in the rest of the sample (German 2.6%, 95% CI 0.87% to 7.8% vs. rest of the sample 1.9%,
95% CI 0.81% to 4.5%). Therefore, a policy of adding EBRT after TARGIT only when the margin is
< 1 mm appears appropriate.
5. Health economic analyses. In the base-case analysis TARGIT was less costly than EBRT (mean incremental
cost –£685) and produced slightly more quality-adjusted life-years (QALYs) than EBRT (mean QALYs
gained 0.034). TARGIT had a positive incremental net monetary benefit that was borderline statistically
significantly different from zero and had a probability of > 90% of being cost-effective. If TARGIT were
given instead of EBRT in suitable patients, it might potentially reduce costs to health-care providers by
£8–9.1 million each year. This does not include environmental, patient and societal costs.
Interpretation
In cases selected as per the TARGIT-A trial protocol, TARGIT during lumpectomy compared with EBRT was
found to have non-inferior local control, similar mortality from breast cancer and significantly lower
mortality from non-breast-cancer causes.
Subgroup analysis found that PgR status influenced the outcome of patients overall and those randomised
to TARGIT; margin status influenced the outcome of those randomised to EBRT. Other patient or tumour
factors had no significant influence on the outcome of patients randomised in the two arms. It appears
that hormone receptor positivity identifies a group in whom local control with TARGIT during lumpectomy
is very similar to that with EBRT.
Other analyses provide further evidence supporting limited irradiation and suggest new hypotheses as well
as demonstrate the cost-effectiveness of TARGIT.
Several large randomised trials of radiotherapy have found that the effect of radiotherapy on local
recurrence is in the first 5 years and that a difference seen at 5 years does not increase with longer follow-up
of up to 25 years. Therefore, these results are based on a sufficient number of patients whose follow-up is
long enough to enable a change of practice. However, as breast cancer is a chronic illness, we are
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committed to longer-term follow-up (the protocol aims for a 10-year follow-up of all patients) for ethical,
moral, scientific and academic reasons, as a higher number of events, which will accrue with time, could
allow for a more in-depth analysis and refinement of our understanding.
Conclusion
For patients with breast cancer selected as per the TARGIT-A trial protocol (women aged ≥ 45 years with
unifocal hormone-sensitive invasive ductal carcinoma that is up to 3.5 cm in size), TARGIT concurrent
with lumpectomy within a risk-adapted approach is as effective as and safer than postoperative EBRT.
Trial registration
This trial is registered as ISRCTN34086741 and ClinicalTrials.gov NCT00983684.
Funding
Funding for this study was provided by University College London Hospitals (UCLH)/University College
London (UCL) Comprehensive Biomedical Research Centre, UCLH Charities, Ninewells Cancer Campaign,
National Health and Medical Research Council and German Federal Ministry of Education and Research
(BMBF). From September 2009 funding for this study was provided by the Health Technology Assessment
programme of the National Institute for Health Research.
DOI: 10.3310/hta20730 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 73
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Vaidya et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxxiii

Chapter 1 Introduction
Parts of the text in this report, with the exceptions of Chapters 4–6 and 11, have been based onVaidya et al.1,2
Research objectives
The TARGeted Intraoperative radioTherapy Alone (TARGIT-A) trial is a pragmatic trial that compares
two treatment policies in patients with early breast cancer who have undergone local excision of a
good-prognosis tumour. The conventional policy is that each patient receives a radical course of
whole-breast external beam radiotherapy (EBRT) according to local treatment guidelines. The experimental
policy is to give TARGeted Intraoperative radioTherapy (TARGIT) in a single dose, recognising that some
patients randomised to this treatment, because of unfavourable features found subsequently in the
pathological examination of the excised lesion, will need to have EBRT in addition (without the boost,
which has been provided by the targeted dose). A nested study allows randomisation of patients to
TARGIT or EBRT after pathological examination of the removed lesion. Patients in this randomisation
stratum who are allocated to TARGIT will require a second surgical procedure for administration of the
radiation. Individual trial centres may opt to use either or both of these strata for entry, although we
encourage using the method in which a single procedure is undertaken, as this is expected to be the norm
if the trial is successful. The main objective of the trial, regardless of the stratum followed, is to compare
local tumour control between the two policies. The secondary outcomes include toxicity and survival.
Background
Breast cancer is the most common cancer in women. In the UK, there were 49,564 new cases
of breast cancer diagnosed in 2010 and 11,556 deaths. The majority of these cases are treated with
breast-conserving surgery followed by whole-breast EBRT, rather than radical mastectomy. Several
randomised clinical trials have reported that this method is safe and effective.3–6 However, EBRT is a long
process, typically taking 3–7 weeks of daily radiotherapy; this commitment is at best inconvenient and
often exhausting and entirely impractical, particularly for elderly women or those whose closest
radiotherapy centre is far from their home.7 In such cases, women can be forced to choose to undergo a
mastectomy for a cancer that could have been treated without losing the breast. Additionally, the
prevalence of the disease is so high that even side effects or complications that affect only a small
proportion of patients have a large absolute burden.
Although the complete omission of radiotherapy increases the risk of local recurrence,8–11 the necessity
of delivering radiation to the entire breast has been challenged.12–14 In total, 90% of early breast
recurrences occur at the site of the original primary tumour, regardless of margin involvement or adjuvant
radiotherapy.13,15,16 This is perhaps surprising given evidence from three-dimensional whole-organ analyses of
mastectomy specimens, > 60% of which host additional cancer foci, with 80% of these foci found remote
from the index quadrant.17 It appears that these cancers in other quadrants lie dormant, rarely manifesting
clinically, and recurrences develop in the tissues immediately surrounding the primary tumour. This could be
because of a tumour-promoting effect of the microenvironment of the surgical wound,18 or the presence of
morphologically normal cells in the peritumoural tissues, which may already be on the path of malignant
progression, as evidenced by their loss of heterozygosity.19,20 This suggests that local control could be
achieved through the targeted irradiation of the tissues in the immediate vicinity of the primary tumour.12–14
In the early 1990s the Christie hospital trial tested index quadrant irradiation with encouraging results;20,21
these results helped us identify two types of breast cancer unsuitable for such an approach: lobular cancers
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and those with an extensive intraductal component (EIC). However, the latter factor may lose its
importance if tumour-free margins are well clear.
To test the hypothesis that localised radiotherapy might be sufficient, we needed to have an elegant
means to provide such radiation. In early 1996 we received a fortuitous enquiry from the Photoelectron
Corporation (Lexington, MA, USA) asking whether we would be interested in developing a radiotherapy
device for breast cancer. From October 1996 to July 1998 we developed the device and the operative
technique22 and treated the first patient on 2 July 1998 in Middlesex Hospital, University College London
(UCL), London, with what we called TARGIT (TARGeted Intraoperative radioTherapy),23,24 in which
low-energy X-rays are delivered to the tumour bed directly – a single dose of radiotherapy given at the
time of the initial lumpectomy to replace several weeks of treatment, travel and stress.
These X-rays are delivered using the INTRABEAM® system, originally developed in collaboration with the
Photoelectron Corporation, USA, and now manufactured by Carl Zeiss (Oberkochen, Germany). The
INTRABEAM uses an electron beam to generate a point source of low-energy X-rays (50 kV maximum) at
the tip of a 3.2-mm diameter tube. A personalised spherical applicator is then used to accurately target the
tissues of the tumour bed for 20–35 minutes. The physics and dosimetry of this device have been well
studied;25,26 the applicator delivers a uniform 20 Gy to the surface of the tumour bed and, as X-rays
attenuate rapidly, spares lower tissues by delivering to them a much lower dose.
The TARGIT-A trial was set up to test whether or not this technique could be used instead of EBRT in the
majority of early breast cancers; our primary outcome was local control, with secondary outcomes
including mortality and radiation toxicity.
To test this widely we designed the trial with a pragmatic approach; patients were randomised to the
TARGIT arm or EBRT arm but, if a patient in the TARGIT arm was found after surgery to have an
unexpectedly higher risk of recurrence, protocol dictated that EBRT also be delivered. We expected this to
be necessary in around 15% of cases. We had also ascertained that the combination of TARGIT and EBRT
is safe, as tested in a 25-patient pilot study in UCL, London.22,27
In fact, giving TARGIT at the time of surgery as a tumour bed boost followed by subsequent EBRT has
been found to result in a very low 5-year recurrence rate of 1.73%,27,28 with favourable toxicity and
cosmetic outcome results;29–32 furthermore, mathematical models of TARGIT have recently suggested that it
could be superior in terms of local control to conventional radiotherapy.33,34 This could be because of the
radiotherapy limiting breast cancer cell proliferation normally caused by the trauma of surgery.17
The biological, economical and technical advantages of TARGIT distinguish this trial from other trials that
have since been launched with a similar aim to irradiate only the index quadrant, such as the ELectron
IntraOperative radiotherapy (ELIOT) trial in Italy,35 the National Surgical Adjuvant Breast and Bowel Project
(NSABP) in the USA [see www.nsabp.pitt.edu/B-39.asp (accessed 14 July 2016)] and the Intensity Modulated
and Partial Organ RadioTherapy – low (IMPORT-low) trial in the UK [see www.icr.ac.uk/our-research/
our-research-centres/clinical-trials-and-statistics-unit/clinical-trials/import_low (accessed 14 July 2016)].
Thus, the TARGIT-A trial was an investigator-initiated trial that was launched in March 2000.36 At the time
of our successful funding application to the Health Technology Assessment (HTA) programme it was
already recruiting from 21 centres (increased from 16 in the previous 12 months) and 1301 patients had
already been recruited. The original accrual goal of 2232 was achieved in April 2010. In July 2010, when
we reported in The Lancet the initial results for local control and early complications as a fast-track
publication,1 the 4-year Kaplan–Meier estimate of local recurrence in the conserved breast was 1.20%
[95% confidence interval (CI) 0.53% to 2.71%] for those randomised to TARGIT and 0.95% (95% CI
0.39% to 2.31%) for those randomised to EBRT. A second analysis was planned after a further 2 years of
follow-up. We continued randomisation until June 2012 to allow accrual in sub-protocols while the data
matured further and closed the trial after accruing the planned 1200 additional patients (1219 accrued,
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total n = 3451) (see Appendix 2). We have recently published2 the updated analyses and 5-year estimates
for local control and the first analysis of overall survival and whether or not the timing of TARGIT in
relation to lumpectomy made a difference to the outcome.
Implications of this trial
The TARGIT technique could potentially save time, money and breasts:
l Time – for the patient and the health system.
l Money – we estimate that TARGIT could save around £30 million per year in the UK alone.37 It is worth
noting that, as EBRT is not needed in around half of the patients in the trial, the trial itself is also likely
to be cost neutral or profitable to hospitals.
l Breasts – TARGIT should allow more women to choose breast-conserving surgical options over
a mastectomy.
l Insight – the immediate effect of radiotherapy on human tissues in vivo can be studied, perhaps
yielding important insight into the mechanism of action of radiotherapy.
l Toxicity – the TARGIT technique does not irradiate vital nearby organs such as the heart or lungs and
this may reduce deaths from radiation toxicity.
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Chapter 2 Methods
The TARGIT-A trial was a pragmatic, prospective, international, multicentre, randomised Phase III trialthat compared TARGIT with the conventional policy of whole-breast EBRT.
Patient selection
Women were eligible for randomisation if they were aged ≥ 45 years with an invasive breast tumour
(T1 and small T2 ≤ 3.5 cm, N0–1, M0, as confirmed by cytology or histology) and conventional
examination regarded them suitable for treatment with wide local excision.
A magnetic resonance imaging (MRI) scan was not necessary for inclusion and only 5.6% (n = 192) of
patients went through this procedure.
All patients gave written informed consent and the protocol was approved by the appropriate regulatory
and ethics authorities for each centre before enrolment could begin.
Inclusion criteria
All patients aged ≥ 45 years with operable invasive breast cancer [tumour, nodes, metastasis (TNM) – T1
and small T2 ≤ 3.5 cm, N0–1, M0], confirmed by cytological or histological examination, who were suitable
for breast-conserving surgery were eligible. The tumour needed to be clinically suitable for breast
conservation on conventional imaging. A MRI scan was not required. Individual centres could restrict entry
to a more exactly defined subset of patients, in which case only patients with these characteristics could be
entered by that particular centre. For example, centres could at the outset decide to recruit only women
aged > 50 years or even only women aged > 65 years. Such treatment policies were predefined in writing
and approved by the International Steering Committee (ISC). Patients needed to be available for regular
follow-up (according to local policies) for at least 10 years.
Exclusion criteria
l More than one obvious cancer in the same breast as diagnosed by clinical examination, mammography
or ultrasonography (MRI not required).
l Bilateral breast cancer at the time of diagnosis.
l Ipsilateral breast had a previous cancer and/or irradiation.
l Patients known to have BRCA gene mutations but testing for gene mutations was not required.
l Lobular cancer or EIC (in EIC ≥ 25% of the tumour is intraductal) on core biopsy or initial pathology
(if performed).
l Patients undergoing primary medical treatment (hormones or chemotherapy) as initial treatment with
neoadjuvant intent of reducing tumour size were excluded; those given short-duration (up to 4 weeks)
systemic therapy could be included.
l Patients presenting with gross nodal disease, considered to be clinically malignant or proven
cytologically or by scanning. In general, four or more positive nodes or extranodal spread meant that a
patient was not suitable for TARGIT alone and should receive EBRT as well. However, individual centres
could decide that anything more than micrometastasis should receive EBRT.
l Patients with any severe concomitant disease that may limit their life expectancy. Previous history of
malignant disease did not preclude entry if the expectation of relapse-free survival at 10 years
was ≥ 90%.
l Any factor included as an exclusion criterion in the local centre’s treatment policy. This was particularly
relevant to patients entered into the postpathology stratum.
l No more than 30 days elapsed between last breast cancer surgery (not axillary) and entry into the trial
for patients in the postpathology stratum.
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Each patient was given time to consider participation and ask questions before giving consent by signing
the patient consent form and randomisation occurred only after fully informed consent was freely given.
The treatments in each of the arms are described in detail in the protocol, which is published in full at
www.nets.nihr.ac.uk/projects/hta/076049 (accessed 14 July 2016). Patients in both arms underwent a
similar primary surgical procedure. The patients in the conventional arm underwent standard EBRT
(according to the centres’ predefined local policy). Patients in the experimental arm underwent TARGIT as
described previously in detail.22,24,36 The papers, presentations and video related to TARGIT are available at
www.targit.org.uk (accessed 29 June 2016) and a video demonstrating the operative technique is available
at http://goo.gl/iuF9ZR (accessed 29 June 2016).
Trial design
The TARGIT-A trial was a pragmatic, randomised clinical trial to directly compare the outcome, primarily in
terms of local control and secondarily in terms of toxicity and mortality, of two approaches to adjuvant
radiotherapy: TARGIT within a risk-adapted approach and conventional EBRT. Nested within the pragmatic
trial was a more selective stratum that was employed in some centres in some or all patients as per a
pre-declared policy. Eligible patients were enrolled once they received information and gave their consent.
The flowchart in Figure 1 shows the trial design.
Protocol amendment
In the initial trial design, randomisation to TARGIT or EBRT was carried out before lumpectomy
(prepathology). However, the trial was also firmly rooted in the principles of pragmatism to test a new
approach (single-dose TARGIT to the tumour bed followed by EBRT in patients with unforeseen adverse
factors). Therefore, when some of the centres planning to join the trial requested us to allow them to give
intraoperative radiotherapy (TARGIT IORT) as a second procedure by reopening the wound, we permitted
this. This decision facilitated a more stringent selection of patients (tumour pathology was available, hence
postpathology) and was logistically easier, allowing enrolment of patients from neighbouring centres who
had already had the lumpectomy. We therefore made a protocol amendment on 22 September 2004,
obtained ethics approval and added this postpathology stratum to the trial, along with a completely
separate randomisation table for such patients.
We specified that postpathology patients should be randomised within 30 days after lumpectomy.
If allocated to TARGIT, patients in the prepathology stratum received it concurrently, immediately after
surgical excision under the same anaesthesia; patients in the postpathology stratum received it as a
subsequent procedure. We planned a separate analysis of the two strata (prepathology vs. postpathology).
The rationale for stratification according to the scheduling of radiotherapy was that randomisation to the trial
after full pathology had become available might theoretically allow better case selection. Conversely,
treatment given at the time of initial lumpectomy could have a greater effectiveness because of its immediacy.
Furthermore, the degree of accuracy of placement of the radiotherapy applicator for giving TARGIT by
reopening the cavity might be quite different from that achieved at the time of original lumpectomy.
The randomisation process
All randomisations were performed by staff at the Trial Operations Group in London, except for those in
Australia (performed in Perth because of the large time difference). Details have been described previously32
and are as follows. The randomisation schedules were generated centrally by computer (securely kept in
trial centres in Perth, Australia, for Australian centres and London, UK, for all other centres). Requests for
randomisation were sent by telephone or fax to the trials office (Perth or London), where a trained member
of staff checked patient eligibility. Treatment was allocated from a preprinted randomisation schedule
available to authorised staff only and not to any clinician or investigators. Written confirmation of
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randomisation was sent by fax to the study site. Neither patients nor investigators or their teams were
masked to treatment given after randomisation. Individual sites were unblinded to treatment given to their
own patients, but they were not given access to these data for other sites. Confidential unblinded reports
for the Data Monitoring Committee (DMC), and blinded reports for the ISC were produced by the trial
statistician. Unblinded analyses were carried out according to a pre-specified statistical analysis plan.
Patients were randomly assigned in a 1 : 1 ratio to receive a risk-adapted approach using single-dose
TARGIT or EBRT as per standard schedules over several weeks, with blocks stratified by site and by
proposed timing of delivery of TARGIT (prepathology and postpathology strata; Figure 2).
A risk-adapted approach meant that if the final pathology report showed unpredicted pre-specified
adverse features, then addition of EBRT to TARGIT was recommended, in which case TARGIT served as the
tumour bed boost. The core protocol defined three such features within the experimental group, the
presence of which resulted in a recommendation to supplement TARGIT with EBRT: tumour-free margin
Eligibility
Age > 45 years
Unifocal invasive ductal carcinoma preferably < 3.5 cm
(MRI not required)
Suitable for breast conserving surgery
Stratification prior to randomisation
STRATIFY
R
an
d
o
m
is
e
Diagnosis established by 
needle biopsy and the patient
has NOT had a lumpectomy
TARGIT given concurrently 
with lumpectomy
EBRT given as usual after 
lumpectomy
(n = 2298)
• If randomised to TARGIT
• If randomised to EBRT
Prepathology stratum
Risk-adapted radiotherapy
TARGeted Intraoperative 
radioTherapy (TARGIT) 
focused to the tumour 
bed and delivered in a single
dose with intrabeam 
If high-risk factors are found 
on final pathology, 
EBRT should be added
(n = 1140)
Conventional radiotherapy
Standard fractionated 
whole-breast External Beam 
RadioTherapy (EBRT)
(n = 1158)
R
an
d
o
m
is
e
Diagnosis is established 
and the patient has already 
has a lumpectomy
TARGIT given as a delayed 
procedure by re-opening 
the wound
EBRT given as usual after 
lumpectomy
(n = 1153)
• If randomised to TARGIT
• If randomised to EBRT
Postpathology stratum
Risk-adapted radiotherapy
TARGeted Intraoperative 
radioTherapy (TARGIT) 
focused to the tumour 
bed and delivered in a single
dose with intrabeam
If high-risk factors are found 
on final pathology, 
EBRT should be added
(n = 581)
Conventional radiotherapy
Standard fractionated 
whole-breast External Beam 
RadioTherapy (EBRT)
(n = 572)
FIGURE 1 Flow chart outlining TARGIT-A recruitment. Reproduced with permission from Vaidya et al.2 Copyright
© Vaidya et al. Open Access article distributed under the terms of CC BY-NC-ND.
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< 1 mm, extensive in situ component or unexpected invasive lobular carcinoma. Pragmatically, individual
centres could pre-specify more than these core factors, such as close margins (e.g. 1–10 mm) or other
adverse prognostic factors (e.g. several positive nodes, extensive lymphovascular invasion) in a treatment
policy document before starting recruitment. Therefore, the trial was a comparison of two policies –
conventional whole-breast radiotherapy for all patients compared with individualised risk-adapted therapy
in which a proportion of patients who received TARGIT were also given EBRT if they were shown to have
adverse tumour factors. This situation was expected in 15% of cases and was incorporated into the power
calculations. All analyses were by intention to treat (ITT).
Randomisation was stratified, first, according to participating site. Patients were then randomised into the
trial in one of three strata.
Thirty-three centres in 11 countries participated in the trial. Data from individual patients were collected by
each centre and sent to the central office using standard case report forms (CRFs).
Stratum 1: prepathology entry
Eligible patients’ consent was sought and randomisation was carried out prior to the surgical removal of
the tumour. Postoperatively, some patients were found to have characteristics that militated against a
single intraoperative dose of radiotherapy (e.g. lobular carcinoma, positive margins at first excision,
extensive lymphovascular invasion, multiple involved axillary nodes). In these cases (as per each centre’s
pre-specified treatment policy), patients were recommended to have a full course of EBRT, without the
tumour bed boost. Grade 3 cancers were not necessarily excluded. This histology was considered in
combination with other factors such as presence of lymphovascular invasion, as specified in each centre’s
policy document. For example, a patient with a screen-detected 1.5-cm grade 3 oestrogen receptor
(ER)-positive tumour would have been eligible and been randomised. However, in rare circumstances she
may postoperatively have been found to have extensive lymphovascular invasion and multiple positive
lymph nodes. This would mean that if she had received TARGIT she would have needed to have EBRT as
well, while remaining in the TARGIT arm of the study. The intraoperatively delivered radiotherapy replaced
Reopen the wound + TARGIT
Postpathology (n = 1153)
Prepathology (n = 2298)
Needle biopsy Approximately 3 weeks
Lump excision Approximately 5 weeks
Lumpectomy + TARGIT
FIGURE 2 Schematic diagram showing the two strata according to timing of randomisation in relation to the initial
tumour excision.
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the boost in this instance. The two arms were compared on the basis of the policy to provide local tumour
control, accepting that some (about 15%) of the patients in the TARGIT arm would also receive EBRT.
This design tested the ‘real-world’ policy as it was the most likely way that TARGIT would be implemented
in the future if proven to be non-inferior and/or less toxic in the trial.
Stratum 2: postpathology entry
Eligible patients were randomised for entry to the trial after they had had their cancer removed with a
lumpectomy. If allocated to the TARGIT arm they had further surgery to reopen the wound, with TARGIT
delivered to the tumour bed. This stratum was added for logistical reasons, particularly in some centres.
Furthermore, this stratum allowed easier operating theatre logistics and a more stringent case selection,
although it required a reoperation to reopen the wound to provide TARGIT as a delayed procedure.
This was a disadvantage for patients in this stratum, although reopening the wound could have been
carried out under local anaesthetic.38 However, it allowed for the entry of patients who had already
received surgery at an outlying centre, a common practice in countries with a large land mass and large
rural populations.
Stratum 3: previous contralateral breast cancer
Most patients who require treatment for a metachronous breast cancer are excluded from entry to trials of
local treatment. However, the second cancer is usually treated in a manner similar to the first one and
intraoperative treatment may be particularly suitable. This trial assessed this stratum only for ipsilateral local
control and data were censored for other end-point assessments.
It is important to recognise that the trial was pragmatic and tested two policies rather than two
techniques. In other words, the trial did not test TARGIT compared with EBRT but a pragmatic policy of
TARGIT (in 100%) ± EBRT (in approximately 15%) compared with EBRT (in 100%), that is, the novel
approach was to use TARGIT in potentially eligible patients and add EBRT if an unexpectedly higher risk
was found postoperatively. From our Phase I/II studies we had established that the TARGIT ± EBRT protocol
was safe22,23 and very effective.27,28,39
Planned interventions
Prior to patient recruitment
Prior to entry of any patients, each centre registered with the ISC and completed a treatment policy
document that defined the categories of patients to be entered (e.g. patients aged > 50 years, all N0)
together with some details of treatment policy (e.g. fractionation and dose of conventional radiotherapy to
be used). Any change to practice during the course of the trial had to be notified to the ISC in writing
prior to implementation. This was to enable the ISC to audit the patients entered and to confirm that
treatment remained true to the core protocol.
Only clinical centres with the INTRABEAM or those that were able to refer patients to such a centre
could enter the trial. Centres with newly acquired equipment were required to consult the TARGIT trial
operations office prior to entering patients into the trial. Confirmation of the quality control of the system
set-up had to be received at the operations office before randomisation could begin.
Before entering any patients into the trial, centres were expected to submit data for each X-ray source
probe and applicator set in use. Each centre was responsible for measuring data for the probe and
applicator set and submitted the data supplied by the manufacturer for comparison with measured data
together with a copy of the letter of acceptance supplied by Carl Zeiss.
In addition, a minimum of five ‘pilot’ cases (non-randomised patients) were performed in every new centre
followed by an audit by a member of the ISC (or an appointed delegate).
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Surgery
All patients had wide local excision of the primary tumour following appropriate clinical work-up.
No special assessments prior to randomisation were required, although mammography and ultrasound
were recommended to try to exclude multifocal disease and to determine as accurately as possible the size
of the tumour.
Surgery was carried out according to usual local practice. Complete macroscopic excision of the tumour was
required. The aim of the local excision was to achieve the widest margin of excision while maintaining a good
cosmetic outcome. The final histological margin needed to be ≥ 1 mm clear of all invasive and in situ disease.
For superficial tumours an ellipse of overlying skin was normally excised. The depth of resection depended
on the position of the tumour within the breast and the size of the breast, but in most instances extended
to the pectoral fascia.
The protocol specified that in all patients, but especially in those women with impalpable tumours in
whom preoperative localisation had been performed, the specimen needed to be well orientated with
sutures or clips according to local protocols and to be radiographed intraoperatively. The specimen
radiograph was examined in theatre to ensure complete excision of the lesion and to help with the
assessment of adequacy of the margins. Further tissue had to be taken (and marked) from a margin if the
radiographic abnormality had extended near the margin.
Either a standard sentinel node biopsy or at least level II axillary node clearance had to be performed in all
patients. The protocol specified that similar surgical techniques should be employed in all patients
regardless of randomisation, wound closure should be performed meticulously (air and water tight) as
described22–24 and sutures (if non-absorbable) should remain in place for 14 days. In our pilot study of
300 patients27,28,39 we had found that, with the meticulous wound closure specified, wound healing was
not a problem whether TARGIT was delivered during the primary surgery or as a secondary procedure.
Prepathology stratum
In this stratum, patients were randomised before the tumour was removed. If randomised to receive
TARGIT, it was given during the initial removal of the cancer. The lumpectomy itself was carried out in the
same way as usual. Following surgery, detailed histopathological examination of the specimen was
discussed in the multidisciplinary team meeting and a decision was made whether whole-breast EBRT
needed to be added or not.
Patients with adverse prognostic factors
If final pathology showed involved or close margins (evidence of invasive or in situ tumour at, or within
1 mm of, an excision margin), re-excision was strongly recommended. In some cases this necessitated a
mastectomy. For patients who had already received TARGIT, such re-excision to clear margins was
recommended to be followed by EBRT, excluding the tumour bed boost.
Additional EBRT was also recommended for patients with other markers linked with a higher risk of relapse
in the breast, especially in the other quadrants (e.g. lobular cancer, EIC).
In 2008 we recommended that every patient receive a preoperative diagnosis with a core biopsy.
When the trial started in 2000, tissue diagnosis of cancer was provided only by fine-needle aspiration
cytology (FNAC) and so lobular carcinoma or extensive ductal carcinoma in situ (DCIS) was not identified
preoperatively. However, almost all centres now perform a core biopsy and exclude these patients, as
recommended in the protocol (but not compulsory, within the pragmatic spirit of the trial). Therefore, our
original recommendation remained that patients found on pathological examination of the operation
specimen to have either invasive lobular cancer or EIC (or other adverse criteria such as extensive
lymphovascular invasion and node involvement, as defined by the local centre) receive EBRT as these
patients are at a higher risk of developing recurrence in the ipsilateral breast at a site other than that of
METHODS
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the excised primary tumour. For those patients randomised to intraoperative radiation this was in addition
to the treatment that they had already received and it was recommended that any boost was omitted.
These patients remained in the trial. However, most of these patients (e.g. those with lobular carcinoma)
would not have been included in the first instance if a preoperative core biopsy had been performed.
Alternatively, a mastectomy could be performed if it was deemed necessary, based on the final
histopathology, multidisciplinary team meeting and joint consultation between the patient and the
clinician, irrespective of the arm of randomisation. This had to be recorded on the patient’s trial CRF;
the patient remained in the trial and continued to be followed according to the protocol.
Postpathology stratum
Patients randomised in this stratum had their cancer removed as a lumpectomy or excision biopsy and
the histopathological examination completed, preferably with clear margins confirmed, before being
randomised. If no other adverse pathological features were present, patients with involved margins could
be randomised provided that repeat excision to clear margins was performed prior to radiotherapy (TARGIT
or EBRT). If after delivering TARGIT it was found that the re-excision margin was also involved, these
patients received EBRT in addition, as repeated positive margins is a poor prognostic factor.40
The procedure for delivering TARGIT was the same as in the prepathology stratum. In this group of
patients, antibiotics were given for 3 days (rather than just one pre-incision dose as used in the
prepathology stratum) and special care was taken to ensure that the wound closure was meticulous and
air and water tight and that sutures were not removed for at least 2 weeks. If an absorbable suture was
used it was specified to be at least 3-0 in thickness and to not be absorbable within 2 weeks (not ‘rapide’)
and Steri-Strips™ (3M, St Paul, MN, USA) were to be used and left in situ for 2 weeks.
Contralateral stratum
Patients were managed as appropriate in the pre- or postpathology stratum.
Pathological examination
Data from pathological examinations was recorded on the appropriate data collection forms.
We recommended that the minimum data as requested on the case record forms were recorded.
Radiotherapy
Targeted intraoperative radiotherapy
Intraoperative radiotherapy was delivered either in the operating theatre immediately after the removal of
the tumour or as a subsequent procedure, a short time later.
The concept and the TARGIT technique, which was pioneered by investigators at UCL, London,22–24 allows
the patient to potentially receive all of the required radiation in a single fraction before she awakes from
surgery22–24,34,37,41–48 (Figure 3). The INTRABEAM device provides a point source of 50-kV energy X-rays at
the centre of a spherical applicator. The appropriately sized (1.5–5 cm diameter) applicator is placed in the
tumour bed using meticulous surgical technique including a carefully inserted purse-string suture that
ensures that breast tissues at risk of local recurrence receive the prescribed dose while skin and deeper
structures are protected. Radiation is delivered to the tumour bed over 20–45 minutes. The surface of the
tumour bed typically receives 20 Gy, which attenuates to 5–7 Gy at a depth of 1 cm.
The procedure has been described previously.22–24 The papers, presentations (see Appendix 3) and video
related to TARGIT are available at www.targit.org.uk (accessed 29 June 2016) and a video demonstrating
the operative technique is available at http://goo.gl/iuF9ZR (accessed 29 June 2016).
All patients should receive a prophylactic dose of antibiotic just before skin incision. The device and the
arm of the stand are wrapped in a sterile clear plastic cover. The individual applicators are sterilised prior to
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the theatre session. The size of the sphere is determined at surgery by the surgeon and/or the radiation
oncologist. An appropriately sized INTRABEAM sphere fits comfortably without tension in the surrounding
tissue so that the skin and subcutaneous tissues can be gathered with a purse-string suture over the
sphere. Any other technique to assist this apposition may also be used. The surgeon and radiation
oncologist should choose the largest possible suitable applicator to ensure that the highest dose is
delivered to the tumour bed tissue.
(a)
Applicator
shank
Skin
Applicator
sphere
Breast
tissue
Electron
target and
X-ray source
Electron
beam drift
tube
(b)
50 kV 
X-ray  
Source 
Articulated 
stand 
(c)
(d)
FIGURE 3 The TARGIT technique: (a) The INTRABEAM device; (b) a schematic diagram showing how the spherical
applicator fits into the tumour bed; (c) IORT being delivered in the operating theatre; and (d) a close-up of the
spherical applicator in the tumour bed. Reproduced with permission from Vaidya et al.2 Copyright © Vaidya et al.
Open Access article distributed under the terms of CC BY-NC-ND.
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It is essential that complete haemostasis is achieved before insertion of the applicator sphere, because even
a small ooze of blood can distort the cavity around the sphere and significantly change the target dose.
The applicator sphere is inserted into the surgical cavity and a deep surgical purse-string suture is inserted
in the breast tissues to bring together the target breast tissue so that it applies well to the surface of the
INTRABEAM applicator sphere and holds it in place during treatment. The skin, but not the breast tissue,
should usually be everted and held away from the delivery device by surgical sutures to prevent direct
contact with the sphere. One patient in the pilot series did develop an area of skin necrosis. It is important
to keep the skin at a distance of at least 1 cm from the applicator.
If necessary, protective caps (made from tungsten-impregnated rubber and available from Carl Zeiss) may
be fashioned by the surgeon to protect deep or superficial structures. If the deep margin of excision is such
that the left anterior descending branch of the coronary artery could receive a significant radiation dose,
then the surface of the applicator sphere should be covered with a protective cap at the chest wall.
However, in most patients the normal thickness of the chest wall (muscle and rib cage) provides adequate
shielding and such a protective cap is not required. Sometimes the superficial skin flap may require
protection with a 0.5-cm thick, cut piece of wet gauze. Care must be taken, however, not to inadvertently
shield the areas of tissue that require radiation treatment. The shaft does not emit radiation so wet gauze
should not be placed between the shaft and the skin. The anterior surface of the tumour bed should be a
relatively thick skin flap so that it can receive radiation from inside without the applicator being too close
to the dermis or if this skin is too thin it can be excised as a skin ellipse to get clear margins.
Radiation protection shielding material should also be used to cover the would around the radiation
device; this significantly reduces the dose to the operating theatre staff to very low levels.
The protocol allowed for two dose prescriptions, each of which was equivalent to 20 Gy at the surface
of the applicator. Each participating site decided on one method and used this procedure for all patients
for the duration of the trial.
l Alternative A. A dose of 20 Gy at the surface of the applicator (in water) was prescribed by the
radiation oncologist and delivered to the breast tissue. This takes approximately 30 minutes, depending
on the size of the applicator.
l Alternative B. A dose of 6 Gy at 1 cm (in water) was prescribed by the radiation oncologist and
delivered to the breast tissue. This also takes approximately 30 minutes, depending on the size of the
applicator. This dose is equivalent to 5 Gy at a 1-cm depth for adipose tissue.
Using prescription A ensured that larger tumours received a slightly higher dose in the tumour bed (> 6 Gy
at 1 cm and beyond). Previous versions of the TARGIT protocol recommended a dose of 5 Gy at 10 mm in
adipose tissue, which is equivalent to 6 Gy at 10 mm in water. Rules in some countries such as Germany
dictate that the prescription should always be at the highest dose delivered. Therefore, we adopted
alternative A but at the same time, as the dose at the surface cannot be physically measured (but rather
estimated), we kept the option of using alternative B, prescribing the dose at 1 cm, because the dose
delivered by both approaches will typically be very similar. With the publication of further research40,45
it was later recommended that 20 Gy at the applicator surface should be adopted by all new sites. Such a
dose prescription is arguably more logical as it ensured that tumour beds from larger tumours received a
higher dose than small tumours.
During the radiation treatment, the anaesthetist, clinician and physicist could remain in the room. To avoid
unnecessary exposure we recommended that as many people as possible vacated the operating theatre
and those remaining either wore a lead apron or remained behind a shielded screen. No modifications to
the operating theatre were required.
After completion of radiation, the conforming stitches are removed. Strict haemostasis needs to be
obtained following the removal of the INTRABEAM device. The skin is sutured meticulously to achieve a
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water-tight closure and a good cosmetic result. If non-absorbable sutures are used they are left in situ
for 14 days and, if absorbable sutures are used, Steri-Strips covering the entire wound are left in place for
14 days.
Conventional radiotherapy: the control arm
Planning protocols for conventional radiotherapy varied from centre to centre but for each centre a written
policy was required. All patients randomised to receive conventional radiotherapy within this trial were
treated in accordance with this policy. Dosage was applied only to the breast; axillary, supraclavicular and
internal mammary nodes were not generally to be irradiated by discrete fields. Patients with previously
irradiated adjacent fields, for example those with previous contralateral breast cancer, needed to have the
radiotherapy fields modified according to local policies. The announcement of the Standardisation of
Breast Radiotherapy (START) trial49 results increased the popularity of a 3- to 4-week schedule in the UK
(but not elsewhere in the world). With the pragmatic nature of the trial and with individual centre
stratification, it was possible to incorporate these changes in practice into the trial without jeopardising its
statistical or scientific integrity. Although it could have altered the economic analysis to some extent,
TARGIT would still maintain its potential advantages in terms of avoiding geographical and temporal
misses and reducing the duration from 15–20 postoperative fractions to a single intraoperative fraction of
radiotherapy while also retaining its promise of significantly improving the accessibility to breast-conserving
surgery in remote areas around the world.
Adjuvant systemic therapy
Following completion of TARGIT, patients were recommended appropriate adjuvant therapy according to
local practice or trial protocols. For all trial patients, the sequencing of these other therapies was not
governed by this protocol, but careful consideration needed to be given for patients randomised to TARGIT
but needing EBRT and adjuvant chemotherapy. The policy for such treatments needed to be declared in
advance in the treatment policy document. It was recommended that even the postpathology TARGIT was
delivered before beginning chemotherapy.
Follow-up and notification of recurrence, adverse events and death
Patients were followed up according to local guidelines, but at least at 6-monthly intervals for the first
5 years and annually thereafter until at least 10 years. At each visit patients were offered a physical
examination and asked whether or not they had experienced any adverse events. We recommended that
mammography of the ipsilateral breast was carried out annually and of the contralateral breast at least
every 3 years. However, usually, annual mammography was performed on both breasts. Any other
examination was at the discretion of the local clinician.
Adverse events
Details of management of adverse events, definitions of suspected serious adverse reactions and suspected
unexpected serious adverse reactions and the reporting requirements are provided in the protocol. The ISC
and the DMC reviewed data on adverse events and complications. Acute and late radiation morbidity was
graded according to the Radiation Therapy Oncology Group (RTOG) criteria and ‘pain due to radiation’
according to the common toxicity criteria.50 These were the only expected adverse events but other adverse
events were also recorded.
Proposed outcome measures
Patient assessments were scheduled at entry, 3 months and 6 months; thereafter, they were scheduled
every 6 months up to 5 years and then yearly for up to 10 years.
METHODS
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Local tumour control was defined as no recurrent tumour (defined as invasive or in situ breast cancer) in
the conserved breast. The primary outcome measure was the absolute difference in local recurrence in the
conserved breast between the TARGIT and the EBRT groups. Power calculations were based on this
outcome measure for an absolute non-inferiority margin of 2.5% (as detailed in section 9 of the protocol)
and the original recruitment goal was 2232 patients in total.
Patients were regularly monitored as per the individual centre’s policy, provided that this met the
minimum criteria for follow-up, that is, 6-monthly for the first 5 years and then yearly until 10 years
after randomisation. Recurrence was confirmed by at least cytology and preferably core biopsy.
Overall survival was the time interval between randomisation and death. The secondary outcomes were
toxicity and overall survival, including breast cancer deaths and non-breast-cancer deaths. An independent
senior clinician, masked to randomisation, reviewed the available data and ascertained the cause of death
in all cases. If breast cancer was present at the time of death, the death was presumed to be from breast
cancer. We pre-specified a formal analysis for deaths from cardiovascular causes and deaths from
other cancers.
Disease-free survival was a global parameter that assessed the health of the patient with regard to the
disease in question. Disease-free survival was calculated as the time interval between randomisation and
relapse or death and local-recurrence-free survival between randomisation and local recurrence or death.
Local toxicity and morbidity were recorded as adverse events related to the primary treatment of the breast
cancer. The expected toxicities of acute skin reaction, wound infection, wound breakdown, late skin
reaction (i.e. after 90 days) and pain from radiation were graded according to RTOG criteria, the
LENT-SOMA (Late Effects in Normal Tissues – Subjective, Objective, Management and Analytic) scales or
common toxicity criteria.50 Any other toxicity was recorded and graded according to standard clinical
criteria. The data were recorded on the complications form, which contained a pre-specified checklist:
haematoma, seroma, wound infection, skin breakdown, delayed wound healing, RTOG (version 2.0)
toxicity grade 3 or 4 for dermatitis, telangiectasia, pain in the irradiated field or other. We analysed seroma
needing more than three aspirations, wound infections needing intravenous antibiotics, any complication
needing surgical intervention or RTOG toxicity grade > 2. Skin breakdown or delayed wound healing or
RTOG toxicity grade > 2 were classified as major toxicity.
To compare the extent of local surgery we analysed the specimen weight, margin status and reoperation
for margins. No changes were made to trial outcomes after commencement of the trial.
Funding for analysis of cosmesis, patient satisfaction, quality of life, patient preference and cardiac toxicity
is being sought and is not covered in this report.
We carried out exploratory analyses for regional recurrence (axilla plus supraclavicular), locoregional
recurrence (local plus regional), distant recurrence, any other recurrence (regional, contralateral breast and
distant recurrence) and all recurrence (local recurrence in the conserved breast and any other recurrence).
Statistical considerations
Proposed sample size
The main objective of the trial was to determine whether or not the use of IORT gave rates of local control
that were not inferior to those obtained using EBRT.
This was a non-inferiority trial with a one-sided design and we selected a clinically meaningful
non-inferiority margin, δ0 > 0. We were interested in testing H0: δ = δ0 compared with H1: δ < δ0 using a
one-sided level-α test with power 1 − β to reject H0 when δ = 0.
DOI: 10.3310/hta20730 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 73
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Vaidya et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
15
We defined the power calculations for this trial using absolute values for local breast relapse. Estimates
were obtained from published data. The Oxford Overview of radiotherapy in breast cancer showed a
baseline rate of about 7.8% at about 10 years.6 However, most of these trials began in or before 1985
and the outcomes have much improved since then such that many papers are reporting much lower rates
with conventional radiotherapy. Hence, we had originally considered a baseline relapse rate of 6% at
5 years and therefore for a power of 80% to detect an absolute increase or decrease in relapse rate of
2.5% (the non-inferiority margin) we would need 2232 patients. If the absolute rate of recurrence is lower,
for example 4%, as may be expected from recently announced trial results,49,51–53 slightly fewer (n = 2153)
patients would allow an 80% chance of detecting a difference of 2.1% (the non-inferiority margin).
Although the odds ratio detectable for an even lower (than 4%) background recurrence rate may not be
as low, the absolute difference in recurrence rates would be very low (< 2%) and clinically acceptable. We
therefore maintained the original accrual goal of a total of 2232 patients to have adequate power to meet
the primary objective. It is possible that the final recurrence rate is low and the numbers accrued will give
substantially more than adequate power.
The sample size was calculated for the main end point – local recurrence – for the whole patient
population. At the time of the funding application to HTA in 2007–8, 70% of patients were in the
single-procedure stratum and 25% in the two-procedure stratum, with < 5% in the contralateral stratum.
The main (ITT) analysis was planned to be performed on the whole population and stratified analyses in
the two main strata. We expected to yield a meaningful answer even in the smaller postpathology
(two-procedure) stratum, in which we initially expected to have about 600 very-low-risk patients. The
reasoning for this is as follows. The background recurrence rate in this stratum was expected to be very
low, possibly as low as 1–2%. As we can clinically accept the original absolute non-inferiority margin
of 2.5%, the nominal statistical hazard is high (e.g. 1.2% vs. 3.7%). Therefore, the statistical power
(one-sided log-rank, 80% power, 95% confidence) of these 600 patients would be adequate for a
meaningful result.
This rationale for power analysis also holds true if we have a significantly lower overall recurrence rate, in
which case the study will have more than adequate power to confidently dismiss a clinically significant
difference in local recurrence rate for establishing non-inferiority.
We alluded to this concept in our original application and were interested to see that it has been used in
the recently published results of the START trial.49
Therefore, once we had recruited > 800 patients with > 3 years of follow up, we planned to perform a
futility analysis, which would be able to inform us whether or not the difference between the two groups
will ever reach a clinically significant level.
Early stopping of the trial because of demonstration of superiority, or non-inferiority, or for significant
safety reasons was within the remit of the DMC.
Our plan was to undertake one formal interim analysis for efficacy when half the expected number of
events had been reached using an O’Brien–Fleming rule with a stringent p-value of < 0.001. Thus,
stopping early for futility would follow an analysis which demonstrates that the 99.9% CIs fall outside the
lower range defined for equivalence (i.e. the upper end of the 99.9% CI of 5-year local recurrence-free
survival rate is < 91.5%).
If, however, any of the following were demonstrated at p < 0.01 the DMC would consider recommending
early stopping:
l a significant increase in grade 4 skin or rib fractures (as a sign of radionecrosis)
l delays in wound healing, which after detailed review by the DMC as to time course and severity were
considered clinically significant.
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Early stopping could be applied to specific strata, with other strata allowed to continue recruitment.
In addition, early stopping would be applied depending on the results of the futility analysis. However,
by that time, most of the target recruitment would have already occurred.
When the original sample size of 2232 was calculated, we based our estimate of the 5-year local
recurrence rate of 6% on the literature available in 1999.6,54 We chose the non-inferiority margin as an
absolute difference of 2.5% because this seemed clinically acceptable to physicians and patients. However,
during the past decade recurrence rates have substantially reduced. The recurrence rate in the control
group of our trial was 0.95% at 3 years. It would be logical to extrapolate the 5-year local recurrence rate
to 1.5%, which is not unexpected. For example, in the UK START trial,55 patients had a worse prognosis
(e.g. 36% had a tumour size of > 2 cm vs. 14% in TARGIT-A and 22% were node positive vs. 17% in
TARGIT-A) and were treated a few years before the patients in our trial. In the START trial the recurrence
rate at 5 years was 2.3%. Therefore, the estimate of 1.5% for our trial is not unrealistic.
Statistical analysis
The major end point was the incidence of local recurrence in the conserved breast. This was compared on
an ITT basis (i.e. all randomised patients were analysed) and the log-rank test was used. This test allows
for the hazards to be non-linear. This was performed once the baseline data had been compared to test
the randomisation and to define whether or not any stratified analyses were required. In addition, ratios of
radiological lesion size to clinical and pathological size, and ratios of specimen weights in the two arms
of the trial, were compared to ensure that the extent of the surgical procedure was similar in both
groups. The baseline comparisons between the two groups were carried out using the chi-square test
for categorical variables and an independent two-sample t-test for all continuous variables. Statistical
significance was defined at the p < 0.05 level in the first analysis and at the p < 0.01 level in the second
analysis. We planned to use Kaplan–Meier curves and proportional hazard regression models to account
for time to event and censoring of the data. Standard tests for non-inferiority were performed with the
margin of non-inferiority set at 2.5% absolute difference in local recurrence at 5 years. We analysed
the non-inferiority statistic by calculating the difference in binomial proportions of local recurrences in the
conserved breast between the two randomised groups (TARGIT vs. EBRT).
All reports of local and regional recurrence and death were checked (before the data were unblinded, thus
masking the randomised allocation), to ensure that they were correct.
To assess stability over time, we also calculated this statistic for the mature cohort (n = 2232), reported in
2010, and for the earliest cohort (excluding the last 4 years of enrolment; n = 1222), who had a median
follow up of 5 years. We calculated the z-score and Pnon-inferiority using established methods53
–55 for the whole
cohort and the two pre-specified strata – prepathology and postpathology.
Early complications were reported in 20101 and complications arising > 6 months after randomisation were
reported in 2014.2
To address the issue of follow-up, we charted the absolute differences in the 5-year Kaplan–Meier
estimates of local recurrence in the conserved breast and overall mortality for patients with prepathology
randomisation in the whole trial along with those for the mature cohort reported in 2010, who had a
longer follow-up (median 3 years 8 months, maximum 12 years) and the earliest cohort.
A patient was deemed to have adequate follow-up if they had at least 5 years of follow-up or if they were
seen within the year before database lock. Patients were censored when they were last seen or withdrawn
from the trial. The database (customised Microsoft Access® 1999 onwards; Microsoft Corporation,
Redmond, WA, USA) as validated on 29 June 2012 was used for this analysis, with 1 June 2012 as a
reference date. SAS (version 9.3; SAS Institute Inc., Cary, NC, USA), Microsoft Excel® 2011, Stata (version
12.0; StataCorp LP, College Station, TX, USA) and IBM SPSS Statistics (version 20.0; IBM Corporation,
Armonk, NY, USA) were used for data compilation, validation and analysis. Kaplan–Meier graphs were
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displayed as recommended by Pocock et al.56 and a log-rank test was used to compare the difference
between the survival function and to obtain p-values (significance level set at p < 0.01 for local recurrence
and p < 0.05 for survival).
The 2010 analysis was prompted by the DMC at the March 2010 ISC meeting. The DMC felt that the data
needed to be made public. The results of the first analyses were therefore submitted to an American
Society of Clinical Oncology (ASCO) meeting and to The Lancet. The Lancet editors chose to put the
manuscript through their fast-track rigorous review process and published it online1 on the same day as
the ASCO presentation on 5 June 2010.
In 2010 it was also recommended by the DMC that the next analysis should be performed after 2 more
years, in 2012. The final 2012 analysis was presented to the ISC and DMC in September 2012 and
submitted with their recommendation to the San Antonio Breast Cancer Symposium (SABCS) as a
late-breaking abstract, where it was accepted and presented on 6 December 2012. The manuscript was
submitted to The Lancet in 2013 and published online in November 2013 and in print in February 2014.2
Planned subgroup analysis
Although most patients recruited in the trial were good-prognosis patients, there was a substantial number
of ‘high-risk’ cases, for example approximately 500 cases were node positive, or grade 3, because of the
broad inclusion criteria. When the TARGIT approach is applied to normal clinical practice, patient selection
will be crucial in ensuring that the results of day-to-day practice reflect the results obtained in the
clinical trial.
Evidence from randomised trials and laboratory research suggested that progesterone receptor (PgR) status
may be a predictive factor for local recurrence. The 2011 Oxford overview3 had found for the first time
that the hormone receptor status of the tumour predicted benefit from radiotherapy. The proportional
reduction in recurrence as a result of radiotherapy was higher in patients with ER-positive tumours (nearly
two-thirds reduction from 22% to 8.7%) than in patients with ER-negative tumours (about one-third
reduction from 43.8% to 28.9%). Furthermore, molecular analysis of tumours in the ELIOT study
presented at the European Breast Cancer Conference EBCC-8 in March 2011 and subsequently published35
suggested that IORT was less effective in patients with non-luminal A (hormone receptor-negative)
tumours. Evidence from Prat et al.57 suggested that tumours that are PgR negative [even though ER
positive and human epidermal growth factor receptor-2 (HER2) negative] should not be classified as
luminal A as they may represent a more aggressive tumour type [IMProving care And Knowledge through
Translational research (IMPAKT) meeting in Brussels, May 2012, and published later57]. Furthermore, three
additional studies from Australia and the USA58–60 have suggested that PgR status is an independent
predictor of local recurrence following radiotherapy, perhaps because PgR status is associated with more
infiltrating and irregular margins and would warrant a wider radiation field. Hence, we considered testing
whether or not PgR status was a predictive factor for local recurrence. Another reason for this was that
most patients in the trial were ER positive (< 10% were ER negative) and there were very few events
overall; therefore, an effect of ER status on local recurrence would not be discernible. On the other hand,
PgR positivity is an expression of a functional ER receptor and, as not all ER-positive cases are PgR
positive, many more cases would be PgR negative and this would make the analysis by PgR status
more meaningful.
In view of these findings, we hypothesised that hormone sensitivity might be predictive of response to
TARGIT and therefore, before the data were unblinded for this analysis, we planned to analyse whether
or not the response to radiotherapy in the TARGIT-A trial was dependent on hormone receptor
responsiveness, using PgR status as a marker.
We also tested whether or not patient age and certain other tumour factors, as defined below, were
predictive of response or prognostic of outcome. This analysis of patient and tumour factors may help
select patients in whom partial breast irradiation (PBI) approaches such as TaRGIT achieve the best results.
METHODS
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These analyses may help refine current guidelines that were mainly based on a presumed risk of recurrence
rather than effectiveness of radiation, for which only randomised evidence can be relied on.
A substantial number (18%) in each stratum were PgR negative (554 among all patients and 535 among
those who had breast-conserving therapy). PgR status was unknown in only 88 patients among the
3104 patients in whom ER status was known.
As described above, we hypothesised that PgR negativity, as a surrogate marker of functional ER status,
might be a predictor of poor response to radiotherapy. Analyses were performed by plotting Kaplan–Meier
curves and tested for significance using the log-rank test and using a p-value of 0.05 as the boundary for
statistical significance.
1. We first analysed whether or not PgR status affected the primary and secondary end points of local
recurrence and survival (deaths from breast cancer and deaths from other causes) in the whole
trial population.
2. As per the updated main results, TARGIT should ideally be used concurrently with the primary excision
of the tumour, that is, as used in the prepathology stratum. Therefore, within the prepathology stratum
we analysed the difference in local control and survival (deaths from breast cancer and deaths from
other causes) between the TARGIT arm and the EBRT arm in PgR-negative and PgR-positive cases.
3. We also subsequently analysed in all patients whether or not certain patient or tumour characteristics
(randomisation arm, timing of randomisation/delivery of TARGIT, age, tumour grade, presence of
DCIS, margin positivity, ER, PgR and HER2 status, whether screen detected or not, presence of
lymphovascular invasion, node positivity) influenced the effect of radiotherapy using the Cox
proportional hazards model.
Ethical arrangements
This trial was set up in 1999–2000 and recruitment started in March 2000 at UCL. UCL has been the
sponsor of this trial and the original ethical approval was obtained from the University College London
Hospitals (UCLH) Ethics Committee (reference number 99/0307). The other UK centres required only local
ethics committee approval as we had already obtained national Multicentre Research Ethics Committee
(MREC) approval. These centres started recruitment in 2005 (Ninewells, Hospital, Dundee), 2008 (Royal
Free Hospital, London, and Royal Hampshire County Hospital, Winchester), 2009 (Whittington Hospital and
Guy’s Hospital, London) and 2012 (Hospital of St John and St Elizabeth, London). Other centres were
sponsored by local institutions and governed by local policies and institutional review boards/ethics
committees. The non-UK sites were responsible for obtaining approvals locally, with a copy of the final
approval letter sent to the Trials Operations Office.
The ethical issues were as follows. In terms of risks and benefits there would be no additional risks for
EBRT patients as they received standard care. For patients randomised to TARGIT there was a small chance
of an increased risk of local recurrence and of a poorer cosmetic outcome because of the high local dose
of treatment. On the other hand, the cosmetic outcome might be better because the whole breast was
not subjected to radiotherapy and local recurrence might be lower because radiotherapy was targeted to
the correct area without a ‘geographical miss’ and was given immediately after surgery without any delay,
that is, before adjuvant chemotherapy, whereas EBRT was normally given after the chemotherapy course
was completed. Furthermore, localisation of radiotherapy to the high-risk areas spared radiation damage to
the nearby heart and lung, which has contributed to significant morbidly and mortality in previous clinical
trials of EBRT. Should recurrence occur in a patient who had received TARGIT, there was the possibility of
further surgery and EBRT without a mastectomy, which is otherwise a common treatment for recurrence.
All trial participants were informed of these potential risks and benefits in the patient information sheet,
which received MREC approval. Every participant was given sufficient time – at least 24 hours, but usually
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several days – to consider the trial before signing the consent form. The trial data were held on secure,
restricted-access computers and were to be retained for at least a 10-year follow-up period.
In our experience, the main ethical issue was the obvious convenience and logical correctness of the
experimental treatment, leading to a demand from some patients that they be given the experimental
treatment without randomisation. We dealt with this issue by explaining that the experimental treatment
was still unproven to be equivalent to the standard treatment and that the new way of giving radiotherapy
was therefore available only in the context of the randomised trial. Once this was explained clearly,
patients were happy to take part in the trial.
Research governance
As this was an international multicentre trial it was agreed that each centre would take responsibility for
the collection and management of its own data. Randomisation was performed centrally through the
TARGIT trial operations office, which was also responsible for the administration of the trial database.
Data could be added by site staff over the internet via a secure website. Access to the entire data set was
restricted to designated trial staff and the trial statistician. Regular electronic reports were produced and
passed to each centre for audit and checking purposes. This not only allowed each centre to have full
responsibility for its own data, but also ensured that there was adequate back-up and central auditing of
the data. Standard operating procedures were in place for any data management or clinical queries.
The project was managed by a four-tiered approach: quarterly meetings of the ISC; biannual meetings
of the DMC; fortnightly meetings of the Trial Operations Group; and weekly meetings of operational staff
in the Trial Operations Group. The trial operations office was based at UCL and the finances were
managed by the university finance office, which ensured propriety.
Quality control
Each new centre underwent structured training on using the IORT equipment, which was organised by the
Clinical Trials Group and involved the co-applicants on the grant applications. After training, the new sites
had to perform at least five pilot cases, which were reviewed by a member of the ISC, and only after a
satisfactory appraisal could patients be randomised into the trial.
Quality control of the radiation delivered with TARGIT was monitored in each individual case by the
physicist who calibrated and controlled the equipment in the operating room.
The trial was initiated on a purely academic basis. The device used for TARGIT was manufactured by
Carl Zeiss, who provided limited funding mainly by means of reimbursement of some of the costs of the
DMC and ISC meetings. Carl Zeiss had some representation on the ISC but had no executive powers and
played no part in the design and conduct of the trial or the analysis or publication of the data.
One member of the DMC was a consumer representative, a well-known patient’s advocate who had been
through the experience of breast-conserving surgery and postoperative radiotherapy herself.
Patient and public engagement
Breast cancer survivors sat on the ISC and DMC. They were involved in all discussions and decisions about
the trial design and management, as well as writing of the manuscripts and dissemination of data.
METHODS
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There has been widespread media coverage about the trial, which has been reported on national and
international television and radio and in daily newspapers and specialist newspapers, including the BBC,
ITV, several channels in the USA and China, online channels, The Times, The Daily Mail, The Telegraph,
The Independent, The New York Times, The Los Angeles Times, The Times of India, The Wall Street
Journal, TIME magazine and Reader’s Digest.
The data from the TARGIT-A trial have been presented at a myriad of conferences – national and
international – as well as to physician and patient groups (see Appendix 3).
The TARGIT websites [see www.targit.org.uk, http://facebook.com/targittrials (accessed 4 July 2016)]
and the Chief Investigator’s Twitter (www.twitter.com; Twitter, Inc., San Francisco, CA, USA) account
( @jsvaidya) generate relatively significant traffic and are another means of public engagement.
The TARGIT treatment is already standard of care in over 250 centres in several countries in Europe
(e.g. Germany) and in several centres in the USA and has been recommended by the Medical Services
Advisory Committee [the National Institute for Health and Care Excellence (NICE) equivalent in Australia]
for NHS funding in Australia and was included in the Australian government’s health budget from 2015
onwards. It was given provisional approval by NICE in the UK for NHS funding in July 2014 and, when
asked by the BMJ why there was a delay in final approval, NICE61 stated that:
While this NICE appraisal is ongoing, intrabeam radiotherapy can continue to be offered to NHS
patients who need it. Until NICE publishes its final guidance, decisions on whether or not to fund
specific treatments are the responsibility of local NHS bodies.
Project timetable and milestones
At the time of the grant submission in 2009 we already had a high and increasing recruitment rate.
We had annually recruited 220, 315, 359 and 408* patients in the years 2005–8, respectively (*based on
204 in the first 6 months of 2008) and the total stood at 1301. At this rate, we expected to reach the
protocol-specified accrual goal of 2232 patients by late 2010. We reached this goal in April 2010.
However, recruitment was continued until June 2012 with 3451 total patients being recruited,
as described earlier (see Appendix 2).
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Chapter 3 Main results
Patient population
The first patient was randomised on 24 March 2000 and the trial recruited 3451 patients from 33 centres
in 11 countries to 25 June 2012. Of these, 1721 patients were randomly allocated to TARGIT and 1730 to
EBRT. Two-thirds of patients (n = 2298) were randomised before lumpectomy (prepathology) and a third
(n = 1153) were randomised after lumpectomy (postpathology). As per protocol, of those who received
TARGIT, 15.2% (239/1571) received both TARGIT and EBRT [21.6% (219/1012) in the prepathology
stratum and 3.6% (20/559) in the postpathology stratum].
Participant flow is shown in the Consolidated Standards of Reporting Trials (CONSORT) diagrams in
Figures 4 and 5. The risk-adapted design is shown in the trial profile, for example of the 1140 patients
allocated TARGIT in the prepathology stratum, 219 received TARGIT and EBRT as per protocol because
they were shown to have characteristics of high-risk disease postoperatively. There was no significant
difference between prepathology and postpathology in the timing of delivery of EBRT (p = 0.58).
3451 patients enrolled and randomised
9 withdrawn
141 did not receive allocated
 treatment
78 received EBRTa
42 had a mastectomy
21 did not receive TARGIT or EBRT
1571 received allocated treatment
1332 received TARGIT
239 received TARGIT or EBRTb
1679 included in analysis of 
breast recurrence
(42 had a mastectomy)
1721 included in analysis of death
1721 Allocated to TARGIT with or without EBRT
27 withdrawn
113 did not receive allocated
 treatment
12 received TARGITa
14 received TARGIT and EBRT
34 had a mastectomy
53 did not receive TARGIT or EBRT
1590 received allocated treatment
1696 included in analysis of 
breast recurrence
(34 had a mastectomy)
1730 included in analysis of death
1730 Allocated to EBRT
FIGURE 4 Consolidated Standards of Reporting Trials (CONSORT) diagram. a, Protocol deviations: 78/1721 (4.5%)
patients allocated to TARGIT received EBRT and 12/1730 (0.7%) patients allocated to EBRT received TARGIT;
b, 239/1721 (13.8%) patients allocated to TARGIT received EBRT after TARGIT as per protocol and 239/1571 (15.2%)
patients who received TARGIT received EBRT after TARGIT (as per treatment received). Reproduced with permission
from Vaidya et al.2 Copyright © Vaidya et al. Open Access article distributed under the terms of CC BY-NC-ND.
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Prepathology: 2298 patients enrolled and randomised 
before excision of cancer
(a)
8 withdrawn
120 did not receive allocated 
treatment
67 received EBRTa
33 had a mastectomy
20 did not receive TARGIT or EBRT
1012 received allocated treatment
793 received TARGIT
219 received TARGIT and EBRTb
1107 included in analysis of 
breast recurrence
(33 had a mastectomy)
1140 included in analysis of death
1140 Allocated to TARGIT with or without EBRT
21 withdrawn
98 did not receive allocated 
treatment
10 received TARGITa
8   received TARGIT and EBRT
31 had a mastectomy
49 did not receive TARGIT or EBRT
1039 received allocated treatment
1127 included in analysis of 
breast recurrence
(31 had a mastectomy)
1158 included in analysis of death
1158 Allocated to EBRT
FIGURE 5 Consolidated Standards of Reporting Trials (CONSORT) diagram for the (a) prepathology; and
(b) postpathology strata. a, Prepathology: protocol deviations: 67/1140 (5.9%) patients allocated to TARGIT
received EBRT and 10/1158 (0.9%) patients allocated to EBRT received TARGIT; b, prepathology: 219/1140 (19.2%)
patients allocated to TARGIT received EBRT after TARGIT as per protocol; c, postpathology: protocol deviations:
11/581 (1.9%) patients allocated to TARGIT received EBRT and 2/572 (0.3%) patients allocated to EBRT received
TARGIT; d, postpathology: 20/581 (3.4%) patients allocated to TARGIT received EBRT after TARGIT as per protocol.
Reproduced with permission from Vaidya et al.2 Copyright © Vaidya et al. Open Access article distributed under the
terms of CC BY-NC-ND. (continued )
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Postpathology: 1153 patients enrolled and randomised 
after excision of cancer
(b)
1 withdrawn
21 did not receive allocated 
treatment
11 received EBRTc
9   had a mastectomy
1   did not receive TARGIT or EBRT
559 received allocated treatment
539 received TARGIT
20 received TARGIT and EBRTd
572 included in analysis of 
breast recurrence
(9 had a mastectomy)
581 included in analysis of death
581 Allocated to TARGIT with or without EBRT
6 withdrawn
15 did not receive allocated 
treatment
2 received TARGITc
6 received TARGIT and EBRT
3 had a mastectomy
4 did not receive TARGIT or EBRT
551 received allocated treatment
569 included in analysis of 
breast recurrence
(3 had a mastectomy)
572 included in analysis of death
572 Allocated to EBRT
FIGURE 5 Consolidated Standards of Reporting Trials (CONSORT) diagram for the (a) prepathology; and
(b) postpathology strata. a, Prepathology: protocol deviations: 67/1140 (5.9%) patients allocated to TARGIT
received EBRT and 10/1158 (0.9%) patients allocated to EBRT received TARGIT; b, prepathology: 219/1140 (19.2%)
patients allocated to TARGIT received EBRT after TARGIT as per protocol; c, postpathology: protocol deviations:
11/581 (1.9%) patients allocated to TARGIT received EBRT and 2/572 (0.3%) patients allocated to EBRT received
TARGIT; d, postpathology: 20/581 (3.4%) patients allocated to TARGIT received EBRT after TARGIT as per protocol.
Reproduced with permission from Vaidya et al.2 Copyright © Vaidya et al. Open Access article distributed under the
terms of CC BY-NC-ND.
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Patient and tumour characteristics are provided in Table 1. Most cancers were small and of good prognosis
[87% (2685/3082) up to 2 cm, 85% (2573/3032) grade 1 or 2, 84% (2610/3112) node negative, 93%
(2874/3093) ER positive, 82% (2462/3016) PgR positive and 69% detected by screening (2102/3063)].
The numbers of patients from each centre and each country are provided in Tables 2 and 3, respectively.
Follow-up
In total, 93.7% (3234/3451) of patients were seen within the year before data lock or had at least 5 years of
follow-up (Figure 7). The whole cohort of 3451 patients had a median follow-up of 2 years and 5 months
[interquartile range (IQR) 12–52 months], 2020 patients had a median follow-up of 4 years and 1222 patients
had a median follow-up of 5 years. The mature cohort of 2232 patients, which was originally reported in
2010, had a median follow-up of 3 years and 7 months (IQR 30–61 months). Figure 8 shows that a large
number of patients, even in the prepathology stratum, had a long median follow-up time.
TABLE 1 Patient and tumour characteristics
Characteristic
TARGIT (n= 1721) EBRT (n= 1730)
n % n %
Age (years)
≤ 50 150 9 122 7 p= 0.274
51–60 527 31 548 32
61–70 781 45 807 47
> 70 263 15 253 15
Pathological tumour size (cm)
≤ 1 611 39 597 39 p= 0.273
1.1–2 751 48 726 48
> 2 190 12 207 14
Unknown 169 10 200 12
Grade
1 538 35 558 37 p= 0.394
2 757 50 720 48
3 232 15 227 15
Unknown 194 11 225 13
Lymphovascular invasion
Absent 1348 87 1343 88 p= 0.224
Present 194 13 178 12
Unknown 179 10 209 12
Nodes involved
0 1307 83 1303 85 p= 0.091
1–3 219 14 211 14
> 3 43 3 29 2
Unknown 152 9 187 11
MAIN RESULTS
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Screen detected
< 60 years
> 1 cm
> 2 cm
Grade 3
Node positive
0 3451
61–70 years
FIGURE 6 Bar chart summarising the data in Table 1. It shows that although most patients had a good prognosis,
there were a substantial number of patients who had a high-risk disease: nearly 3000 patients were < 70 years and
between 400 and 550 patients had tumours > 2 cm, or grade 3 or node positive.
TABLE 1 Patient and tumour characteristics (continued )
Characteristic
TARGIT (n= 1721) EBRT (n= 1730)
n % n %
ER status
ER +ve 1441 92 1433 94 p = 0.090
ER –ve 120 8 99 7
Unknown 160 9 198 12
PgR status
PgR +ve 1232 81 1230 82 p = 0.179
PgR –ve 289 19 265 18
Unknown 200 12 235 14
HER 2 receptor
Positive 170 11 178 12 p = 0.585
Negative 1329 89 1309 88
Unknown 222 13 243 14
The denominator for unknown percentages is the total number randomised (n= 1721 and n = 1730) and the denominator
for each category is the total number of known cases. Most of the unknown data are from the 342 patients randomised in
the last 6 months before data lock. The bar chart in Figure 6 provides a summary of the data. The percentage subtotals in
each category (known) may not add up to 100% because of rounding. There was no significant difference in patient and
tumour characteristics between the two randomised arms.
Reproduced with permission from Vaidya et al.1 Copyright © Vaidya et al. Open Access article distributed under the terms
of CC BY-NC-ND.
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TABLE 2 Centres that participated in the TARGIT-A trial
Centre name (in order of first patient recruited) Number of patients
UCL, London, UK 189
Sir Charles Gairdner Hospital, Perth, WA, Australia 385
Centro di Riferimento Oncologico, Aviano, Italy 309
Ninewells Hospital, Dundee, UK 270
University of California, San Francisco, CA, USA 110
Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Germany 186
Frauenklinik vom Roten Kreuz, Munich, Germany 257
Sankt Gertrauden-Krankenhaus, Berlin, Germany 54
Universität Frankfurt am Main, Frankfurt, Germany 44
University of Southern California, Los Angeles, CA, USA 75
Ospedale San Giuseppe di Empoli, Empoli, Italy 57
Medical University of Lublin, Lublin, Poland 42
University of Nebraska Medical Center, Omaha, NE, USA 18
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 9
Ludwig Maximilians Universität, Munich, Germany 100
Herlev/Rigs Hospitals, Copenhagen, Denmark 514
Royal Free/Whittington Hospitals, London, UK 115
Lafayette Surgical Clinic, Lafayette, IN, USA 12
Princess Margaret Hospital, Toronto, ON, Canada 24
Sentara Surgery Specialists, Hampton, VA, USA 11
Universitätsklinikum des Saarlandes, Homburg, Germany 65
Brust-Zentrum Seefeld, Zurich, Switzerland 59
Royal Hampshire County Hospital, Winchester, UK 115
St Olav’s University Hospital, Trondheim, Norway 111
Universitäts Spital Zurich, Zurich, Switzerland 39
Guy’s Hospital, London, UK 22
Vassar Brothers Medical Center, Poughkeepsie, New York, NY, USA 36
St John’s Riverside Health Hospital, Dobbs Ferry, New York, NY, USA 4
Medizinische Hochschule Hannover, Germany 28
Centre René Gauducheau, Nantes, France 72
Instituto Oncologico Veneto, Padova, Italy 110
Hospital of St John and St Elizabeth, London, UK 3
Institut Bergonié, Bordeaux, France 6
MAIN RESULTS
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FIGURE 7 Completeness of follow-up. Reproduced with permission from Vaidya et al.2 Copyright © Vaidya et al.
Open Access article distributed under the terms of CC BY-NC-ND.
TABLE 3 Countries that participated in the TARGIT-A trial
Country Number of cases
UK 714
Australia 394
Italy 476
Germany 734
USA 266
Poland 42
Denmark 514
Canada 24
Switzerland 98
Norway 111
France 78
Total 3451
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Extent of surgery
The analysis of amount of tissue excised was presented in the 2010 paper in The Lancet1 and included the
first 2232 patients. Table 4 shows that the median amount of tissue excised during breast-conserving
surgery was similar in the two groups, as was the proportion of first excisions with free margins. The
difference in re-excision rate was not significant between the two main strata [prepathology 119 (7.8%)
vs. postpathology 63 (9.0%); p = 0.31] or between the two randomised groups (p = 0.07).
Complications and local toxicity
All complications were reported in the 2010 paper in The Lancet1 and complications after 6 months were
reported in the 2014 paper in The Lancet.2 The number of patients with any complication (Table 5) was
similar between the groups. Table 6 shows the five clinically significant complications reported, three of
which had a similar rate in the two groups. Wound seroma needing more than three aspirations were
more frequent in the TARGIT group than in the EBRT group (2.1% vs. 0.8%) whereas a RTOG score of 3
or 4 was more frequent in the EBRT group than in the TARGIT group (2.1% vs. 0.5%). The total rate of
major toxicities was similar in the two groups.
In the 2014 analysis of complications 6 months after randomisation,2 we noted no significant difference
in any protocol-defined wound-related complication (Table 7). There were fewer grade 3 or 4
radiotherapy-related skin complications with TARGIT than with EBRT (4/1721 vs. 13/1730, p = 0.029).
Local recurrence and mortality
Table 8 shows the results of the test of non-inferiority in terms of local recurrence in the conserved breast.
TARGIT was non-inferior to EBRT for the whole trial (Pnon-inferiority = 0.00000012) and for the prepathology
stratum (Pnon-inferiority = 0.0000000013), but not for the postpathology stratum (Pnon-inferiority = 0.06640).
TABLE 4 Extent of surgery in the first 2232 patients
TARGIT EBRT
Specimen weight (g)a 45.5 (28–72) 47 (29–76)
Margins at first excision
Free 970/1072 (90.49) 968/1073 (90.21)
DCIS only 46/1072 (4.29) 43/1073 (4.01)
Invasive 56/1072 (5.22) 62/1073 (5.78)
Unknown 41/1113 (3.68) 46/1119 (4.11)
Re-excision for margins
Prepathology stratum 52/766 (6.79) 65/768 (8.72)
Postpathology stratum 27/347 (7.78) 36/351 (10.26)
Total 79/1113 (7.1) 106/1119 (9.2)
a Specimen weight was available for 1219 patients (TARGIT, n= 614; EBRT, n= 605). The denominator for unknown
percentages is the number of randomised patients and the denominator for each category is the number of
known cases.
Data are median (IQR) or n/N (%).
Reproduced with permission from Vaidya et al.1 Copyright © Vaidya et al. Open Access article distributed under the terms
of CC BY-NC-ND.
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TABLE 7 Wound-related complications after 6 months
Complication Total number of patients TARGIT vs. EBRT
Haematoma/seroma requiring more than three aspirations or surgery 3445 4 vs. 2
Wound infection requiring intravenous antibiotics or surgery 3431 12 vs. 9
Skin breakdown/delayed wound healing 3443 3 vs. 5
Total 19 vs. 16 (p = 0.599)
Reproduced with permission from Vaidya et al.1 Copyright © Vaidya et al. Open Access article distributed under the terms
of CC BY-NC-ND.
TABLE 5 Numbers of patients with any complication
Number of complications per patient
TARGIT EBRT
n % n %
0 917 82.39 946 84.54
1 151 13.57 139 12.42
2 29 2.61 27 2.41
3 11 0.99 5 0.45
4 3 0.27 0 0.00
5 2 0.18 0 0.00
6 0 0.00 3 0.27
All complications 196 17.61 174 15.46 chisq 1.74, p= 0.19
Total cases 1113 1119
chisq, chi-squared test.
Reproduced with permission from Vaidya et al.1 Copyright © Vaidya et al. Open Access article distributed under the terms
of CC BY-NC-ND.
TABLE 6 Numbers of patients with clinically significant complications
Complication
TARGIT EBRT
Statistical significancen % n %
a Hematoma requiring surgical evacuation 11 0.99 7 0.63 chisq 0.92, p= 0.34
b Seroma requiring more than three aspirations 23 2.07 9 0.80 chisq 6.29, p= 0.012
c Infection requiring intravenous antibiotics or
surgical intervention
20 1.89 14 1.25 chisq 1.11, p= 0.29
d Skin breakdown or delayed wound healinga 31 2.79 21 1.88 chisq 2.02, p= 0.16
e RTOG toxicity grade 3 or 4 (nil grade 4) 6 0.54 23 2.06 chisq 10.0, p= 0.002
f Major toxicity (d + e) 37 3.32 44 3.93 chisq 0.59, p= 0.44
chisq, chi-squared test.
a Some of the patients in the first three rows (haematoma requiring surgical evacuation, seroma needing more than three
aspirations, infection needing intravenous antibiotics or surgical intervention) could be included in the fourth row (skin
breakdown or delayed wound healing).
Reproduced with permission from Vaidya et al.1 Copyright © Vaidya et al. Open Access article distributed under the terms
of CC BY-NC-ND.
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For the first 1222 patients randomised in the trial the median follow-up was 5 years and the test for
non-inferiority found that TARGIT was non-inferior to EBRT in terms of local recurrence in the conserved
breast for both strata together (Pnon-inferiority = 0.040) and for the prepathology stratum (Pnon-inferiority = 0.00914),
but not for the postpathology stratum (Pnon-inferiority = 0.35108).
For all 3451 patients, the 5-year estimated risk for local recurrence in the conserved breast (with deaths
censored) was 3.3% (95% CI 2.1% to 5.1%) for TARGIT and 1.3% (95% CI 0.7% to 2.5%) for EBRT;
the difference was not statistically significant (log-rank p-value 0.04, which was above the pre-specified
TABLE 8 Test of non-inferiority in terms of local recurrence in the conserved breast between TARGIT and EBRTa
Cohort
Number of patients:
total number
(TARGIT vs. EBRT
patients with
conserved breast)b
Median
follow-up
Number
of events
(TARGIT
vs. EBRT)
Difference in
the binomial
proportionsc
of local
recurrenceb in
the conserved
breast, (TARGIT
minus EBRT),
absolute
difference
(90% CI) (%) z-score
Pnon-inferiority
for the
non-inferiority
margin of 2.5%
Whole trial All patients n= 3451
(1679 vs. 1696)
2 years
5 months
23 vs. 11 0.72 (0.2 to 1.3) –5.168 0.00000012
Mature cohort
n = 2232
(1078 vs. 1093)
3 years
7 months
22 vs. 10 1.13 (0.3 to 2.0) –2.652 0.004
Earliest cohort
n = 1222 (593 vs. 592)
5 years 15 vs. 8 1.14 (–0.1 to 2.4) –1.75 0.040
Prepathology
(TARGIT given
concurrent with
lumpectomy)
All patients n= 2298
(1107 vs. 1127)
2 years
4 months
10 vs. 6 0.37 (–0.2 to 1.0) –5.954 0.0000000013
Mature cohort
n = 1450 (689 vs. 710)
3 years
8 months
9 vs. 5 0.6 (–0.3 to 1.5) –3.552 0.00019
Earliest cohort n= 817
(n= 398 vs. 405)
5 years 6 vs. 3 0.76 (–0.4 to 2.0) –2.36 0.00914
Postpathology
(TARGIT given
as a delayed
procedure by
reopening the
wound)
All patients n= 1153
(581 vs. 572)
2 years
4 months
13 vs. 5 1.39 (0.2 to 2.6) –1.503 0.06640
Mature cohort
n = 782 (389 vs. 383)
3 years
7 months
13 vs. 5 2.04 (0.3 to 3.8) –0.429 0.33390
Earliest cohort n= 405
(195 vs. 187)
5 years 9 vs. 5 1.8 (–1.2 to 4.8) –0.382 0.35108
a This table gives the values of Pnon-inferiority for the whole cohort, the mature cohort and the earliest cohort (Pnon-inferiority gives
the probability that the observed non-inferiority is seen purely by chance, so Pnon-inferiority < 0.05 means that non-inferiority
is established). The mature cohort consisted of the first 2232 patients for whom data were previously reported in 2010.
The earliest cohort consisted of all patients enrolled in the first 8 years of the study (excluding the last 4 years of
recruitment).
b Local recurrence in patients who had a conserved breast (i.e. those who had not already had a mastectomy before local
recurrence). There was no statistically significant difference in the number of mastectomies prior to local recurrence
between TARGIT and EBRT (p= 0.342).
c Binomial proportion = number of recurrences/number of patients.
Reproduced with permission from Vaidya et al.2 Copyright © Vaidya et al. Open Access article distributed under the terms
of CC BY-NC-ND.
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limit of 0.01) (Table 9 and Figure 9). Half of the patients with local recurrence (17/34) were treated with
a mastectomy and there was no significant difference between TARGIT and EBRT in the need for
mastectomy for recurrence (p = 0.271).
Breast cancer mortality was much the same in the two groups [5-year rate 2.6% (95% CI 1.5% to 4.3%)
for TARGIT vs. 1.9% (95% CI 1.1% to 3.2%) for EBRT; p = 0.56] but there were significantly fewer
non-breast-cancer deaths in the TARGIT group than in the EBRT group [1.4% (95% CI 0.8% to 2.5%) vs.
3.5% (95% CI 2.3% to 5.2%); p = 0.0086], attributable to fewer deaths from cardiovascular causes and
other cancers (Table 10 and Figure 10). Overall, mortality at 5 years for TARGIT was numerically 1.4%
lower than for EBRT [TARGIT 3.9% (95% CI 2.7% to 5.8%) vs. EBRT 5.3% (95% CI 3.9% to 7.3%);
p = 0.099]. Overall, in absolute terms, there were 12 additional local recurrences but 14 fewer deaths in
the TARGIT group (see Table 9).
Analysis limited to the mature cohort, first reported in 2010 (n = 2232, median follow-up of 3 years
7 months), in which most events had occurred (32 of 34 local recurrences and 85 of 88 deaths), yielded
much the same results.
The effect of timing of randomisation and delivery of radiotherapy in relation
to lumpectomy: the prepathology and postpathology strata
Figure 11 shows the Kaplan–Meier graphs for the prepathology and postpathology strata.
In the prepathology stratum (n = 2298), that is, when TARGIT was delivered during the initial lumpectomy,
the risk of local recurrence in the conserved breast was much the same for TARGIT as for EBRT [TARGIT
2.1% (95% CI 1.1% to 4.2%) vs. EBRT 1.1% (95% CI 0.5% to 2.5%); p = 0.31]. In total, 17 patients
died from breast cancer in the TARGIT group and 15 patients died from breast cancer in the EBRT group
[TARGIT 3.3% (95% CI 1.9% to 5.8%) vs. EBRT 2.7% (1.5% to 4.6%); p = 0.72]; the equivalent figures
for non-breast-cancer mortality were 12 and 27, respectively [TARGIT 1.3% (95% CI 0.7% to 2.8%) vs.
EBRT 4.4% (95% CI 2.8% to 6.9%); p = 0.016]. Thus, in absolute terms, there were four additional local
recurrences but 13 fewer deaths in the prepathology stratum.
In the postpathology stratum (n = 1153), that is, when TARGIT was delivered as a delayed procedure by
reopening the lumpectomy cavity, the difference between the two groups in local recurrence in the conserved
breast was larger than 2.5% [TARGIT 5.4% (95% CI 3.0% to 9.7%) vs. EBRT 1.7% (95% CI 0.6% to 4.9%);
p = 0.069]. In total, three patients died from breast cancer in the TARGIT group and one patient died from
breast cancer in the EBRT group [TARGIT 1.2% (95% CI 0.4% to 4.2%) vs. EBRT 0.5% (95% CI 0.1% to
3.5%); p = 0.35]; the equivalent figures for non-breast-cancer mortality were five and eight, respectively
[TARGIT 1.58% (95% CI 0.62% to 3.97%) vs. 1.76% (95% CI 0.7% to 4.4%); p = 0.32]. Thus, in absolute
terms, there were eight additional local recurrences and one less death in the postpathology stratum.
Figures 12–14 show more detailed results for the prepathology stratum. Figure 12 shows the primary
(local recurrence in the conserved breast) and secondary (deaths) outcomes. Figure 13 shows the
differences in 5-year estimates for these outcomes for the whole cohort, the mature cohort and the
earliest cohort. This figure demonstrates the stability of the results with longer follow-up and the trade-offs
between the two outcomes. Figure 14 shows the 10-year Kaplan–Meier graph for the prepathology
stratum, which shows that the small difference in local recurrence does not increase with longer follow-up.
One possible concern might be that the addition of EBRT was different between the two strata.
If prespecified unsuspected adverse factors were found when the full pathology report was available,
whole-breast radiotherapy was recommended. This was more common in the prepathology stratum than
in the postpathology stratum (21% vs. 3%). To assess whether or not more frequent use of additional
EBRT could be the cause of better outcomes in the prepathology stratum, we performed an exploratory
non-randomised comparison of tumour characteristics and primary and secondary outcomes between
prepathology and postpathology patients who received TARGIT alone.
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FIGURE 9 Kaplan–Meier plots for patients who had breast-conserving therapy (a) for local recurrence in the
conserved breast; (b) for regional recurrence (axillary and supraclavicular); and (c) for deaths in all patients.
Regional recurrence was an exploratory outcome. Three of the 14 regional recurrences had breast recurrence as
well (n= 1 TARGIT and n= 2 EBRT). Reproduced with permission from Vaidya et al.2 Copyright © Vaidya et al. Open
Access article distributed under the terms of CC BY-NC-ND.
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TABLE 9 Raw numbers and 5-year Kaplan–Meier estimates for local recurrence in the conserved breast (primary
outcome) and death (secondary outcome)
Cohort n Outcome
Events; 5-year cumulative risk
(95% CI) (%)
Absolute difference
(TARGIT minus EBRT)
TARGIT EBRT
Difference in K–M
point estimate at
5 years (%)
All patients 3375 Local recurrence in
the conserved breast
23 11 12
3.3 (2.1 to 5.1) 1.3 (0.7 to 2.5) +2.0
3451 Death 37 51 –14
3.9 (2.7 to 5.8) 5.3 (3.9 to 7.3) –1.4
Prepathology
(TARGIT given
concurrently with
lumpectomy)
2234 Local recurrence in
the conserved breast
10 6 4
2.1 (1.1 to 4.2) 1.1 (0.5 to 2.5) +1.0
2298 Death 29 42 –13
4.6 (1.8 to 6.0) 6.9 (4.3 to 9.6) –2.3
Postpathology
(TARGIT given as
a delayed second
procedure)
1141 Local recurrence in
the conserved breast
13 5 8
5.4 (3.0 to 9.7) 1.7 (0.6 to 4.9) +3.7
1153 Death 8 9 –1
2.8 (1.3 to 5.9) 2.3 (1 to 5.2) +0.5
K–M, Kaplan–Meier.
Reproduced with permission from Vaidya et al.2 Copyright © Vaidya et al. Open Access article distributed under the terms
of CC BY-NC-ND.
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FIGURE 10 Kaplan–Meier plots for (a) breast cancer deaths; and (b) non-breast-cancer deaths. Reproduced with
permission from Vaidya et al.2 Copyright © Vaidya et al. Open Access article distributed under the terms of
CC BY-NC-ND. (continued )
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FIGURE 10 Kaplan–Meier plots for (a) breast cancer deaths; and (b) non-breast-cancer deaths. Reproduced with
permission from Vaidya et al.2 Copyright © Vaidya et al. Open Access article distributed under the terms of
CC BY-NC-ND.
TABLE 10 Causes of death
Causes of death other than breast cancer TARGIT EBRT
Other cancers 8 16
Cardiovascular causes
Cardiac included a ‘sudden death at home’ in EBRT group 2 8
Stroke 0 2
Ischaemic bowel 0 1
Other causes: TARGIT: 2 diabetes, 1 renal failure, 1 liver failure,
1 sepsis, 1 Alzheimer’s disease, 1 unknown. EBRT: 1 myelopathy,
1 perforated bowel, 1 pneumonia, 1 old age and 4 unknown
7 8
Total 17 35
5-year risk = 1.4% vs. 3.5%
Log-rank p= 0.0086
Reproduced with permission from Vaidya et al.2 Copyright © Vaidya et al. Open Access article distributed under the terms
of CC BY-NC-ND.
DOI: 10.3310/hta20730 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 73
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Vaidya et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
37
TARGIT
EBRT
Log-rank p = 0.31
10%
(a)
5%
C
u
m
u
la
ti
ve
 r
is
k
0%
0 1 2
Years
Prepathology (n=2298)
Local recurrence in the conserved breast
16 events
3 4 5
1107
1127
Number at risk
TARGIT
EBRT
790
787
603
601
442
444
316
315
190
200
TARGIT
EBRT
Log-rank p = 0.069
10%
(b)
5%
0%
0 1 2
Years
Postpathology (n=1153)
Local recurrence in the conserved breast
18 events
3 4 5
572
569
Number at risk
TARGIT
EBRT
461
457
360
355
237
230
175
164
100
96
C
u
m
u
la
ti
ve
 r
is
k
FIGURE 11 Primary and secondary outcomes for the two strata defined by timing of randomisation and delivery of
TARGIT: (a and c) prepathology (n= 2298) (randomised before lumpectomy and TARGIT given concurrently with
lumpectomy); (b and d) postpathology (n= 1153) (randomised after lumpectomy and TARGIT given by reopening
the wound). Kaplan–Meier plots for local recurrence in the conserved breast in patients who had breast-conserving
surgery (a and b) and for deaths in all patients (c and d). Reproduced with permission from Vaidya et al.2 Copyright
© Vaidya et al. Open Access article distributed under the terms of CC BY-NC-ND. (continued )
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FIGURE 11 Primary and secondary outcomes for the two strata defined by timing of randomisation and delivery of
TARGIT: (a and c) prepathology (n= 2298) (randomised before lumpectomy and TARGIT given concurrently with
lumpectomy); (b and d) postpathology (n= 1153) (randomised after lumpectomy and TARGIT given by reopening
the wound). Kaplan–Meier plots for local recurrence in the conserved breast in patients who had breast-conserving
surgery (a and b) and for deaths in all patients (c and d). Reproduced with permission from Vaidya et al.2 Copyright
© Vaidya et al. Open Access article distributed under the terms of CC BY-NC-ND.
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FIGURE 12 Primary and secondary outcomes for the prepathology stratum (n = 2298). Kaplan–Meier plots for
(a) local recurrence in the conserved breast in patients who had breast-conserving surgery; (b) breast cancer deaths
in all patients; and (c) non-breast-cancer deaths in all patients. Reproduced with permission from Vaidya et al.2
Copyright © Vaidya et al. Open Access article distributed under the terms of CC BY-NC-ND.
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Patients in the super-selected postpathology stratum had a much better prognosis than patients in the
prepathology stratum, as seen from the tumour size, tumour grade, lymph node status and breast cancer
survival (Table 11). Despite this, the 5-year local control in prepathology cases who received TARGIT alone
appears to be better than that in the postpathology cases who received TARGIT alone (2.7% vs. 5.9%)
and similar to that in the whole prepathology stratum (2.1%).
These data suggest that TARGIT during lumpectomy is effective and that the accurate and timely
application of radiation to the fresh tumour bed avoiding spatial and temporal miss rather than the
addition of EBRT in higher-risk cases is responsible for the better results in the prepathology stratum.
Analysis of the earliest cohort of over 800 patients randomised in the first 8 years in the
prepathology stratum of the TARGIT-A trial, and who have a median follow-up of 5 years
We paid special attention to the earliest cohort of over 800 patients randomised in the first 8 years in the
prepathology stratum of the TARGIT-A trial. This cohort had a median follow-up of 5.01 years. As well as
being a conventional yardstick, this 5-year point happens to be considerably in excess of the known peak
hazard of local recurrence. In addition, the effect of radiotherapy on local recurrence is limited to the first
TABLE 11 Results according to treatment received: non-randomised comparison. Despite the poor prognostic
factors for survival in the group selected to receive TARGIT plus EBRT, as shown by increased breast cancer
mortality, local recurrence was low in this group and did not differ from local recurrence in those who received
TARGIT alone. In addition, despite having worse prognosis (features in bold) patients who received TARGIT
alone in the prepathology stratum had a local recurrence rate of only 2.7% compared with 5.9% in the
postpathology stratum
Variable
Prepathology patients
who received TARGIT
alone (n= 793)
Prepathology patients
who received
TARGIT+ EBRT
(n= 219)
Postpathology patients
who received TARGIT
alone (n= 539)
Tumour size (cm)
≤ 1 36% (256/703) 24% (47/199) 52% (269/515)
1–2 52% (366/703) 49% (98/199) 43% (223/515)
> 2 12% (81/703) 27% (54/199) 5% (23/515)
Grade
1 27% (188/707) 19% (38/200) 59% (285/486)
2 54% (380/707) 60.5% (121/200) 38% (182/486)
3 20% (139/707) 20.5% (41/200) 4% (19/486)
Lymph node positivity
Node negative 85% (604/712) 63% (126/201) 95% (492/519)
1–3 nodes involved 13% (94/712) 29% (59/201) 5% (27/519)
> 3 nodes involved 2% (14/712) 8% (16/201) 0 (0/519)
5-year local recurrence in the
conserved breast (95% CI)
2.7 (1.3 to 5.5) 0.9 (0.1 to 6.1) 5.9 (3.3 to 10.5)
5-year risk of breast cancer death
(95% CI)
1.8 (0.7 to 4.6) 8.0 (3.5 to 17.5) 0.6 (0.2 to 2.5)
5-year risk of death from
non-breast-cancer causes (95% CI)
1.9 (0.9 to 4.0) 0 1.5 (0.6 to 4.3)
Only 20 postpathology patients received TARGIT + EBRT and therefore their data are not given.
Reproduced with permission from Vaidya et al.2 Copyright © Vaidya et al. Open Access article distributed under the terms
of CC BY-NC-ND.
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5 years. From the results of the main analysis it was determined that giving TARGIT during lumpectomy
should be the preferred option and hence we analysed these earliest patients.
This section provides details of the analysis for this cohort of patients who were randomised in the first 8 years
of the TARGIT-A trial, that is, from 2000 to 2008. All patients randomised in this period in the prepathology
stratum were included. These patients happen to have the longest follow-up and have not been ‘cherry-picked’.
In total, there were 817 patients in the prepathology stratum of the earliest cohort. For local recurrence in
the conserved breast, TARGIT was non-inferior to EBRT (Pnon-inferiority = 0.0091). The Kaplan–Meier plots are
shown in Figure 15.
The 5-year estimated risk was not statistically different between groups for local recurrence [TARGIT 1.8%
(95% CI 0.84% to 4.2%) vs. EBRT 0.84% (95% CI 0.3% to 2.6%); p = 0.32] or deaths from breast cancer
[TARGIT 3.9% (95% CI 2.3% to 6.7%) vs. EBRT 3.0% (95% CI 1.7% to 5.4%); p = 0.34]. However, there
were significantly fewer deaths from causes other than breast cancer with TARGIT [1.9% (95% CI 0.9 to
3.9)] than with EBRT [5.1% (95% CI 3.2% to 8.0%); p = 0.04.]
It should be noted that the number needed to prove non-inferiority was calculated to be 5851 and,
therefore, this earliest cohort of 817 patients had enough power to draw reliable conclusions.
From this analysis it is clear that, if the trial had been stopped after 8 years of recruitment, there would have
been an adequate number of patients for testing the hypothesis with a median follow-up of 5 years. The
patients who were recruited more recently should not be perceived as weakening the result because the
Kaplan–Meier analysis as well as the cohort analysis for non-inferiority (see Table 8) takes it all into account.
Disease-free survival and survival without local recurrence
For the whole trial cohort and the prepathology stratum, disease-free survival was similar between the
groups (p = 0.78 and p = 0.69 respectively), as shown in Figures 16 and 17, respectively.
The Kaplan–Meier estimates for disease-free survival for the whole trial were similar for TARGIT and EBRT
(log-rank p = 0.78). Five-year disease-free survival was 90.5% (95% CI 88.1% to 92.5%) for TARGIT and
91.0% (95% CI 88.6% to 92.98%) for EBRT and 10-year disease-free survival was 77.7% (95% CI 65.5%
to 86.8%) for TARGIT and 71.5% (95% CI 49.8% to 85.1%) for EBRT.
The Kaplan–Meier estimates for disease-free survival for the prepathology stratum, in which TARGIT was
given during surgical removal of the cancer, were not statistically different for TARGIT and EBRT (log-rank
p = 0.69): 5-year disease-free survival was 91.6% (95% CI 88.7% to 93.8%) for TARGIT and 90.1%
(95% CI 86.8% to 92.6%) for EBRT and 10-year disease-free survival was 81.3% (95% CI 71% to 88%)
for TARGIT and 71.2% (95% CI 49% to 85%) for EBRT.
Finally, survival without local recurrence (in which deaths are not censored, in line with recommendations
by the US Food and Drug Administration62 and elsewhere63) was not statistically different between the
two arms [TARGIT vs. EBRT, all patients: 93.1% (95% CI 90.8% to 94.9%) vs. 93.8% (95% CI 91.7% to
95.4%), p = 0.81; prepathology: 93.9% (95% CI 90.9% to 95.9%) vs. (95% CI 89.7% to 94.6%),
p = 0.35] (Figure 18). These results are shown in the form of a pictogram (Figure 19) that can be used
during discussion between the clinician and the patient before breast-conserving (lumpectomy) surgery for
breast cancer. It explains the outcome for patients treated with TARGIT IORT compared with the outcome
for those receiving EBRT, based on randomised evidence.
Thus, the clinical effectiveness with TARGIT was at least as good as that with EBRT.
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FIGURE 15 Kaplan–Meier plots for the earliest cohort of patients randomised in the first 8 years of the trial:
(a) local recurrence in the conserved breast; (b) breast cancer deaths; and (c) non-breast-cancer deaths.
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FIGURE 16 Ten-year disease-free survival for all patients in the trial.
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FIGURE 18 Kaplan–Meier plot: true representation of how patients with breast cancer would fare in the first
5 years following treatment with TARGIT during lumpectomy or EBRT with respect to local control. Censoring is
carried out at the point of last follow-up or withdrawal. For any patient, the chance of being alive without local
recurrence can be read off this plot. Five-year survival without local recurrence is 93.9% (95% CI 90.9% to 95.9%)
for TARGIT and 92.5% (95% CI 89.7% to 94.6%) for EBRT (p= 0.35). Reproduced from Vaidya et al.64 © 2015
The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/ licenses/by-nc-nd/4.0/).
What happened to women with early breast cancer,
treated with TARGIT during lumpectomy compared with those treated EBRT,
over the first 5 years?
There was no statistically significant difference in survival without local recurrence
1 dot = 1 woman
TARGIT-A international multicentre trial included 3451 women randomised to receive TARGIT or EBRT.
These figures are created by applying Kaplan–Meier estimates of 5-year survival without local recurrence to 
1000 women having breast-conserving therapy in the two trial arms. Distant or regional disease not shown:
there was no difference seen between TARGIT and EBRT.
939 women alive without local recurrence
20 women alive after treatment of local recurrence
1 woman died after local recurrence
40 women died
1000 women randomised to TARGIT
925 women alive without local recurrence
10 women alive after treatment of local recurrence
1 woman died after local recurrence
64 women died
1000 women randomised to EBRT
FIGURE 19 A pictogram to help patients and doctors make a shared well-informed decision. Adapted with
permission from Vaidya et al.64
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Chapter 4 Planned subgroup analysis
Background
The results presented in the previous chapter suggest that the prepathology approach, in which TARGIT is
delivered under the same anaesthetic concurrently with the first excision of breast cancer rather than at a
later date by reopening the wound (i.e. postpathology), would currently lend itself to be the preferred
option of delivery of TARGIT. In this prepathology stratum TARGIT achieved statistically similar breast cancer
control to EBRT and maintained a statistically significant lower mortality rate from other causes than EBRT.
Although most patients recruited to the trial were good-prognosis patients, there was a substantial
number of ‘high-risk’ cases, for example approximately 500 cases were node positive, or grade 3, or larger
than 2 cm, because of the broad inclusion criteria. When the TARGIT approach is applied to normal clinical
practice, patient selection will be crucial in ensuring that the results of day-to-day practice reflect the
results obtained in the clinical trial.
Shortly before the statistical analysis plan was finalised on 14 June 2012, new data suggesting that hormone
sensitivity, particularly PgR status, may be an important factor in determining outcome from radiotherapy
were presented. Details of the rationale are described in Chapter 2 (see Planned subgroup analysis).
Therefore, before the trial database was unblinded for this analysis, we hypothesised that PgR negativity, as
a surrogate marker of functional ER status, might be a predictor of the effectiveness of radiotherapy.
This analysis of the randomised data may help refine current guidelines for selecting patients for PBI
approaches, which are mainly based on a presumed risk of recurrence rather than the effectiveness of
radiation, for which only randomised evidence can be relied on.
Methods
We performed an analysis with respect to PgR status for the primary and secondary end points of local
recurrence and survival (deaths from breast cancer and deaths from other causes) in the whole trial
population. Given the main results, which suggested that TARGIT should preferably be used concurrently
with the primary excision of the tumour, that is, as used in the prepathology stratum, we also analysed
within the prepathology stratum the difference in local control and survival (deaths from breast cancer and
deaths from other causes) between TARGIT and EBRT in PgR-negative and PgR-positive cases.
Analyses were performed by plotting Kaplan–Meier curves and testing for significance using the log-rank
test; a p-value of 0.05 was used as the boundary for statistical significance.
We subsequently analysed in all patients whether certain patient or tumour characteristics (timing of
randomisation/delivery of TARGIT, age, whether screen detected or not, tumour grade, presence of DCIS,
margin positivity, ER, PgR and HER2 status, lymphovascular invasion, node positivity) influenced the effect
of radiotherapy using the Cox proportional hazards model.
Fitting a separate regression model is equivalent to fitting an interaction of the treatment arm with all of
the independent risk factors in the model and also assumes that the variance in both treatment groups is
similar. We also fitted a full model with a treatment by PgR status interaction.
For visual representation of the non-inferiority results, we created a forest plot for the non-inferiority test
for each of these subgroups. In this plot we also added two groups of the prepathology stratum based on
a median follow-up of < 5 years and ≥ 5 years.
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Results
There were 2298 patients in the prepathology stratum in whom randomisation occurred before lumpectomy
and TARGIT was delivered concurrently with lumpectomy a median of 23 days after initial diagnostic needle
biopsy and a median of 7 days after randomisation. The postpathology stratum consisted of those patients
who had already had their tumour excised up to 30 days before randomisation (n = 1153). When allocated
TARGIT, it was delivered as a second surgical procedure by reopening the wound (median 62 days after
initial diagnostic needle biopsy, 37 days after the initial surgery and 17 days after randomisation).
A substantial number (18%) in each stratum were PgR negative (554 among all patients and 535 among
those who had breast-conserving therapy). PgR status was unknown in only 77 patients among the
3093 patients in whom ER status was known. In total, 99.5% (2449/2462) of PgR-positive cases were also
ER positive and 85.2% (2449/2874) of all ER-positive cases were also PgR positive. ER status was known in
89.6% (3093/3451) of cases, of whom PgR status was known in 97.5% (3016/3093).
These results have been presented at the European Cancer Congress 2013.65
Effect of progesterone receptor status
Figure 20 shows the Kaplan–Meier plots, 5-year risks with CIs and significance levels for all patients, that
is, both prepathology and postpathology strata combined.
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FIGURE 20 Local recurrence (a and b) and overall mortality (c and d) for the pre-specified subgroups defined by
PgR status. (continued )
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Among patients who had PgR-positive tumours, there was no significant difference in the primary
outcome of local recurrence in the conserved breast at 5 years between TARGIT and EBRT [13/1204 vs.
10/1203, 5-year risk 2.3% (95% CI 1.3% to 4.3%) vs. 1.5% (95% CI 0.75% to 3.0%); p = 0.51] and
there were significantly fewer deaths with TARGIT than with EBRT [22/1232 vs. 37/1230, 5-year risk 2.7%
(95% CI 1.6% to 4.5%) vs. 4.9% (95% CI 3.3% to 7.1%); p = 0.0487].
Among patients who had PgR-negative tumours, local recurrence in the conserved breast was higher in
the TARGIT arm than in the EBRT arm [9/276 vs. 1/259, 5-year risk 7.0% (95% CI 3.5% to 13.6%) vs.
0.5% (95% CI 0.1% to 3.7%); p = 0.017]. Overall mortality was similar between the groups [13/289 vs.
11/265, 5-year risk 8.1% (95% CI 4.4% to 14.7%) vs. 6.3% (95% CI 3.2% to 12.3%)].
Effect of progesterone receptor status in the prepathology stratum when targeted
intraoperative radiotherapy was given concurrently with lumpectomy
Figure 21 shows the Kaplan–Meier plots, 5-year risks with CIs and significance levels for the prepathology
stratum. Figure 22 shows the local recurrence and overall mortality in cohorts of patients with increasing
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FIGURE 20 Local recurrence (a and b) and overall mortality (c and d) for the pre-specified subgroups defined by
PgR status.
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FIGURE 21 Effect of PgR status on primary and secondary outcomes in the prepathology stratum (TARGIT given
concurrently with lumpectomy): (a)–(c) PgR positive; (d)–(f) PgR negative. (a) Local recurrence in the conserved
breast – events: TARGIT n= 4, EBRT n= 5; (b) deaths from breast cancer – events: TARGIT n= 8, EBRT n = 9;
(c) deaths from other causes – events: TARGIT n= 10, EBRT n= 22; (d) local recurrence in the conserved breast –
events: TARGIT n= 5, EBRT n= 1; (e) deaths from breast cancer – events: TARGIT n= 8, EBRT n= 5; and (f) deaths
from other causes – events: TARGIT n= 2, EBRT n = 5. (continued )
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FIGURE 21 Effect of PgR status on primary and secondary outcomes in the prepathology stratum (TARGIT given
concurrently with lumpectomy): (a)–(c) PgR positive; (d)–(f) PgR negative. (a) Local recurrence in the conserved
breast – events: TARGIT n= 4, EBRT n= 5; (b) deaths from breast cancer – events: TARGIT n= 8, EBRT n= 9;
(c) deaths from other causes – events: TARGIT n= 10, EBRT n= 22; (d) local recurrence in the conserved breast –
events: TARGIT n= 5, EBRT n= 1; (e) deaths from breast cancer – events: TARGIT n= 8, EBRT n= 5; and (f) deaths
from other causes – events: TARGIT n= 2, EBRT n= 5.
DOI: 10.3310/hta20730 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 73
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Vaidya et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
53
5.
0%
4.
0%
3.
0%
2.
0%
1.
0%
0.
0%
Absolute difference in 5-year risk (TARGIT minus EBRT)
0
1
2
3
W
h
o
le
 
co
h
o
rt
n
 =
 1
62
5
M
ed
ia
n
 
fo
llo
w
-u
p
2.
6 
ye
ar
s
M
at
u
re
co
h
o
rt
n
 =
 1
11
6
M
ed
ia
n
 
fo
llo
w
-u
p
3.
8 
ye
ar
s
Ea
rl
ie
st
 
co
h
o
rt
n
 =
 6
36
M
ed
ia
n
 
fo
llo
w
-u
p
5 
ye
ar
s
M
ed
ia
n
 
fo
llo
w
-u
p
4
5
–1
.0
%
–2
.0
%
–3
.0
%
–4
.0
%
–5
.0
%
D
if
fe
re
n
ce
 in
 5
-y
ea
r 
ri
sk
 o
f 
ip
si
la
te
ra
l b
re
as
t
re
cu
rr
en
ce
D
if
fe
re
n
ce
 in
 5
-y
ea
r 
ri
sk
 o
f 
o
ve
ra
ll 
m
o
rt
al
it
y
 St
an
d
ar
d
 e
rr
o
r
FI
G
U
R
E
22
Lo
ca
l
re
cu
rr
en
ce
in
th
e
co
n
se
rv
ed
b
re
as
t
an
d
o
ve
ra
ll
m
o
rt
al
it
y
fo
r
Pg
R
-p
o
si
ti
ve
ca
se
s
in
th
e
p
re
p
at
h
o
lo
g
y
st
ra
tu
m
.
PLANNED SUBGROUP ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
54
follow-up periods. This demonstrates that the results remain stable with longer follow-up periods,
including in the earliest cohort of 636 patients with a median follow-up of 5 years.
When TARGIT was given concurrently in patients who had PgR-positive tumours (n = 1625), local recurrence
in the conserved breast [1.4% (95% CI 0.5% to 3.9%) vs. 1.2% (95% CI 0.5% to 2.9%)] and breast cancer
mortality [1.78% (95% CI 0.7% to 4.4%) vs. 1.98% (95% CI 0.94% to 4.2%)] were similar for TARGIT and
EBRT and mortality from other causes was significantly lower by 2.9% in the TARGIT arm [1.6% (95% CI
0.74% to 3.4%) vs. 4.5% (95% CI 2.8% to 7.3%); p = 0.04], leading to a 3.1% reduction in overall
mortality [3.3% (95% CI 1.8% to 6.0%) vs. 6.4% (95% CI 4.3% to 9.6%); p = 0.083].
For patients with PgR-negative tumours (n = 366), local recurrence in the conserved breast was
numerically, but not statistically, higher in the TARGIT arm than in the EBRT arm. There was no difference
between the two arms in breast cancer mortality, non-breast-cancer mortality or overall mortality.
Thus, when TARGIT is delivered at the time of primary surgery, the chance of remaining free from local
recurrence at 5 years possibly drops from 99% to 98% (p= 0.31), but the chance of staying alive possibly
increases from 93.1% to 95.4% (p= 0.12). The p-value expresses the probability of the difference we found
being observed if there was no real difference between the two treatments. Alternatively, one can say that there
is no difference in local recurrence or mortality, with a large benefit of having the treatment in one sitting.
Cox model
The following factors were entered into the Cox model for the primary outcome of local recurrence in
the conserved breast: randomisation arm, timing of randomisation/delivery of TARGIT, age, whether
screen detected or not, tumour grade, presence of DCIS, margin positivity, ER, PgR and HER2 status,
lymphovascular invasion and node positivity.
We found that age, whether screen detected or not, tumour grade, ER status, HER2 status, lymphovascular
invasion and nodal status did not appear to have any influence on local recurrence, whereas timing of
randomisation and delivery of TARGIT [hazard ratio (HR) for delayed TARGIT 2.26, 95% CI 1.07 to 4.78;
p = 0.033] were significant predictors of local recurrence. PgR status was a significant predictor of local
recurrence overall (HR for PgR negative 2.46, 95% CI 1.11 to 5.47; p = 0.027) and in the TARGIT arm
(HR for PgR negative 3.14, 95% CI 1.29 to 7.61; p = 0.011). Margin status was significant overall (HR for
positive first margin 2.68, 95% CI 1.08 to 6.68; p = 0.034) and in the EBRT arm (HR for positive first
margin 5.17, 95% CI 1.50 to 17.8; p = 0.009), but not in the TARGIT arm. Fitting a separate regression
model is equivalent to fitting an interaction of treatment arm with all of the independent risk factors in the
model and also assumes that the variance in both treatment groups is similar. We also fitted a full model
with a treatment by PgR status interaction, giving an overall Wald statistic p-value of 0.08.
For those patients who received only TARGIT during lumpectomy, multivariate analysis showed that only
PgR status (HR for PgR negative 5.57, 95% CI 1.23 to 25.21; p = 0.026) remained significant. Other factors,
such as younger age, grade (grade 3), tumour size > 2 cm or node positivity, did not influence the difference
between the two randomised arms: the 5-year rates of local recurrence in the conserved breast were as
follows: for 263 patients with age ≤ 50 years [events 3/145 vs. 3/118, TARGIT 2.9% (95% CI 0.94% to
8.64%) vs. EBRT 6.2% (95% CI 1.99% to 18.47%); p = 0.70]; for 436 grade 3 cancers [events 2/20 vs.
2/216, TARGIT 1.5% (95% CI 0.37% to 5.87%) vs. EBRT 1.7% (95% CI 0.42% to 6.45%); p = 0.98]; for the
363 patients with tumour ≥ 2 cm [events 1/173 vs. 1/190, TARGIT 0.75% (95% CI 0.1% to 5.2%) vs. EBRT
0.86% (95% CI 0.1% to 6.0%); p = 0.95]; for the 472 node positive patients [events 1/245 vs. 2/227, TARGIT
0.72% (95% CI 0.1% to 5.0%) vs. EBRT 1.3% (95% CI 0.3% to 5.2%); p = 0.56].
Forest plot
The forest plot in Figure 23 shows that TARGIT was non-inferior to EBRT in every subgroup apart from the
ER-negative and PgR-negative subgroups.
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FIGURE 23 Forest plot showing the non-inferiority statistic for each of the subgroups. The green shaded area is the
non-inferiority margin and each of the green squares is the local recurrence rate in terms of binomial proportions
along with the 90% CI. From this plot it appears that only ER and PgR status affects whether or not there is a
difference between TARGIT and EBRT. LVI, lymphovascular invasion.
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Discussion
This planned subgroup analysis found that hormone receptor status is the only factor that influences the
outcome of patients treated with TARGIT versus EBRT. In patients with PgR-positive tumours (almost all of
whom were ER positive), there was no statistically significant difference between TARGIT and EBRT in
terms of local control and overall survival was better by 2.2% with TARGIT than EBRT. The only factor that
predicted a less favourable outcome for patients in the TARGIT arm was negative hormone receptor
status. Other factors such as younger age, higher grade (grade 3), tumour size > 2 cm or node positivity
changed the local recurrence rate equally in the two randomised arms. There were a substantial number
of such patients in the trial and TARGIT was found to be as effective as EBRT in patients with these
higher-risk factors.
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Chapter 5 Other analyses
Other quadrant recurrences: confirmation of the original
hypothesis tested in the TARGIT-A trial – cancer foci in other
quadrants do not need treatment with whole-breast radiotherapy
Background
In 1996 we reported that 63% of specimens of mastectomy performed for a unifocal cancer harbour other
cancer foci, with 80% of these foci in other quadrants.13 In contrast, local recurrence after a lumpectomy
occurs mainly at the site of the original tumour. Therefore, we hypothesised that the cancer foci in other
quadrants remain dormant even in the absence of radiation treatment to the whole breast. This academic
insight led us to develop the TARGIT technique and the INTRABEAM device. In the TARGIT-A randomised
trial (n = 3451) we compared risk-adapted TARGIT vs. whole-breast radiotherapy.2
Method
Randomisation occurred either before surgery (prepathology stratum; TARGIT given during lumpectomy) or
after surgery (TARGIT given as a delayed procedure). In the prepathology stratum we assessed the number
of local recurrences that occurred in other quadrants in the patients who received only TARGIT and in the
patients who received EBRT. We also estimated the number of cancer foci in quadrants other than that
with the original tumour.
Results
In total, 94.4% of cases in the TARGIT-A trial did not undergo a preoperative MRI scan. A total of
793 patients in the prepathology stratum randomised to TARGIT had only TARGIT as their radiotherapy.
With 2098 women-years of follow-up, there were nine recurrences in the conserved breast. The 5-year
local recurrence rate in those who received TARGIT alone was 2.7% (95% CI 1.3% to 5.5%), which was
not different from that in the whole prepathology cohort randomised to TARGIT [2.1% (95% CI 1.1% to
4.2%)]. In these 793 patients, one would expect 63% (i.e. 500) to have additional foci of cancer in their
breasts and 80% of these (i.e. 400) should be in quadrants other than the index quadrant. In reality, after
2098 women-years of follow-up, seven patients had recurrence in the scar, six had new contralateral
cancers and two had cancers growing in other quadrants, implying that the remaining 398 foci had
remained dormant. Among 935 patients who received whole-breast radiotherapy the same number of
cancers (n = 2) grew in other quadrants and there were five new contralateral cancers. In the randomised
comparison, there were two local recurrences in other quadrants in each of the randomised arms of
the trial.
Conclusion
Cancer foci in breast that are away from the site of the primary tumour remain dormant and behave no
differently from those in the contralateral breast. They also appear to be unaffected by whole-breast
radiotherapy. This analysis provides level 1 evidence supporting PBI.
Axillary recurrence: omitting whole-breast radiotherapy did
not increase axillary recurrence in the TARGIT-A trial
These data were presented at the St Gallen Symposium in March 2013 (poster presentation)66 and at the
American Society for Radiation Oncology (ASTRO) Annual Meeting in September 2013 (oral presentation).67
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Background
The Z–11 trial68 found that, even when axillary clearance is not performed after finding one or two positive
sentinel nodes, it does not affect local control, despite 23% of patients in the axillary clearance (control)
arm (and, therefore, those in the experimental arm as well) having positive nodes. However, every patient
in this trial received whole-breast radiotherapy and it has been suggested that inadvertent non-therapeutic
irradiation of the lower axilla that occurs with tangential fields of conventional whole-breast radiotherapy
could be responsible for controlling the growth of the minimal residual axillary disease. Therefore,
questions are being raised whether following the concept of sentinel node biopsy or not dissecting the
axilla after one to two positive nodes is applicable to patients receiving PBI.
Methods
We compared the risk of axillary recurrence in patients with negative sentinel node biopsy and those with
one to two positive nodes as per treatment received – whether they received EBRT or TARGIT only within
the updated TARGIT-A trial.2 It is important to note that this was a comparison as per treatment received
rather than as per randomised allocation (Figure 24).
Results
Overall, 3375 patients underwent breast-conserving surgery. In total, 1222 patients had a median follow-up of
5 years and all patients had a median follow-up of 2 years 5 months, giving 9491 women-years of follow-up.
The trial patients had a generally good prognosis but a substantial number (> 1200) were aged ≤ 60 years
and > 500 were node positive and/or grade 3.
In total, 91% of patients had a sentinel node biopsy, 90% of whom had < 10 nodes removed if this was
negative. Eleven patients had axillary recurrence, one of whom had previously undergone axillary clearance
with the other 10 having a negative sentinel node biopsy. The risk of axillary recurrence was similar whether
the patients received EBRT [6/1762, 5-year risk 0.82% (95% CI 0.34% to 2.02%)] or not [5/1613, 5-year
As TARGIT does not treat the axilla, any difference in
 outcome of the axilla may be attributed to EBRT
Analysis by treatment received
≈85%
≈15%
Excision of
cancer + concurrent
TARGIT
Excision of
cancer + EBRT
Risk adapted 
vs.
conventional
Randomisation:
Breast cancer
patient
(> 45 years)
suitable for
breast-conserving
surgery
TARGIT-A trial
randomisation
No further
radiotherapy
If high risk
factors:
EBRT
For this paper, 
these two groups
of patients were 
analysed in a
non-randomised
comparison
A
B
BA
No EBRT
given
(TARGIT 
alone)
EBRT 
given
FIGURE 24 Comparison of the two non-randomised groups for the outcome of local recurrence, with or
without EBRT.
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risk 0.68% (95% CI 0.28% to 1.6%); HR 0.84 (95% CI 0.26 to 2.74); p = 0.8]. The results were similar if
only patients with one or two positive axillary nodes were included (EBRT 1/255 vs. no EBRT 0/127)
(Figures 25 and 26).
Conclusion
Omitting whole-breast radiotherapy after a sentinel node biopsy in this good-prognosis population was not
associated with an increased axillary recurrence rate.
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FIGURE 25 Numbers of patients and axillary recurrences in the EBRT and no EBRT groups (non-randomised comparison).
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FIGURE 26 Kaplan–Meier plot for axillary recurrence in patients who were given EBRT and patients who were not
given EBRT.
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Reduction in non-breast-cancer mortality as a beneficial effect of targeted
intraoperative radiotherapy
Background
The TARGIT-A randomised trial tested the outcomes of breast cancer treatment between traditional EBRT
given over several weeks versus a risk-adapted approach using single-dose TARGIT. In the prepathology
stratum TARGIT was given concurrently with lumpectomy. If on postoperative histopathological
examination of the operative specimen any unsuspected high-risk factors were found, EBRT was added in
15–20% of cases. The main results showed that for the for local control, compared with EBRT, TARGIT
achieved non-inferior local control in all cases and identical local control when given concurrently with
lumpectomy in ER-positive, PgR-positive cases. Interestingly, the patients in the TARGIT arm had a
significantly lower risk of dying from non-breast-cancer causes such as heart attacks and other cancers.
We investigated whether or not this difference could be fully explained by the avoidance of the effects of
EBRT on the heart and other organs in the TARGIT arm.
These data were first presented at the March 2013 St Gallen Symposium (poster presentation) and in
September 2013 at the ASTRO Annual Meeting (poster presentation).69,70
Methods
1. We compared cardiac deaths for left- and right-sided breast cancer.
2. We estimated cardiac deaths based on age, sex and follow-up.
3. We compared survival between the two randomised arms in the prepathology stratum, but limited to
those who had received EBRT. Therefore, the control arm included patients who were allocated EBRT
and the experimental arm included patients who were allocated TARGIT and received EBRT in addition;
because both groups received EBRT, any difference that was found between the groups would be
attributable to TARGIT (Figure 27).
Results
In the whole trial there was a highly significant reduction in non-breast-cancer mortality in the TARGIT arm
(HR 0.47; p = 0.0086):
1. There were two cardiac deaths in the TARGIT arm and eight in the EBRT arm, with similar numbers in
each arm for left- and right-sided breast cancer (1/775 vs. 4/795 for left; 1/776 vs. 4/746 right).
2. Among the 1730 patients randomised to receive EBRT, the number of cardiac deaths (n = 8) was not
higher than the 12 estimated based on age, sex and follow-up period.
3. There were no deaths from non-breast-cancer causes in the TARGIT + EBRT group compared with 24 in
the EBRT group. Thus, there were significantly fewer deaths in those patients who received TARGIT
(0/218 vs. 24/892; log-rank p = 0.012) (see Figure 27).
Conclusion
One might expect irradiation for left-sided cancers to result in higher cardiac toxic effects. However, the
ratio of cardiac risk of left- to right-sided cancers is small (1.34 according to Darby et al.71). Furthermore,
Darby et al.71 recorded no significant effect of laterality on cardiac toxic effects per Gy. With modern
radiotherapy designed to reduce the cardiac dose, the absolute difference in cardiac deaths between those
with left-sided breast cancer and those with right-sided breast cancer is likely to be even lower and
undetectable with few events. Note that an absence of an effect of laterality on cardiac deaths cannot be
used to imply that there is no cardiac toxicity, because the difference in the effect between the two sides is
not likely to be large. Finally, with eight cardiac deaths a ratio of 1.34 would not be detectable (e.g. it
would need to be distributed as 3.5 vs. 4.7, with even 3 vs. 5 already being a ratio of 1.7). Therefore, an
absence of a difference between the left and the right sides should not be interpreted as an absence of
cardiac toxicity.
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A risk similar to that in the age-matched population should be interpreted with the knowledge that
patients in clinical trials are generally in better general health than the normal population and we should
therefore have expected a lower risk of cardiac mortality in the trial population.
The most interesting finding was that there were significantly fewer deaths among patients who were
allocated to TARGIT + EBRT compared with those allocated to EBRT. In this comparison the only difference
between the two groups was the delivery of TARGIT in one group, because both groups received EBRT,
albeit with a slightly higher dose – the boost – in the EBRT group. It suggests that the difference in
non-breast-cancer mortality could arise from an increase in mortality from EBRT toxicity, as one would
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FIGURE 27 Non-randomised comparison between those who received TARGIT + EBRT and those who received EBRT
for deaths from non-breast-cancer causes: (a) schema of the analysed cohorts of patients; and (b) Kaplan–Meier
plot depicting deaths from causes other than breast cancer in prepathology patients who received EBRT –
non-randomised comparison.
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think conventionally, as well as a reduction in mortality because of a potential beneficial effect of TARGIT.
The latter is a radically new hypothesis that the local effect of TARGIT on the tumour bed by inhibiting
cancer-stimulating cytokines17 may spill over to reduce the systemic inflammatory response to trauma and
have significant long-term systemic beneficial effects that might be protective against cardiac and cancer
mortality (Figure 28). This remarkable finding, albeit a non-randomised comparison, could potentially have
far-reaching implications. It is fortuitous that it will be tested in the HTA programme-funded TARGeted
Intraoperative radioTherapy Boost (TARGIT-B) randomised trial (ISRCTN43138042), which will compare
TARGIT boost with EBRT boost, with both randomised arms receiving whole-breast radiotherapy (Figure 29).
Adequacy of 1mm as the threshold for a negative margin: the policy
of adding external beam radiotherapy to targeted intraoperative
radiotherapy when the tumour-free margin is < 1mm (rather than
10mm) is appropriate – data from the TARGIT-A trial
Background
In the TARGIT-A trial protocol,36 a positive margin leads to a recommendation of additional EBRT after
TARGIT. The core protocol defined 1 mm as an adequate tumour-free margin but individual centres were
allowed to pre-specify a wider margin. In all German centres EBRT was recommended after TARGIT
if the margin was < 10 mm. We analysed the impact of such a decision on treatment received and
local recurrence.
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FIGURE 28 Targeted intraoperative radiotherapy abrogates the tumour-stimulating effect of surgical wound fluid.
AgRP, Agouti-related protein; EGFR, epidermal growth factor receptor; FAS/TNFRSF6, FAS receptor or tumour
necrosis factor receptor superfamily member 6; FGF-4, fibroblast growth factor 4; Flt-3, Fms-like tyrosine kinase 3;
G-CSF, granulocyte colony-stimulating factor; GRO, growth-regulating oncogene; HGF, hepatocyte growth factor;
IGFBP-6, insulin-like growth factor-binding protein 6; IL, interleukin; MCP-1/-2, monocyte chemoattractant protein
1/2; Mip-1a/1d, macrophage inflammatory protein 1a/1d; PDGF-BB, platelet-derived growth factor BB; RANTES,
regulated on activation, normal T cell expressed and secreted; sTNFR-I/-II, soluble tumour necrosis factor
receptor I/II; Tie-1/-2, tyrosine kinase containing immunoglobulin and epidermal growth factor homology domain-1
and 2; uPAR, urokinase-type plasminogen activator receptor; VEGF-R3, vascular endothelial growth factor
receptor 3.
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Methods
All German cases were planned to be treated in the prepathology stratum, that is, randomisation before
excision of the tumour and TARGIT delivered during lumpectomy.
Therefore, we analysed in the prepathology stratum the proportion of cases in whom additional EBRT
was actually given after TARGIT, as well as the primary (local recurrence in the conserved breast) and
secondary (breast cancer and non-breast-cancer mortality) outcomes. We compared these values for the
German cohort with the equivalent values for the rest of the trial population in a post hoc exploratory
non-randomised analysis.
Results
Additional EBRT was given in nearly twice the number of patients in the TARGIT arm in the German
centres as in the TARGIT arm in the rest of the trial population [31.3% (96/306) vs. 17.4% (123/706)].
However, the 5-year local recurrence rate in the German cohort was the same as in rest of the trial
population [German 2.6% (95% CI 0.87% to 7.8%) vs. rest of the trial population 1.9% (95% CI 0.81%
to 4.5%)]. Furthermore, there was no significant difference between the German cohort and rest of the
trial population in breast cancer mortality [2.5% (95% CI 0.64% to 9.7%) vs. 3.3% (95% CI 1.7% to
6.4%)] or non-breast-cancer mortality [0.78% (95% CI 0.11% to 5.4%) vs. 1.7% (0.8% to 3.7%)].
Conclusion
The greater use of additional EBRT as seen in the German cohort prompted by the higher limit of a 10-mm
tumour-free margin may not be necessary and a policy of adding EBRT after TARGIT when the margin is
< 1 mm appears to be appropriate.
Is TARGIT protective against cardiac and cancer mortality?
TARGIT-B trial is testing the superiority of a TARGIT boost to EBRT boost in young/high-risk
breast cancer patients for local control
It will also be a platform to test this new hypothesis formally
Study arm Control arm
TARGIT boost EBRT boost
TARGIT-B trial
High-risk breast cancer suitable for conservation
< 45 or > 45 years but at high risk/post neoadjuvant
Randomisation
Whole-breast EBRT
Trial to test superiority (n = 1796)
TARGIT-B trial is
open to recruitment
Please contact
jayantvaidya@gmail.com
FIGURE 29 Could TARGIT be protective against heart attacks and deaths from other cancers? This hypothesis will
be tested in the TARGIT-B trial.
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Chapter 6 Cost–utility analysis of external beam
radiotherapy compared with targeted intraoperative
radiotherapy in breast cancer
Background
There is limited evidence about the cost-effectiveness of TARGIT. Picot et al.72 recently undertook a
systematic review of published economic evaluations and found two primary studies.73,74 Both were
modelling studies using aggregate data from the TARGIT-A trial supplemented with data from other
sources. Alvarado et al.73 found that TARGIT was less costly and produced more quality-adjusted life-years
(QALYs) than EBRT and concluded that TARGIT was the dominant strategy. Based on the results of a
cost-minimisation analysis,72 TARGIT was associated with substantial cost savings compared with whole-
breast irradiation delivered using three-dimensional conformal radiotherapy or accelerated PBI delivered
with intensity-modulated radiotherapy. Both studies were based in the USA and because of differences in
treatment practices and patients the results are unlikely to be applicable to the UK.
Picot et al.72 undertook a UK-based cost–utility analysis of TARGIT using data from the TARGIT-A trial
supplemented with data from other sources. They found that TARGIT was less costly than EBRT and also
less effective, producing fewer QALYs. This is more relevant than the studies by Alvarado et al.73 and
Shah et al.74 because it is a UK-based study, but it is a modelling study using aggregate data from the
TARGIT-A trial. Hence, we undertook a cost–utility analysis of TARGIT compared with EBRT using
patient-level data from the TARGIT-A trial.
Methods
Patients
The analysis was based on costs and outcomes for the 817 patients randomised in the ‘earliest cohort’ in
the prepathology stratum of the TARGIT-A trial. Several issues were considered when deciding which
cohort of patients to include in the cost–utility analysis:
1. We did not include the postpathology stratum from the earliest cohort because the results in this group
were less favourable than those of the prepathology stratum. Hence, it is highly unlikely that TARGIT
would be adopted in clinical practice for this group. As patients from this stratum were not included in
the analysis, the results cannot be applied to this group.
2. The number of participants needed to prove non-inferiority was calculated to be 585 and therefore the
earliest cohort of 817 patients had enough power to draw reliable conclusions.
3. The earliest cohort was randomised between 2000 and 2008 and the average follow-up was 5 years,
permitting a reasonable follow-up period without a large number of missing data. The complete
prepathology stratum from TARGIT-A consisted of 2298 patients, with an average follow-up of 2 years
4 months. Hence, by including the full cohort we would have substantially increased the proportion of
missing data in the sample if we wanted to use a 5-year time horizon or we would have had to use a
shorter time horizon.
We therefore balanced the number of patients in the whole cohort compared with the number in the
earliest cohort against the duration of follow-up in the two cohorts against the fact that the earliest cohort
had enough statistical power to draw reliable conclusions and decided to base our analysis on the 817
patients randomised in the earliest cohort of the TARGIT-A trial in the prepathology stratum. In this cohort,
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as in the mature cohort in the prepathology stratum and all patients in the prepathology stratum, TARGIT
was non-inferior to EBRT with respect to local recurrence and the 5-year estimated risks of local recurrence
were not statistically different between the treatment groups.
Overview of the cost–utility analysis
We undertook a cost–utility analysis to compare the costs and outcomes associated with TARGIT compared
with EBRT in the prepathology stratum of the TARGIT-A trial. The outcome measure was QALYs, which
combine length of life and quality of life, consistent with NICE guidelines.75 Cost-effectiveness was
expressed as incremental net monetary benefits.75 The analysis took a UK NHS and personal social services
(PSS) perspective.75 Resource use data were included from all participating centres and UK unit costs were
applied. Costs are presented in 2013/14 UK pounds. The time horizon was 5 years, reflecting the average
follow-up in the earliest cohort in the prepathology stratum of the TARGIT-A trial. Extrapolation beyond
the end of the trial using decision-analytical modelling was not undertaken because the within-trial analysis
found no evidence of significant differences in QALYs between the groups. This probably reflects the main
finding from the TARGIT-A trial that TARGIT was non-inferior to EBRT with regard to local recurrence.
Although there was some evidence of differences in costs, these differences were accrued during the first
year, with no evidence of significant differences in costs beyond the first year. Hence, the 5-year time
horizon was long enough to reflect all important differences in costs or outcomes between the two
treatments. An annual discount rate of 3.5% was applied to costs and outcomes.75
Resource use and costs
Cost components
We calculated the costs incurred by every patient during the 5-year time horizon using resource use and
event data collected prospectively in the trial. The following costs were included: TARGIT, EBRT, index
procedure, additional procedures, chemotherapy, mastectomy, complications, recurrence-free survival,
local recurrence, distant recurrence, breast cancer deaths and non-breast-cancer deaths. Unit costs were
obtained from published sources72,76–80 (Table 12), inflated when appropriate82 and multiplied by resource
use. Annual costs were calculated for every patient for each year of the 5-year time horizon. These were
discounted and summed across all 5 years to calculate total costs per patient over the whole period.
TABLE 12 Unit costs
Cost item Unit costa Notes/source
TARGIT £1882 per patient Picot et al.72 Base-case value calculated assuming 126
procedures performed per year and a 10-year lifetime
of the INTRABEAM device
EBRT £123 per fraction Department of Health76 – Currency code SC23Z.
Outpatients
£769 for planning
meeting
Department of Health76 – Currency code SC52Z.
Outpatients
EBRT boost £126 per fraction Department of Health76 – Currency code SC23Z.
Outpatients
£769 for planning
meeting
Department of Health76 – Currency code SC52Z.
Outpatients
NHS patient transport £68 per return journey Department of Health77 – Currency code PTS.
Outpatients
Index procedure £1128 per procedure Department of Health76 – Currency code JA09G.
Combined day case/ordinary elective spell
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TABLE 12 Unit costs (continued )
Cost item Unit costa Notes/source
Overnight stay related to index
procedure
£227 per additional
overnight stay
Department of Health76 – Currency code JA09G.
Long stay for days exceeding time point
Mastectomy with breast reconstruction £6504 per procedure Department of Health76 – Currency code JA16Z.
Combined day case/ordinary elective spell
Additional procedures (excision of
positive margins, axillary dissection or
clearance)
£1128 per procedure Department of Health76 – Currency code JA09G.
Combined day case/ordinary elective spell
Chemotherapy £2087 per course of
treatment
NICE78 – docetaxel infusion every 21 days (six cycles).
Department of Health76 – Currency code first
attendance SB14Z, subsequent attendance SB15Z.
Outpatient
Complications
Surgical evacuation of haematoma £362 per procedure Department of Health76 – Currency Code JA12C.
Day case
Aspiration for seroma £397 per complication Department of Health76 – treatment function 370,
consultant led WF01B for first and WF01A for second
and third aspirations. Only applied each time three
aspirations of seroma noted. Outpatient
Wound infection requiring oral
antibiotics
£2.60 per course of
treatment
British National Formulary79 – treatment using
flucloxacillin 500mg, £2.60 for a 28-tablet pack
(1 week)
Wound infection requiring
intravenous antibiotics
£362 per course of
treatment
Department of Health76 – Currency code JA12C.
Day case
Skin breakdown/delayed wound
healing
£29 per course of
treatment
British National Formulary79 – soft non-woven dressing
impregnated with Intrasite® (Smith & Nephew,
London, UK) gel, 10 cm × 10 cm, £1.70 (2 weeks) =
£23.80 plus flucloxacillin 500 mg, £2.60 for a
28-tablet pack (2 weeks)= £5.20
RTOG toxicity grade 3 £5 per course of
treatment
British National Formulary79 – aqueous cream 500 g
RTOG toxicity grade 4 £23.80 per course of
treatment
British National Formulary79 – soft non-woven dressing
impregnated with Intrasite® gel, 10 cm× 10 cm, £1.70
(2 weeks)= £23.80
Pain in the irradiated field £3 per course of
treatment
British National Formulary79 – paracetamol 500 mg,
100-tablet pack
Events
Recurrence free £1057 per year Hind et al.81 – one oncologist visit per year for 5 years,
one mammogram per year for 5 years, 5 years of
anstrozole/tamoxifen (70 : 30) hormonal therapy
Local recurrence Mean £4956 (SD
£3953) per recurrence
Mean (SD) from patient-level costing
Distant recurrence £1040 per month Hind et al.81 – monthly cost of supportive care for
metastatic breast cancer
Breast cancer death £3659 per death Hind et al.81 – cost of death from breast cancer
Non-breast-cancer death £3659 per death Hind et al.81 – assumed to be the same as cost of
death from breast cancer
SD, standard deviation.
a Costs are in 2013/14 UK pounds.
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Targeted intraoperative radiotherapy
A fixed cost per patient was assumed for TARGIT, based on recently published calculations by Picot et al.72
This cost includes one-off capital costs and annual maintenance costs associated with the INTRABEAM
device; one-off, annual and per-treatment costs requiring additional staff resources; the cost of
consumables required for each use of the device; and the cost of additional operating theatre time for
each use of the device. The capital and one-off costs were annualised using a device lifetime of 10 years.
These costs and the annual costs were assigned to individual treatments assuming that each device was
used to undertake 126 procedures per year. On this basis Picot et al.72 calculate the unit cost per patient to
be £1882 (2013/14 prices), which is the value that we used in our analysis for the base case. This was
varied in sensitivity analysis.
External beam radiotherapy
Patient-level data were collected in the TARGIT-A trial on the number of fractions of EBRT received by each
patient. A proportion of patients randomised to TARGIT also received EBRT and these were also included
in the analysis. The mean [standard deviation (SD)] number of fractions given to patients in the trial
who received EBRT was 23 (5). This is higher than current recommendations stating that 15 fractions
are required to complete a course of treatment for patients with early invasive breast cancer after
breast-conserving surgery or mastectomy.78 In our base case we therefore assumed that all patients in the
TARGIT-A trial who received EBRT received a fixed number of 15 fractions. We applied a unit cost per
fraction plus a one-off cost for a planning meeting (see Table 12). In sensitivity analyses we estimated
cost-effectiveness based on the actual number of fractions of EBRT received in the trial.
Standard treatment of breast cancer includes an EBRT boost as part of the course of whole-breast
radiotherapy; however, it is sometimes omitted in patients at a lower risk of local recurrence.83–85 In the
TARGIT-A trial, patient-level data were also recorded on whether or not patients received an EBRT boost
and if so the number of fractions received. These were included in our base case. We applied a unit cost
per fraction plus a one-off cost for an additional planning meeting (see Table 12). In sensitivity analysis we
estimated cost-effectiveness assuming no EBRT boost.
External beam radiotherapy requires several trips to hospital for treatment, incurring time and travel costs
for patients and their families. Our analysis was undertaken from a NHS and PSS perspective and so we did
not include these costs. However, some patients use NHS patient transport to travel to hospital for EBRT,
which is a cost incurred by the NHS. We were unable to find any pre-existing evidence on the proportion
of EBRT patients who use NHS patient transport and so we undertook a short survey at two sites. The first
site was Great Western Hospital in Swindon, where patients receiving EBRT typically travel to radiotherapy
centres at the John Radcliffe Hospital, Oxford, the Royal United Hospital, Bath, or Cheltenham General
Hospital for treatment. The second was Princess Alexandra Hospital, Harlow, where patients typically travel
to North Middlesex Hospital, Enfield, for treatment. Patients were asked to indicate their method of
transport to the radiotherapy centre, with possible responses being by car, by hospital transport or by
public transport. We received 37 responses (17 from patients at Great Western Hospital and 20 from
patients at Princess Alexandra Hospital), with five (13.5%) patients reporting using hospital transport. In
our base case we therefore assumed that 13.5% of patients receiving EBRT use NHS patient transport over
the course of their treatment and applied a unit cost per return journey (see Table 12). We varied the
proportion of patients using NHS patient transport to travel to hospital for EBRT in sensitivity analysis.
Other cost components
The cost of the index procedure included the cost of the lumpectomy procedure itself plus the cost of any
associated hospital stay, which was recorded in the trial. Any additional procedures related to excision of
margins or axillary dissection and/or clearance were recorded, as well as whether or not the patient
received chemotherapy and had a mastectomy. For the index procedure, additional procedures and
mastectomies, unit costs based on NHS reference costs76 were applied. Costs for a course of chemotherapy
were based on current treatment recommendations.78
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Data were recorded in the trial on the number of the following complications: haematoma requiring
surgical evacuation; seroma requiring three or more aspirations; infection requiring oral or intravenous
antibiotics or surgical intervention; skin breakdown or delayed wound healing; and RTOG toxicity of grade
3 or 4. Details were recorded on how each individual complication was treated and these were costed
separately and included in the analysis (see Table 12).
We included the costs of remaining recurrence free, local recurrence, distant recurrence, breast cancer
death and non-breast-cancer death. Unit costs were taken from a published source81 and applied to
patient-level data from the trial. Treatments for local recurrence were recorded in the trial and were costed
on an individual patient basis. Treatments for local recurrence included mastectomy, TARGIT, EBRT,
hormone therapy and chemotherapy. The mean (SD) cost per patient of local recurrence was £4956
(£3953; see Table 12).
Utilities and quality-adjusted life-years
The outcome measure in our cost–utility analysis was QALYs, which combine length of life and quality of
life, the latter being measured by utility scores. A utility score of 1 represents full health and a score of 0
denotes death; negative values represent states worse than death.
Utility data were not collected in the TARGIT-A trial. Patient-level data on the timing of events were
collected and for every patient we created a data set describing the health state that they were in during
every day of the 5-year time horizon. Utility values from published sources were then applied to each
health state. These were used to construct five 1-year utility profiles for every patient covering the 5-year
time horizon. QALYs for every patient for each year were calculated as the area under the utility profile for
that year. These were discounted and summed across all 5 years to calculate QALYs per patient over the
whole period.
The health states included in the cost–utility analysis were recurrence free, local recurrence, distant
recurrence, breast cancer death and non-breast-cancer death. A review of the Cost-Effectiveness Analysis
Registry86 was undertaken using the search term ‘breast cancer’ to identify studies reporting relevant utility
scores and 1291 results (utility scores) were identified. Picot et al.72 recently undertook an extensive
literature search of studies providing utility values for such patients and identified nine suitable studies.
The criteria for the values that they selected in their analysis were that they would ideally be based on
EQ-5D scores, would ideally have been derived from UK patients and these patients would ideally reflect
the younger age range of patients in the TARGIT-A trial. The values that they selected, from studies by
Turnbull et al.87 and Lidgren et al.,88 were as follows:
l recurrence free in first year: 0.7728
l recurrence free after first year: 0.8112
l local recurrence: 0.8112
l recurrence free after local recurrence: 0.8112
l distant recurrence: 0.658.
We used these values in our base case. The values imply that the utility associated with local recurrence is
the same as the utility associated with being recurrence free after the first year and the utility associated
with being recurrence free after local recurrence. We undertook a sensitivity analysis using values from an
alternative study by Hayman et al.,89,90 which have been used in previous studies, as follows:
l recurrence free: 0.92
l local recurrence: 0.87
l recurrence free after local recurrence: 0.92
l distant recurrence: 0.70.
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Patients who died in the TARGIT-A trial (either from breast cancer or from other causes) were assigned a
utility value of 0 at their date of death until the end of the 5-year time horizon.
In the cost–utility analysis we did not incorporate utility losses associated with additional procedures,
chemotherapy, mastectomy or complications. Given the low incidence of these events, that they were
evenly distributed between treatment groups and that the time period affected is likely to be short, this is
unlikely to affect the QALYs associated with each treatment group. We also did not include any utility
losses associated with EBRT. Therefore, this would make our estimates more conservative because such an
omission would work against TARGIT.
Missing data
There were some missing data on patient follow-up, meaning that for some patients we did not know
whether or not they had experienced events. This affected both the total costs incurred by each patient
and the total QALYs. Multiple imputation was used to impute missing data separately for costs in years
1–5, total costs, QALYs in years 1–5 and total QALYs. The following variables were included in the
imputation models as additional explanatory variables: cost of EBRT, cost of the index procedure, cost of
additional procedures, cost of chemotherapy, cost of mastectomy, whether or not the patient had each
type of complication, age at randomisation, tumour size in millimetres at randomisation, ER status at
randomisation, PgR status at randomisation, contralateral cancer or not, whether the cancer was screen
detected or not, study centre, year of randomisation and treatment allocation. We used multivariate
normal regression to impute missing values and generated 20 imputed data sets. We repeated the multiple
imputation several times using different random number seeds to investigate whether or not the
conclusions of the analysis changed.
Statistical methods
Mean costs, outcomes and net monetary benefits were compared between all patients randomly assigned
to EBRT and TARGIT, irrespective of which treatment was administered and whether or not patients
received additional therapies of either type. We calculated differences in mean costs and QALYs and
incremental net monetary benefits between groups. Net monetary benefits for EBRT and TARGiT were
calculated as the mean QALYs per patient multiplied by the maximum willingness to pay for a QALY minus
the mean cost per patient. Incremental net monetary benefits were calculated as the difference in mean
QALYs per patient with TARGIT compared with EBRT multiplied by the maximum willingness to pay for a
QALY minus the difference in mean costs per patient. We used the cost-effectiveness threshold range
recommended by NICE of £20,000–30,00075 as the lower and upper limits of the maximum willingness to
pay for a QALY. If the incremental net monetary benefit is positive (negative) then TARGIT (EBRT) is
preferred on cost-effectiveness grounds. The QALYs gained and incremental costs were adjusted for age at
randomisation, tumour size in millimetres at randomisation, ER status at randomisation, PgR status at
randomisation, contralateral cancer or not, whether the cancer was screen detected or not, study centre
and year of randomisation. For each of the 20 imputed data sets we ran 1000 bootstrap replications and
combined the results using equations described by Briggs et al.91 to calculate standard errors (SEs) around
mean values accounting for uncertainty in the imputed values, the skewed nature of the cost data and
utility values and sampling variation. SEs were used to calculate 95% CIs around point estimates. A similar
analytical approach has been used previously.92
Sensitivity analyses
We undertook deterministic sensitivity analyses to evaluate the impact of uncertainty in the following
components. In each case the changes made were applied one at a time to the base case.
l No adjustment for age at randomisation, tumour size in millimetres at randomisation, ER status at
randomisation, PgR status at randomisation, contralateral cancer or not, whether the cancer was screen
detected or not, study centre and year of randomisation.
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l Complete case analysis without imputing missing values.
l Complete case analysis without imputing missing values plus with no adjustment for age at
randomisation, tumour size in millimetres at randomisation, ER status at randomisation, PgR status at
randomisation, contralateral cancer or not, whether the cancer was screen detected or not, study
centre and year of randomisation.
l EBRT costs based on number of fractions received in the trial [mean (SD) number of fractions
administered per patient who received EBRT in the trial was 23 (5)].
l No EBRT boost.
l Costs of EBRT per fraction of £101 and £154, based on the lower and upper values of the IQR of the
NHS reference costs.76
l Costs of TARGIT of £1300, £1500, £1700, £1900, £2100, £2300, £2500 and £2700. The value of
£1300 corresponds to the minimum value in Picot et al.,72 in which the capital and one-off costs were
annualised using a device lifetime of 10 years and these costs and the annual costs were assigned to
individual treatments assuming that each device was used to undertake 631 procedures per year.
The value of £2500 corresponds to the maximum value in Picot et al.,72 with a device lifetime of
5 years and 100 procedures per year.
l Percentage of patients using NHS transport for EBRT of 0% (no patients use NHS transport) and 30%.
l Health states valued using utilities from Hayman et al.89,90
A cost-effectiveness acceptability curve93 showing the probability that TARGIT was cost-effective compared
with EBRT at a range of values for the maximum willingness to pay for a QALY was generated based on
the proportion of the bootstrap replications across all 20 imputed data sets with positive incremental net
monetary benefits.94 The probability that TARGIT was cost-effective at a maximum willingness to pay for a
QALY of £20,000 and £30,000 was reported, based on the proportion of bootstrap replications with
positive incremental net monetary benefits at these values.
Results
Resource use and costs
In total, 15.2% of patients randomised to TARGIT also received EBRT (Table 13). We assumed that every
patient receiving EBRT received 15 fractions. In total, 38% of patients randomised to EBRT also received
an EBRT boost [mean (SD) 5 (2) fractions]. We assumed that 13.5% of all EBRT patients used NHS
transport to travel to hospital for their radiotherapy treatment. The mean (median) number of nights in
hospital for the initial procedure was 4 (3) for both TARGIT and EBRT patients. A total of 19% of EBRT
patients received additional procedures, compared with 12% of TARGIT patients. In total, 20% of EBRT
patients received chemotherapy and 4% had a mastectomy; for TARGIT the figures were 23% and 3%,
respectively. The incidence of complications was low in both treatment groups. The number of events for
TARGIT and EBRT were local recurrences (6 vs. 3), distant recurrences (21 vs. 18), breast cancer deaths
(13 vs. 11) and non-breast-cancer deaths (7 vs. 18).
Accounting for missing data using multiple imputation, mean total costs per patient (95% CI) were £11,840
(£11,422 to £12,259) in the EBRT group (n = 416) and £11,404 (£10,800 to £12,008) in the TARGIT group
(n = 401; Table 14). The mean radiotherapy cost per patient (summing the cost of TARGIT plus EBRT plus
EBRT boost plus NHS transport for EBRT) was £3373 in the EBRT group and £2307 in the TARGIT group.
Other costs were similar for EBRT and TARGIT. Values were similar for complete cases (Table 15).
Quality-adjusted life-years
Accounting for missing data using multiple imputation, mean QALYs per year were similar for the two
groups and there was a decline over time. Mean QALYs per patient (95% CI) fell from 0.810 (0.808 to
0.812) in the EBRT group in year 1 to 0.657 (0.640 to 0.674) in year 5. In the TARGIT group the values
were 0.811 (0.810 to 0.811) and 0.674 (0.660 to 0.689), respectively. Mean total QALYs per patient over
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the 5-year period were 3.663 (3.614 to 3.713) in the EBRT group and 3.704 (3.664 to 3.744) in the
TARGIT group (see Table 14). QALYs were similar for complete cases (see Table 15).
Cost–utility analysis
Accounting for missing data using multiple imputation, the mean net monetary benefits for EBRT and TARGIT
were £61,426 (95% CI £60,299 to £62,544) and £62,678 (95% CI £61,542 to £63,762) at a maximum
willingness to pay for a QALY of £20,000 and £98,059 (95% CI £96,470 to £99,644) and £99,720 (95% CI
£98,228 to £101,147) at a maximum willingness to pay for a QALY of £30,000 (see Table 14).
TABLE 13 Summary of data used in the cost–utility analysis
Resource EBRT (n= 416) TARGIT (n= 401)
EBRT, % 100 15.2
Fractions of EBRT, n 15 15
EBRT boost, % 38 0
Boost fractions, mean (SD) 5 (2) –
NHS transport for EBRT, % 13.5 13.5
Index procedure, number of nights
Mean (SD) 4 (4) 4 (4)
Median (IQR) 3 (1–6) 3 (1–6)
Additional procedures, n (%)
0 338 (81) 353 (88)
1 72 (17) 46 (11)
2 5 (1) 1 (0)
3 1 (0) 1 (0)
Chemotherapy, n (%) 84 (20) 93 (23)
Mastectomy, n (%) 17 (4) 13 (3)
Complications, n (%)
Haematoma requiring surgical evacuation or seroma
needing three or more aspirations
1 (0) 1 (0)
Infection requiring oral or intravenous antibiotics or
surgical intervention
5 (1) 5 (1)
Skin breakdown or delayed wound healing,
number (%)
3 (1) 2 (0)
RTOG toxicity grade 3 or 4 9 (2) 2 (0)
Events, n
Local recurrence 3 6
Distant recurrence 18 21
Breast cancer death 11 13
Non breast cancer death 18 7
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TABLE 14 Mean QALYs, costs and net monetary benefits: multiple imputation
Variable
EBRT (n= 416) TARGIT (n= 401)
Mean 95% CI Mean 95% CI
Costs (£)a
TARGIT 0 b 1882 b
EBRT 2659 b 405 b
EBRT boost 557 487 to 628 0 b
NHS transport for EBRT 157 154 to 160 21 b
Total EBRT 3373 3300 to 3447 425 b
Total EBRT plus TARGIT 3373 3300 to 3447 2307 b
Index operation 2069 1986 to 2153 2101 2009 to 2193
Additional procedures 230 182 to 279 143 103 to 184
Chemotherapy 421 341 to 502 484 397 to 571
Mastectomy 266 142 to 390 211 98 to 324
Costs associated with health statusc
Year 1 1099 1063 to 1135 1124 1052 to 1196
Year 2 1176 1073 to 1278 1254 1123 to 1384
Year 3 1126 1014 to 1237 1265 1108 to 1423
Year 4 1059 945 to 1173 1269 1099 to 1438
Year 5 1020 879 to 1161 1246 1072 to 1420
Total costs 11,840 11,422 to 12,259 11,404 10,800 to 12,008
QALYs
Year 1 0.810 0.808 to 0.8120 0.811 0.810 to 0.811
Year 2 0.774 0.766 to 0.781 0.777 0.772 to 0.782
Year 3 0.728 0.714 to 0.742 0.738 0.727 to 0.749
Year 4 0.695 0.679 to 0.710 0.704 0.691 to 0.717
Year 5 0.657 0.640 to 0.674 0.674 0.660 to 0.689
Total QALYs 3.663 3.614 to 3.713 3.704 3.664 to 3.744
Net monetary benefits (£)
£20,000 61,426 60,299 to 62,544 62,678 61,542 to 63,762
£30,000 98,059 96,470 to 99,644 99,720 98,228 to 101,147
a Costs are in 2013/14 UK pounds.
b Values do not vary by patient.
c Costs associated with being disease free, local recurrence, distant recurrence, breast cancer death, non-breast-cancer
death and complications.
Notes
Data include values imputed using multiple imputation (see Missing data and Statistical methods). The 95% CIs were
derived from 1000 bootstrap replications of each of the 20 imputed data sets (see Missing data and Statistical methods).
The net monetary benefit is calculated at a maximum willingness to pay for a QALY of £20,000 and £30,000.
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In the base-case analysis TARGIT was less costly than EBRT (mean incremental cost –£685) and produced
slightly more QALYs than EBRT (mean QALYs gained 0.034; Table 16). The difference in costs between the
two groups was statistically significant (mean incremental cost for TARGIT vs. EBRT –£685, 95% CI –£1131
to –£63) but the difference in QALYs was not (mean QALYs gained 0.034, 95% CI –0.026 to 0.095). The
incremental net monetary benefit for TARGIT compared with EBRT was positive indicating that TARGIT was
cost-effective: at a maximum willingness to pay for a QALY of £20,000 or £30,000 the mean incremental
net monetary benefit was £1363 and £1730 (see Table 16). The incremental net monetary benefit was not
significantly different from zero at a maximum willingness to pay for a QALY of £20,000 (mean £1363,
95% CI –£66 to £2838) or £30,000 (mean £1730, 95% CI –£284 to £3740). However, the incremental net
monetary benefit for TARGIT compared with EBRT was borderline significantly different from zero: at a
maximum willingness to pay for a QALY of £20,000 the 90% CI was £175 to £2818 and at £30,000 it was
TABLE 15 Mean QALYs, costs and net monetary benefits: complete cases
Variable
EBRT TARGIT
Mean SD n Mean SD n
Costs (£)a
TARGIT 0 0 416 1882 0 401
EBRT 2659 0 416 405 0 401
EBRT boost 557 733 416 0 0 401
NHS transport for EBRT 157 28 416 21 0 401
Total EBRT 3373 760 416 425 0 401
Total EBRT plus TARGIT 3373 760 416 2307 0 401
Index operation 2069 865 416 2101 937 401
Additional procedures 230 506 416 143 409 401
Chemotherapy 421 839 416 484 882 401
Mastectomy 266 1289 416 211 1153 401
Costs associated with health statusb
Year 1 1099 347 406 1125 730 393
Year 2 1184 1040 395 1261 1325 388
Year 3 1129 1130 387 1264 1600 382
Year 4 1052 1113 360 1279 1771 354
Year 5 1057 1301 266 1260 1916 233
Total costs 11,956 4656 266 11,789 7301 233
QALYs
Year 1 0.810 0.019 406 0.811 0.006 393
Year 2 0.773 0.078 395 0.777 0.052 388
Year 3 0.726 0.143 387 0.737 0.110 382
Year 4 0.689 0.167 360 0.700 0.136 354
Year 5 0.631 0.214 266 0.651 0.183 231
Total QALYs 3.593 0.620 266 3.642 0.518 231
a Costs are in 2013/14 UK pounds.
b Costs associated with being disease free, local recurrence, distant recurrence, breast cancer death, non-breast-cancer
death and complications.
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£38 to £3746. In a hypothesis test, this would indicate that against a null hypothesis the incremental net
monetary benefit equals zero; the p-value for rejecting the null hypothesis would be between 0.05 and 0.1.
We repeated the analysis several times using alternative versions of the multiple imputation process using
different random number seeds to investigate whether or not the conclusions of the analysis changed;
in every case the results were qualitatively the same.
Sensitivity analyses
In all but one of the scenarios tested in the deterministic sensitivity analysis TARGIT was less costly than EBRT
(Table 17). The exception was when the cost of TARGIT was £2700 per patient, which is higher than the
maximum value in Picot et al.72 (£2500). The costs were statistically significantly lower for TARGIT compared
with EBRT (the 95% CI did not cross zero) when EBRT costs were based on the number of fractions received
in the trial, the unit cost per fraction of EBRT was £154 (the upper quartile unit cost in the NHS reference
costs76), the cost of TARGIT was ≤ £1900 per patient and the alternative utility values were used.
In every case the QALYs gained were small, positive and non-significant. Note that these were unlikely to
change given that the parameters varied in the deterministic sensitivity analysis were mainly cost parameters.
In all cases tested the incremental net monetary benefits for TARGIT compared with EBRT were positive
at a maximum willingness to pay for a QALY of £20,000 and £30,000. The incremental net monetary
benefits were significantly greater than zero (the 95% CI did not cross zero) when EBRT costs were based
on the number of fractions received in the trial, the unit cost per fraction of EBRT was £154 and the
cost of TARGIT was ≤ £1700 per patient at a maximum willingness to pay for a QALY of £20,000 or
≤ £1300 per patient at a maximum willingness to pay for a QALY of £30,000.
The probability that EBRT is cost-effective is equal to 1 minus the probability that TARGIT is cost-effective
at each value of the maximum willingness to pay for a QALY. The cost-effectiveness acceptability curve
shows that, at a maximum willingness to pay for a QALY of £20,000 (£30,000), the probability that
TARGIT was cost-effective was 0.965 (0.950) in the base case (Figure 30 and see Table 17). In the
deterministic sensitivity analyses the probability that TARGIT was cost-effective at a maximum willingness
TABLE 16 Incremental cost-effectiveness of TARGIT compared with EBRT: base case
Parameter Mean 95% CI
Incremental costs (£),a TARGIT vs. EBRT –685 –1341 to –63
QALYs gained, TARGIT vs. EBRT 0.034 –0.026 to 0.095
Incremental net monetary benefits (£), TARGIT vs. EBRT
£20,000 1363 –66 to 2838
£30,000 1703 –284 to 3740
Probability TARGIT cost-effective p-value
£20,000 0.965
£30,000 0.950
a Costs are in 2013/14 UK pounds.
Notes
Data include values imputed using multiple imputation (see Missing data and Statistical methods). The 95% CIs were
derived from 1000 bootstrap replications of each of the 20 imputed data sets (see Missing data and Statistical methods).
The QALYs gained and incremental costs are adjusted for age, tumour size, ER status and PgR status at baseline, whether
the cancer was detected by screening or not, contralateral breast cancer or not, year of randomisation and centre. The
incremental net monetary benefit and the probability that TARGIT is cost-effective are based on the adjusted QALYs gained
and incremental costs and calculated at a maximum willingness to pay for a QALY of £20,000 and £30,000.
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to pay for a QALY of £20,000 was > 0.75 in every case. At a maximum willingness to pay for a QALY of
£30,000 the probability that TARGIT was cost-effective was > 0.80 in every case.
Potential budget impact
The cost savings per patient found in our base case could translate into cost savings per year for the NHS if
TARGIT was carried our routinely instead of EBRT in eligible patients. The latest available evidence suggests
that in 2011 there were 49,936 new cases of breast cancer in the UK.95 Figures from Germany96 based
on 1108 new cases of breast cancer treated at a single centre between 2003 and 2009 suggest that
258 patients (23.3% cases) would have met the eligibility criteria for participation in the TARGIT-C trial
(ClinicalTrials.gov NCT02290782),97 which has similar but more restrictive inclusion and exclusion criteria
than the TARGIT-A trial (e.g. age ≥ 50 years rather than ≥ 45 years, tumour size ≤ 2 cm rather than
≤ 3.5 cm). This conservatively suggests that around 49,936 × 23.3% = 11,600 patients may be eligible for
TARGIT in the UK each year. Applying the cost saving per patient in our base case to this estimate
suggests that the NHS might save around 11,600 × –£685 = £8 million a year.
Figures from France98 based on two cohorts of patients between 1980 and 2008 indicate that, across
a combined total of 12,025 patients receiving breast-conserving surgery, 5545 patients (46%) would have
been eligible for TARGIT according to the eligibility criteria of the TARGIT-A trial. Approximately 58%
of newly diagnosed patients with breast cancer in the UK undergo lumpectomy.99 Therefore, according to
these figures, around 49,936 × 58% × 46% = 13,300 patients may be eligible for TARGIT in the UK each
year. Applying the cost saving per patient in our base case to this estimate suggests that the NHS might
save around 13,300 × £685 = £9.1 million a year.
Combined, these calculations suggest that if TARGIT was carried our routinely instead of EBRT in eligible
patients the potential cost savings to the NHS would be around £8–9.1 million each year.
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FIGURE 30 Cost-effectiveness acceptability curve showing the probability that TARGIT is cost-effective compared
with EBRT at different values of the maximum willingness to pay for a QALY.
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Discussion
Summary
We undertook a cost–utility analysis comparing TARGIT versus EBRT in the prepathology stratum of the
earliest cohort of the TARGIT-A trial. In our base case TARGIT was statistically significantly less costly than
EBRT, produced similar QALYs, had a positive incremental net monetary benefit that was borderline
statistically significantly different from zero and had a probability of > 90% of being cost-effective.
Although there appears to be some uncertainty about the statistical significance of the differences in costs
and whether or not the incremental net monetary benefit is different from zero, the appears to be little
uncertainty in the point estimates, based on deterministic and probabilistic sensitivity analyses.
Comparison with other studies
Alvarado et al.73 found that TARGIT dominated EBRT (was less costly and more effective) in that it resulted in
a QALY gain of 0.00026 compared with EBRT and cost US$5191 less. Based on their analysis using TARGIT-A
trial data, Shah et al.74 reported that use of TARGIT was associated with cost savings of US$3.6–4.3 million
per 1000 patients compared with EBRT. Neither study reported CIs around the point estimates and so it is
unclear if the QALYs gained or cost savings were significantly different from zero. Our results are qualitatively
similar to those of Alvarado et al.73 in that based on the point estimates in our base case we also found a cost
saving for TARGIT and a small QALY gain compared with EBRT. Our findings are also qualitatively similar to
those of Shah et al.74 in that we also found a cost saving with TARGIT compared with EBRT. However, given
that both studies were US based it is difficult to draw close comparisons.
Picot et al.72 found that TARGIT produced a small cost saving compared with EBRT and a small QALY loss; the
authors’ conclusion was that EBRT was associated with more QALYs than TARGIT at a broadly similar overall
cost. The point estimates of the costs saved per QALY lost were < £20,000, indicating that TARGIT was not
cost-effective (in cases in which an intervention is less costly and less effective than the comparator then for it
to be cost-effective the incremental cost-effectiveness ratio must lie above the threshold value). CIs around
the cost and outcome differences and the incremental cost-effectiveness measures were not reported and so
it is difficult to make a full comparison of the findings. Other than the use of patient-level data, the main
differences between the study by Picot et al.72 and the present study were the time horizon and the range of
costs included. Picot et al.72 modelled costs and outcomes using a time horizon of 40 years, whereas the time
horizon in the present study was 5 years based on the average length of follow-up in the trial. We did not
extrapolate beyond the end of the trial because the within-trial analysis found no evidence of significant
differences in QALYs between the groups and, although there was some evidence of differences in costs,
these differences were all accrued during the first year. In terms of costs included, there were several
differences between the present study and that by Picot et al.72 During the radiotherapy treatment period the
present study included the cost of EBRT boost and NHS transport costs for EBRT, which were not included in
the study by Picot et al.72 More generally, the total cost per patient in the study by Picot et al.72 over the
40-year period, based on the costs included in the analysis, was around £2300 in both groups. In our study
the total cost per patient over the 5-year period, based on the costs included in the analysis, was around
£11,600 in both groups, suggesting large differences in the range of cost components included.
Strengths and limitations
The main strength of our analysis is that it is based on a large international multicentre randomised trial
with detailed information on resource use and events for a median follow-up period of 5 years.
There are several limitations. First, the time horizon was 5 years. Extrapolation beyond the end of the trial
using decision-analytical modelling was not undertaken because the within-trial analysis found no evidence
of significant differences in QALYs between groups during the 5-year period. This probably reflects the
main finding from the TARGIT-A trial that TARGIT was non-inferior to EBRT with regard to local
recurrence. Although there was some evidence of differences in costs these differences were all accrued
during the first year; there was no evidence of significant differences in costs beyond the first year. Hence,
the 5-year time horizon was long enough to reflect all important differences in costs or outcomes between
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the two treatments. Although local recurrence (and other events) are likely to continue to occur over a
patient’s lifetime, the evidence from the TARGIT-A trial is that TARGIT is non-inferior to EBRT. Hence,
taking a longer time horizon is unlikely to have affected the results of the incremental analyses.
Second, utility data were not collected in the TARGIT-A trial. We therefore applied utility values from
published sources to the health states experienced by patients in the trial. The utility values that we applied
may not reflect the values of patients in the study. Given the relatively small number of events, and that
the numbers of events were largely not different between the two groups, the QALY differences between
the two groups may not be expected to change much with alternative utility values. This is borne out by
our sensitivity analysis, which showed that the results did not change appreciably when we used
alternative values. We did not incorporate utility losses associated with additional procedures,
chemotherapy, mastectomy or complications in our analysis. Given the low incidence of these events, that
they were evenly distributed between treatment groups and that the time period affected is likely to be
short this is unlikely to affect the QALYs associated with each treatment group. We also did not include
any utility losses associated with EBRT. Therefore, this would make our estimates more conservative
because such an omission would work against TARGIT.
Third, the dose of EBRT administered to patients in the TARGIT-A trial does not reflect current UK
treatment guidelines. This reflects the multinational nature of the trial, plus that it began recruiting patients
in 2000 when treatment recommendations were different. We accounted for this in our base case by
assuming that all patients in the TARGIT-A trial who received EBRT received a fixed number of 15 fractions.
Fourth, the analysis took a NHS/PSS perspective on costs. A wider perspective (e.g. societal) could have
been taken to measure costs, including impacts on the rest of society, patients, families and businesses.
If a wider perspective was taken this should include the additional costs borne by patients and families in
terms of time and travel costs associated with additional radiotherapy visits for EBRT compared with
TARGIT. If these costs were included it is likely that the cost savings attributable to TARGIT would be
greater than demonstrated. Taking the example of the transport costs, we used the figure of 13.5% for
the proportion of patients for whom the NHS paid for transport for radiotherapy visits for EBRT. Assuming
that the same cost is paid out of pocket by the remaining patients, the difference in costs between TARGIT
and EBRT would be increased by £877 to £1562 per patient, taking the total saving to the UK national
economy to between 11,600 × £1562 = £18.1 million and 13,400 × £1562 = £20.9 million each year.
These are crude estimates and further research to evaluate the wider impacts of TARGIT, including on
other costs to the rest of society, would be useful.
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Chapter 7 Discussion
Summary of findings
Targeted intraoperative radiotherapy is risk-adapted one-shot radiotherapy to peritumoural tissues,
designed to be completed during the lumpectomy procedure for removal of cancer, whereas EBRT is given
over a 3- to 6-week course of daily treatments at the radiotherapy centre, a few weeks after lumpectomy.
The TARGIT-A trial found that there was no significant difference in the 5-year local recurrence rate
between TARGIT and EBRT. Non-inferiority was established overall and in the prepathology stratum but
not in the postpathology stratum. There was no difference in 5-year breast cancer mortality between these
two treatments but 5-year mortality from causes other than breast cancer was significantly lower in the
TARGIT arm than in the EBRT arm. Subgroup analysis found that only hormone receptor status had any
impact on the effectiveness of TARGIT. TARGIT was more cost effective than EBRT. As the trial was
conducted in 33 different centres in 11 countries in North America, Europe and Australia, we believe that
the findings would be generalisable to the eligible patient population of at least these continents. There
are 250 centres in five continents now using TARGIT IORT as a part of standard treatment for suitable
patients with breast cancer and about 20,000 patients have been treated as of October 2015.
Non-inferiority for local recurrence
Our primary outcome was non-inferiority in terms of local recurrence. We tested for non-inferiority of the
TARGIT technique for local control within a risk-adapted design. When we designed the trial in 1999, we
set the margin of non-inferiority to be an absolute difference in the local recurrence rate of 2.5%. This is a
stringent and relatively conservative margin compared with that in contemporary studies. For example, the
only other trial of IORT – the ELIOT trial35 – was set up with the assumption that a difference of 7.5% in
local recurrence between the experimental and the control groups would result in the two treatments
being considered as equivalent. The Cancer and Leukemia Group B (CALGB) study11 found that there was
a 7% difference in local recurrence when radiotherapy was omitted in low-risk (T1N0) patients aged
> 70 years and concluded that this difference was not significant. Furthermore, two patient preference
studies conducted in parallel with the main trial have also corroborated that, given the convenience of a
single treatment session, the median increase in local recurrence that patients would be ready to accept is
2.5%.100,101 Most importantly, analyses by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
indicate that an absolute increase in local recurrence of < 10% does not result in any increase in mortality
and therefore we did not feel that there were any ethical concerns in setting up this study.4–6 We were also
certain that the trial was well powered to detect a difference of ≥ 2.5% and therefore that if the results
showed non-inferiority they could be relied on. In fact, we provided detailed calculations of how, in view
of the recurrence rates seen in the trial, 585 patients would have provided sufficient power for the trial.
Although non-inferiority trials are becoming more common, especially when cure rates are high and a
reduction in treatment toxicity without a loss of efficacy is desirable, the concept of non-inferiority can be
difficult to grasp. The TARGIT-A trial was such a non-inferiority trial, which meant that, even if there was a
statistically significant difference between the groups, as long as it was less than the pre-specified value
(2.5% in the TARGIT-A trial), the two groups would be judged to be non-inferior to each other. In these
circumstances, less expensive, less toxic or more convenient treatment becomes the preferred choice
(Figure 31).
The pre-specified non-inferiority boundary of a 2.5% absolute difference in local recurrence is very
conservative and has been validated in patient preference studies.101,103,104 It is much smaller than the 7.5%
margin in the ELIOT trial105 and lower than the difference considered ‘acceptable’ by the CALGB (5%
difference)11 and Post-operative Radiotherapy In Minimum-risk Elderly (PRIME) II (3% difference)106 studies.
At this boundary, TARGIT was non-inferior to EBRT (Pnon-inferiority < 0.00001). Within the trial of 3451
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patients, the first 1222 patients had a median follow-up of 5-years; the safety, efficacy and non-inferiority
results of these 1222 patients were similar to those seen in all patients (see Table 8).2
We found that, when all patients were analysed together, the risk of local recurrence for TARGIT was
non-inferior to that for EBRT (5-year risk: TARGIT 3.3% vs. EBRT 1.3%). We had pre-specified that the
significant p-value for difference for the log-rank test would be < 0.01 for local recurrence, as this was
the second such analysis. Therefore, the 2% absolute difference was not only within the non-inferiority
margin but also, as the p-value was 0.04, strictly speaking, it was not statistically significant.
We used the standard method of using binomial proportions to calculate the non-inferiority statistic,
rather than using single 5-year point estimates, which do not represent absolute events and can lead to
erroneous conclusions, especially when the event rate is low. The standard method that we used makes a
comprehensive assessment of the whole follow-up period, which stretches from the day of randomisation
to the longest follow-up of more than 12 years and includes all events in that period. To address the issue
of follow-up, we repeated the analysis by restricting the analysis to cohorts randomised early in the trial,
including the earliest 1222 patients; these patients had a median follow-up of 5 years. The multiple
comparisons issue does not apply here as we have not chosen one of several comparisons to make our
conclusions but rather used all three comparisons to draw an informed conclusion.
When analysed according to the timing of randomisation/delivery of TARGIT, we found that, whereas the
trial as a whole as well as the prepathology stratum confirmed the non-inferiority of TARGIT, the difference
in local recurrence in the postpathology stratum was > 2.5%. Therefore, we have recommended that
TARGIT should be used during the initial lumpectomy, as in the prepathology stratum (note that this is a
stratum not a subgroup), in which the difference between the two treatments was undoubtedly not
statistically significant (p = 0.31). Finally, survival without local recurrence (in which deaths are not
censored, in line with recommendations by the US Food and Drug Administration62 and elsewhere63)
was not statistically different between the two arms (see Figures 18 and 19).
Toxicity
There was no increased wound-related toxicity with TARGIT and there was reduced radiotherapy-related
skin toxicity. This was not negated by the EBRT boost delivered to 15% of the TARGIT arm patients;
toxicity was the same whether such an EBRT boost was applied to TARGIT or EBRT patients.107
There were significantly fewer grade 3 or 4 radiotherapy-related complications in the TARGIT arm;
however, one should note that the incidence of these complications was very low in both arms of the trial.
This, and the low local recurrence rate reported, is a testament to the high-quality radiotherapy given in
the EBRT arm.
Studies conducted parallel to the TARGIT-A trial in individual centres have shown that TARGIT delivers a
better cosmetic outcome,108 lower short-term and long-term skin toxicity and an overall better quality
of life.107,109,110
Mortality
Although the number of breast cancer deaths did not differ significantly between groups, there were
significantly fewer deaths from other causes in the TARGIT arm of the trial (number of deaths from causes
other than breast cancer: TARGIT 17, EBRT 35). In particular, there were far fewer deaths from cancers
other than breast cancer (TARGIT 8 vs. 16) or from cardiovascular disease (EBRT 2 vs. 11).
This early decrease in cardiovascular deaths was somewhat surprising as it was previously believed that any
EBRT-related increase in cardiovascular disease would not be apparent until 7–10 years after radiation.3
On the other hand, given the size of the trial, it is unlikely that there was a significant imbalance in
baseline comorbidities and, statistically, the probability of observing the difference we observed if, in
reality, there was no real difference in non-breast-cancer mortality between the randomised arms, is very
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low (p = 0.0086). The difference is also unlikely to be caused by poor EBRT delivery, given the low rates of
local recurrence (1.2%) and grade 3/4 radiotherapy toxicity (2.1%) among patients receiving EBRT. These
results therefore deserve a search for an explanation, rather than dismissal.
Indeed, a large recent study from a group from Oxford, UK, published in the New England Journal of
Medicine, has shown that EBRT toxicity appears within the first 5 years.71 The authors found an increase in
cardiac mortality of 16.3% per gray in the first 5 years, 15.5% in the second 5 years, 1.2% in the years
10–19 and 8.2% after 20 years. As the effect appears to be the largest in the first 10 years – more than
twice that of the average – the yardstick should be based on the period of follow-up and it would be
wrong to use the average value of a 7.4% increase in cardiac mortality per gray as a yardstick. The higher
increase in the first 5 and 10 years is consistent with our findings as they fall within each others’ 95% CIs.
It is possible that the TARGIT-A trial may have uncovered a very small increase in non-breast-cancer
mortality associated with EBRT that has previously been masked by breast cancer deaths. The 5-year risk of
breast cancer mortality was 2.2% in TARGIT-A, compared with, for instance, 30% in the Cancer Research
Campaign (CRC)1 trial111 (Figure 32). The absolute difference in non-breast-cancer mortality in the
TARGIT-A trial was just 2.1% (TARGIT 1.4% vs. EBRT 3.5%) and approximately one-third of this increase
(0.6%) was from cardiac causes.
As can be seen in Figure 32, the difference in deaths from other causes starts becoming apparent only
when the deaths from breast cancer start levelling off. The slope of the curve denoting breast cancer
deaths at 10 years in the CRC1 trial is similar to that seen in the TARGIT-A trial from the beginning, which
has probably allowed us to see the small difference in non-breast-cancer morality between those who
received some irradiation to the heart and other organs and those who did not. This idea may well explain
the recently published results of a meta-analysis of randomised trials comparing PBI and whole-breast
irradiation.112 The meta-analysis demonstrates a reduction in non-breast-cancer and overall mortality with
PBI compared with whole-breast irradiation.
Alternatively, we believe that TARGIT may in fact be protective against deaths from cardiovascular causes
and other cancers,69,70,113 perhaps through a reduction of the systemic inflammatory response that
potentiates cardiovascular diseases or cancers; this, in combination with the reduced radiation toxicity, may
be the cause of the difference that we have observed here. The first hints of this may be found in the
finding of a significantly lower non-breast-cancer mortality hazard in patients who received TARGIT + EBRT
than in those receiving EBRT alone. It is worth keeping in mind, however, that this comparison was
non-randomised and the numbers were small.
Further research into the potential positive effects of TARGIT given alongside EBRT is currently under way
in the TARGIT-B trial, which is looking at the impact of TARGIT given as a radiotherapy boost.
Strengths and limitations
Trial design: experimental treatment = a risk-adapted approach
The TARGIT-A trial was a pragmatic trial that tested two radiotherapy policies for non-inferiority in local
recurrence after breast-conserving surgery: risk-adapted radiotherapy and conventional standard
radiotherapy given daily over several weeks.
Following breast-conserving surgery, the control arm received EBRT over several weeks according to local
treatment guidelines. This conventional treatment does not normally vary with tumour characteristics and
everyone receives the same dose of whole-breast radiation, although there could be variation between
centres. There could also be some variation in terms of delivery or omission of the tumour bed boost
depending on the age of the patient.
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The experimental arm, on the other hand, aimed to deliver all radiotherapy in a single dose in the majority
of patients, using the TARGIT technique and the INTRABEAM device. TARGIT was given either at the time
of lumpectomy (the prepathology stratum, 2298 patients) or as a second procedure several days after the
initial lumpectomy, by reopening the wound (the postpathology stratum, 1153 patients).
The risk-adapted design meant that, if after TARGIT adverse features were found in the final
histopathological specimen, the trial protocol mandated the addition of EBRT to the rest of the breast
(excluding a tumour bed boost). Individual centres decided on the set of histological adverse features
before randomisation began, in addition to the factors stipulated in the core protocol: the presence of
positive margins, evidence of an invasive lobular carcinoma or an EIC.
Such additional EBRT was needed in 15% of cases, as per our original estimations. This proportion was
higher in the prepathology stratum, with one-fifth of the patients receiving TARGIT at the time of their
primary surgery also being given EBRT because of adverse prognostic factors as determined in the
multidisciplinary discussion of the full histopathology after surgery. This adaptation of the treatment based
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on risk should ensure that the experimental group in our clinical trial reflects how TARGIT would be delivered
in the real world; meanwhile, the patients in the EBRT arm provided a good control group, representing how
the treatment is currently given, according to local guidelines. The trial should therefore tell us how the
outcome for patients would change (or not) if TARGIT were to be introduced into routine clinical practice.
We believe that this is the only method of accurately reflecting practice in the real world, without sacrificing
statistical validity; it may be disappointing for the women who needed supplemental EBRT but it is worth
remembering that TARGIT allows the large majority of patients to avoid several weeks of EBRT.
We believe that this type of pragmatic non-inferiority design is a strength of the trial, although at the
same time it could make it more difficult for purists to interpret the results. This is quite contrary to how
patients and the lay public interpret the results – they have consistently felt that the small statistically
non-significant difference in local recurrence was really not a concern, particularly compared with the great
benefit and convenience of patients being able to have all of their treatment in one sitting100,101,103,104,114,115
[see http://goo.gl/j3jyM1, http://goo.gl/x6Sk80, http://goo.gl/j8xwHZ, www.bbc.co.uk/programmes/
p01lhjm2, www.telegraph.co.uk/women/womens-health/10439775/A-revolution-in-breast-cancer-therapy.
html, www.bbc.co.uk/news/health-28485504, http://goo.gl/dJQKAF, www.dailymail.co.uk/health/article-
1378267/Me-operation-Targeted-intraoperative-radiotherapy.html and www.wsj.com/articles/alternative-
way-to-treat-early-stage-breast-cancer-with-radiation-1440448587 (accessed 5 July 2016)]. The observed
reduction in non-breast-cancer mortality was an added advantage.
Accrual, power and follow-up duration
The current analysis represents mature data from a large number of patients. Fifteen years ago our original
power calculations expected a background local recurrence rate of 6% and, if we accept a non-inferiority
margin of 2.5%, the sample size required to achieve 80% power and 95% confidence would then have
been 2232 patients. The local recurrence rate measured in the EBRT group of the TARGIT-A trial at 5 years
was in fact just 1.5% and, given this lower value, we needed only 585 patients to achieve 80% power and
95% confidence (Table 18).1,116 It has been well documented that, in the first 5 years after treatment, breast
cancer patients face the highest risk of local recurrence. The peak hazard of local recurrence is between
2 and 3 years after surgery, as seen in many studies, including the Oxford overview4,117,118 (Figure 33).
Esserman et al.120 have recently applied a decision-analytic framework to conclude that the median
follow-up of the TARGIT-A trial is sufficient to strongly recommend wide adoption.
Indeed, a large recent study with a 20-year follow up, conducted by Wickberg et al.,121 has shown that,
whereas radiotherapy decreases the number of recurrences in the first 5 years, it ceases to have any effect
TABLE 18 Sample size calculations
Scenario
Background
recurrence
rate (%)
Background+ non-
inferiority margin of
2.5%= recurrence
rate in the
experimental arm (%)
Total sample
size required
for 80% power
and 95%
confidence
Number of patients
with median
follow-up of 5 years
in the TARGIT-A trial
at the last data lock
Expected at the time of trial
set-up in 1999
6 8.5 2232 1222
Expected following recent
publications (e.g. START trial)49
3 5.5 1151
Control arm (EBRT group) of
the TARGIT trial in 2010
1.5 4 585
With a background recurrence rate of 1.5%, only 585 patients are needed in total - these patients already had a median
follow-up of 54 months (4.5 years) in 2010, long enough to draw reasonable conclusions. In the 2013 publication,
1222 patients had a median follow-up of 5 years; thus, the trial had adequate power.2
Reproduced and amended with permission from Vaidya et al.1 Copyright © Vaidya et al. Open Access article under the
terms of CC BY-NC-ND.
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after the first 5 years; thus the rate of local recurrence after the first 5 years following radiotherapy is
similar to that in patients who received only lumpectomy. This is best demonstrated in Figure 34, which
depicts how the lines representing local recurrence are parallel after 5 years and most of the hazard of not
taking radiotherapy is in the first 5 years.122
The first patient in the TARGIT-A trial was randomised on 25 March 2000 and the last patient > 12 years
later on 25 June 2012. This report presents data from all of the patients randomised in this period:
3451 women in 33 centres across 11 countries. Of these 3451 patients, the first 1222 (called the earliest
cohort in our 2014 paper), recruited in the first 8 years of the trial, have a median follow-up of 5 years and
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the first 2232 patients, originally deemed necessary for our power calculations (called the mature cohort in
our 2014 paper2), have a median follow-up of close to 4 years.
Figure 35a plots each patient’s follow-up according to when they were recruited; one can see that the rate
of accrual was slow initially and increased over the last few years of the trial, giving us a misleadingly lower
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total median follow-up. This is already accounted for in our statistical tests: Kaplan–Meier curves and the
log-rank test. These give accurate calculations for risk at 5 years for the entire trial. We have also
conducted our main analyses for patients randomised in the first 8 years of the trial, as these patients have
a median follow-up of 5 years. The results for these 817 patients in the prepathology stratum (more than
the 585 needed for statistical power) matched our overall results.
We therefore believe that the trial is sufficiently powered to demonstrate that TARGIT is non-inferior,
particularly in the prepathology stratum, that is, when TARGIT is given simultaneously with the initial
lumpectomy, which is the approach that we believe is preferable, based on current data, to using TARGIT
as a second procedure by reopening the initial lumpectomy wound.
Two strata, two distinct treatments
The original trial design set out that patients should be randomised before the initial lumpectomy and, if
allocated to TARGIT, this should be delivered at the time of surgery. When the Australian centre joined, they
found it logistically difficult to give TARGIT during the first procedure. They suggested that they would like to
give TARGIT as a second procedure by reopening the wound. This required us to add a new stratum with its
own randomisation table: the postpathology stratum. The new stratum allowed patients to be randomised
after lumpectomy. Although this allowed more stringent case selection, and simplified the logistics of
arranging the theatre slot and staffing for each case, it also necessitated the reopening of the surgical wound.
Thus, the difference between the postpathology stratum and the original prepathology stratum was in the
timing of randomisation in relation to removal of the cancer either as a lumpectomy or an excision biopsy.
The two strata differed in two major aspects: (1) in the postpathology stratum case selection could be more
stringent as the tumour had already been examined and (2) in the postpathology stratum the experimental
intervention was practically very different from that in the prepathology stratum: radiation was delivered to a
reopened wound, with an accuracy that may not be as good as when it is delivered immediately after
lumpectomy, and it was delivered to tissues that were fibrous scar rather than a pliable fresh wound.
A separate analysis was planned for these two strata of patients from the outset.
Randomisation in the TARGIT trial was carried out before lumpectomy in 2298 patients, or after the
excision of the cancer in 1153 patients, in the prepathology and postpathology strata, respectively, whose
treatment, selection and ultimately, the outcomes differed.
Having two strata allowed more centres to participate and we believed that the more stringent criteria
would give us a nested cohort with a better cancer prognosis in whom the results might be even better.
However, we did not realise that the immediacy may be so important and that irradiating the scarred
tumour bed may not be as effective as giving radiation to the fresh tumour bed. Therefore, although the
better case selection might have allowed for a better outcome, the different mode of delivery of radiation
may have jeopardised local control, albeit by a small amount.
When analysed together, local recurrence with TARGIT was non-inferior to EBRT and there was a trend
towards lower mortality with TARGIT. There was no significant difference in deaths from breast cancer but
there was a significant reduction in the number of deaths from cardiovascular causes and other cancers in
the TARGIT arm compared with the EBRT arm.
Analysis of the prepathology stratum also found similar results: non-inferiority for local recurrence, no
significant difference in breast cancer mortality and a significant reduction in non-breast-cancer mortality.
However, in the postpathology stratum, the difference in local recurrence between TARGIT and EBRT was
more than the pre-specified 2.5% non-inferiority margin. There was no difference in mortality. This
relatively reduced efficacy of postpathology delivery of TARGIT may be attributable to the need to reopen
the surgical wound (increasing trauma), the reduced accuracy in placement of the applicator, the radiation
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being given to scar tissue or missing a critical temporal window in radiation delivery; the median time
between the primary surgery and TARGIT delivery in the postpathology stratum was 37 days.
Statistical tests comparing the two strata were not planned, as such comparisons would be non-
randomised. Nevertheless, we believe that the difference observed is the result of the difference in TARGIT
timing, as the two EBRT groups were similar in breast cancer recurrence (1.1% prepathology vs. 1.7%
postpathology; p = 0.49) and non-breast-cancer mortality.
The postpathology stratum has therefore highlighted the importance of temporal precision in the delivery
of radiation using this technique; the results from the postpathology stratum are not favourable, in terms
of a higher local recurrence but, reassuringly, there was no decrease in mortality.
When we assessed whether or not more frequent use of additional EBRT could be the cause of better
outcomes in the prepathology stratum (21% vs. 3% in postpathology stratum), we found that patients in
the super-selected postpathology stratum had a much better prognosis than those in the prepathology
stratum, as expected. Despite this worse prognosis, the 5-year local control in prepathology cases who
received TARGIT alone appears to be better – not worse – than those in the postpathology stratum who
received TARGIT alone (2.7% vs. 5.9%, respectively) and similar to that in the whole prepathology stratum
(2.1%). These data suggest that delivery of TARGIT IORT at the time of initial lumpectomy leads to the
accurate and timely application of radiation to a well-vascularised, undisturbed, fresh tumour bed that
ensures temporal and spatial accuracy rather than that the addition of EBRT in higher-risk cases is
responsible for the favourable results in the large prepathology stratum.
Furthermore, it has been reported that surgical wounds promote tumorigenesis,123 possibly via a
T-cell-dependent mechanism.124 Delivered at the time of surgery, TARGIT has been shown to reduce the
motility of the wound fluid, thereby perhaps reducing recurrence through a beneficial effect on the tumour
microenvironment, that is, it abrogates the stimulation of motility, proliferation and invasiveness.17,125
Recent translational work126,127 has identified increased levels of microRNA-223 when TARGIT is delivered
to the fresh surgical wound, which reduces the malignant potential of cancerous cells. TARGIT appears to
act through an epidermal growth factor receptor (EGFR) pathway. A possible mechanism is shown in
Figure 36. These data suggest that giving TARGIT at the time of lumpectomy would be preferable to giving
it as a second procedure.
Risk-adapted approach
About one-fifth of the patients receiving TARGIT at the time of their first surgery were also given EBRT;
this was indicated if pathology conducted after lumpectomy showed any adverse prognostic factors as
determined in the treatment policy document and the multidisciplinary discussion of the full histopathology
after surgery. Overall, that is when postpathology stratum is included, 15% of patients randomised to the
risk-adapted TARGIT arm were given both TARGIT and EBRT.
We believe that a design in which the experimental arm was a risk-adapted approach was the best
method of accurately reflecting practice in the real world, without sacrificing statistical validity; it may be
disappointing for the women who needed supplemental EBRT but it is worth remembering that TARGIT
allows the large majority of patients (80–85%) to avoid several weeks of EBRT.
Is ‘no radiotherapy’ an option? Only if one is prepared to take the risk of local recurrence
Sceptics have suggested that these 15% of patients who received both TARGIT and EBRT were indeed
those very patients who would otherwise have recurred without radiation, but who did not do so because
they received EBRT. The remaining 85% of patients, so the sceptics argue, were therefore those who
would never have recurred even without radiation and TARGIT did not really prevent any recurrences,
only the added EBRT did. If this were true, the trial guidelines detailing when EBRT was to be added have
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extraordinarily managed to identify all patients who might recur, based on tumour characteristics alone!
Obviously, such an algorithm for case selection is currently impossible.
Although this would be fortunate, it is clearly not the case. Other studies testing the benefits of EBRT
over no radiotherapy have enrolled patients whose tumour characteristics were far better than those in
the TARGIT arm who did not receive EBRT have found that entirely omitting radiotherapy results in a
significantly higher recurrence rate.11,106,129 Additionally, as the postpathology stratum usually did not need
additional EBRT, as this stratum was randomised after lumpectomy and pathology, these patients provided
an internal control. As seen in Table 11, the tumour characteristics in this postpathology stratum were
much better than those in the prepathology TARGIT arm who did not receive EBRT, but recurrence was
much higher, again indicating that TARGIT, delivered at the correct time, is particularly good at avoiding
local recurrence.5,130
A recently published CALGB randomised clinical trial,11 which has addressed this even in the very best
prognosis patients (age >70 years, T1N0M0, ER positive), found that giving ‘no radiotherapy’ leads to a
significantly higher local recurrence rate (9%, i.e. one in every 11, vs. just 2% with radiotherapy). In a
more recently reported PRIME II trial106 with super-selected patients with an extremely good prognosis
(much better than that of the TARGIT-A trial patients), there was a statistically significant reduction in
disease-free survival when radiotherapy was omitted and local recurrence without radiotherapy was 4.1%.
Even in these highly selected good-prognosis patients, the subgroup of patients who were ER positive had
a local recurrence rate of 3.2% without compared with 0.8% with radiotherapy, which is relatively much
higher than that achieved by TARGIT during lumpectomy in ER-positive, PgR-positive cancers (1.4% with
TARGIT vs. 1.2% with EBRT). If such patients were treated by TARGIT IORT initially, they could avoid the
need for EBRT with its associated risks, inconvenience and costs as well as the increased risk of recurrence
associated with completely withholding radiotherapy (see Table 20).
Other trials
Several other systems of delivering a targeted dose of radiation to the affected area of the breast have
been trialled; these have been reviewed elsewhere.112,131 It is worth keeping in mind that, of these,
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the TARGIT-A trial alone took a truly risk-adjusted approach. A recent meta-analysis of the TARGIT-A trial
and the GEC-ESTRO (Groupe Européen de Curiethérapie ESTRO) trial of PBI with interstitial wires has
found that the local control with PBI is non-inferior to whole-breast irradiation and there is a reduction in
non-breast-cancer mortality.132 Importantly, the overall survival benefit of using TARGIT IORT instead
of traditional EBRT has been confirmed in the meta-analysis of all randomised trials of PBI versus
whole-breast irradiation.112
The ELIOT trial,35,133 which recently published results indicating poorer outcomes with IORT using the
NOVAC-7 (New Radiant Technology) device than with EBRT,35 was the only other randomised trial testing
intraoperative partial breast radiotherapy. Their technique used 4- to 12-MeV electrons to deliver 21 Gy
over 3–5 minutes; this seems comparable to TARGIT’s 50 kV over 20–30 minutes to deliver 20 Gy to the
tumour bed surface, a dose that attenuates to 5–7 Gy at a 1-cm depth. However, the preparation for
delivery is fundamentally different. Whereas the TARGIT technique delivers radiotherapy from within the
breast, with the radiation source sitting in the tumour bed – where the tumour was before its excision –
and radiation given directly to the well-vascularised tissues of the tumour bed, in the ELIOT trial
radiotherapy was delivered from outside the body; this therefore requires the extensive mobilisation of the
mammary gland, insertion of a prepectoral lead shield and the apposition of the edges of the tumour bed.
Such dissection could in theory lead to relative ischaemia, at least in the short term, of the edges of the
mobilised breast gland, the very tissues that are being immediately irradiated. The higher (albeit low in
absolute terms) recurrence rate seen in the ELIOT trial might therefore be because of the lower oxygen
saturation of the tissues being irradiated as it is well known that tissue ischaemia reduces the effectiveness
of radiation.134–141 In addition, theoretically, some at-risk tissue such as the retracted skin and subcutaneous
breast tissue and the prepectoral tissue behind the shield would not receive any radiation while exposing
more raw surface to tumour seeding.
Health economics
A cost–utility analysis comparing TARGIT during lumpectomy with EBRT (prepathology stratum) was carried
out. The base case showed that TARGIT was statistically significantly less costly than EBRT, produced
similar QALYs, had a positive incremental net monetary benefit that was borderline statistically significantly
different from zero and had a probability of > 90% of being cost-effective.
In our base case we assumed that 15.2% of patients randomised to TARGIT also received EBRT. Although
standard practice during most of the period of the TARGIT-A trial was a 6-week course of EBRT, we used
15 as the number of EBRT fractions delivered because that is now standard practice in the UK. In the trial,
38% of patients randomised to EBRT also received an EBRT boost; we used this proportion for the base
case as it is expected to be the norm today as well. We used costs from Picot et al.72 of £1882.00 for
TARGIT and £2659 for 15 fractions of EBRT.
In the base-case analysis TARGIT was less costly than EBRT (mean incremental cost –£685) and produced
slightly more QALYs than EBRT (mean QALYs gained 0.034; see Table 16). The difference in costs between
the two groups was statistically significant (mean incremental cost for TARGIT vs. EBRT –£685, 95% CI
–£1131 to –£63) but the difference in QALYs was not (mean QALYs gained 0.034, 95% CI –0.026
to 0.095).
Based on the findings of this cost–utility analysis, there could be a potential budget saving to the NHS if
TARGIT was carried our routinely instead of EBRT in eligible patients. The potential cost savings to the NHS
would be around £8–9.1 million each year.
Taking a wider perspective (e.g. societal) to measure costs resulted in even greater potential cost savings.
For example, with regard to transport costs, we assumed that 13.5% of EBRT patients used NHS transport.
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Assuming that the same cost is paid out-of-pocket by the remaining EBRT patients, the difference between
TARGIT and EBRT would increase to £1562 per patient, taking the total saving to the UK national
economy to between £18.1 million and £20.9 million each year.
The main strength of our analysis is that it was based on a large international multicentre randomised trial
with detailed information on resource use and events for a median follow-up period of 5 years.
Limitations include the fact that the time horizon was 5 years. Extrapolation beyond the end of the trial
using decision-analytic modelling was not undertaken because the within-trial analysis found no evidence
of significant differences in QALYs between groups during the 5-year period. Although there was some
evidence of a difference in costs, these differences were all accrued during the first year; there was no
evidence of significant differences in costs beyond the first year. Hence, the 5-year time horizon was long
enough to reflect all important differences in costs or outcomes between the two treatments. Although
local recurrence (and other events) are likely to continue to occur over a patient’s lifetime, the evidence
from the TARGIT-A trial is that TARGIT is non-inferior to EBRT; hence, taking a longer time horizon is
unlikely to have affected the results of the incremental analyses.
Utility data were not collected in the TARGIT-A trial. We therefore applied utility values from published
sources to the health states experienced by patients in the trial. Given the relatively small number of
events, and that the number of events was largely not different between the two groups, the QALY
differences between the two groups may not be expected to change much with alternative utility values.
This was borne out by our sensitivity analysis, which showed that the results did not change appreciably
when alternative values were used. We did not incorporate utility losses in our analysis associated with
additional procedures, chemotherapy, mastectomy or complications. Given the low incidence of these
events, that they were evenly distributed between treatment groups and that the time period affected is
likely to be short this is unlikely to affect the QALYs associated with each treatment group.
Our estimates of cost savings from the use of TARGIT are likely to be conservative because, first, we did
not include any utility losses associated with EBRT and, second, the analysis took a NHS/PSS perspective on
costs. A wider perspective (e.g. societal and environmental costs such as carbon footprint) could have
been taken to measure costs, including impacts on the rest of society, patients, families and businesses.
If these costs were included it is likely that the cost savings attributable to TARGIT would be greater than
demonstrated. Finally, we used the current standard dose used for EBRT (3 weeks rather than the
5–6 weeks planned for in the TARGIT-A trial).
Case selection
The results of analysis of the tumour and patient characteristics appear to predict which patients would be
best suitable for TARGIT. This section discusses the findings of the subgroup analysis of tumour and
patient factors that had an effect on the outcomes. As the number of events is small, some interactions
may have been missed and this should be taken into consideration when interpreting the results.
Hormone sensitivity
We used PgR status as a surrogate marker for a functionally active ER receptor and found that PgR status
appears to predict response to radiotherapy. Patients whose tumours were less hormone sensitive, as
shown by a negative PgR status, had a significantly higher risk of local recurrence overall and in the
TARGIT arm.
Interestingly, however, no such difference was observed in the EBRT arm of our trial. This could be because
of the small number of events in the EBRT arm (n = 11) or because of the nature of PgR-negative tumours:
the more infiltrative margins57–59 should perhaps most appropriately be irradiated by the wide and uniform
field of EBRT. The smaller volume of tissue irradiated with partial breast radiotherapies could result in a
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failure to wholly irradiate the cancerous cells. Furthermore, the EGFR pathway by which TARGIT increases
mi223 levels and therefore reduces tumour growth is PgR dependent; in ER-positive, PgR-positive patients,
this may contribute to the clinical effectiveness of appropriately timed TARGIT given during lumpectomy,
but with a hormone-insensitive tumour this mechanism of local recurrence reduction would not be in
place. This may explain why, even though among PgR-positive cases (n = 2462) there was no significant
difference between the TARGIT and the EBRT arms (2.3% vs. 1.5%; p = 0.51), in the PgR-negative cases
(n = 554) local recurrence was significantly higher in the TARGIT arm (7.0% vs. 0.5%; p = 0.017).
It is possible that with more events the TARGIT and EBRT local recurrences for PgR-negative cases may
equalise and that the current finding is only a mere chance finding. However, the decision to analyse by
PgR status was made before unblinding of the database rather than while analysing multiple other factors.
The plan for this analysis was prompted by results from other studies, for example molecular analysis of
the tumours in the ELIOT trial35 had revealed IORT to be less effective with hormone receptor-negative
(non-luminal A) tumours and evidence from Perou’s group (Prat et al.57) presented in 2012 suggested that
PgR-negative tumours in particular should not be classified as luminal A at all. Furthermore, statistically,
both separate models and an interaction model produced statistically similar results for PgR status, hence
minimising the probability that it is a chance finding.
Margin status
We found that margin status was a predictive factor for local recurrence in the EBRT arm (HR 5.17) and
overall (HR 2.68). However, margin status did not significantly affect recurrence in the TARGIT arm;
although this could be a chance finding (although the p-value = 0.034), it could also be because of the
temporal and spatial accuracy of radiotherapy delivery that TARGIT facilitates. It is worth remembering
that, although in both arms of the trial > 90% of patients with initial positive margins did undergo
re-excision, only 25% of re-excision specimens had tumour present on histology, perhaps indicating
inaccurate removal. Alternatively, the proliferation of the remaining tumour cells until the start of EBRT
may be responsible for the local recurrence and delay does not occur when TARGIT is given immediately
after lumpectomy under the same anaesthetic, so margin positivity did not come out as a factor predicting
outcome after TARGIT IORT.
Forest plot
The forest plot in Figure 23 clearly shows how it is mainly ER and PgR receptor status that affected the
difference between the two arms. Other factors such as age, grade, tumour size or nodal status did not
have an effect; for example, TARGIT was as effective as EBRT in younger patients or those with larger or
grade 3 or node-positive tumours.
Suggested modification to American SocieTy for Radiation Oncology and European
SocieTy for Radiotherapy & Oncology criteria
The results of the trial suggest that effective cancer control, a reduction in toxicity and improved patient
quality of life can be achieved by switching suitable patients to TARGIT, delivered at the time of surgery.
The suitability criteria for PBI that have been suggested by ASTRO142 and the European SocieTy for
Radiotherapy & Oncology (ESTRO)143 might be refined based on the TARGIT-A trial results. The ASTRO and
ESTRO guidelines would normally exclude many of the patients with ‘adverse’ factors who were in fact
eligible for the TARGIT-A trial’s risk-adapted approach, and in the TARGIT-A trial it was found that these
‘adverse’ factors do not predict a worse outcome with TARGIT compared with EBRT. One exception is
hormone sensitivity, with TARGIT appearing to work best for patients who are ER and PgR positive.
Table 19 shows how the suitability criteria for PBI may be altered using the data from the TARGIT-A trial.
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TABLE 19 Suitability criteria for PBI according to the ASTRO and ESTRO guidelines and eligibility criteria for the
TARGIT-A trial (given in bold)
Patient and tumour
characteristics
Suitable for PBI based
on ASTRO consensus
Suitable for PBI based
on ESTRO consensus
Eligibility and treatment as
per TARGIT-A trial protocol
Age ≥ 60 years > 50 years ≥ 45 years
Tumour size ≤ 2 cm ≤ 3 cm ≤ 3.5 cm
Grade Any Any Any
Histology Invasive ductal Invasive ductal Invasive ductal
Invasive lobular Not allowed Not allowed Not allowed/add EBRT if
found later
Pure DCIS Not allowed Not allowed Not allowed
ER status Positive Any Positive had better results
PgR status Any Any Positive had better results;
results might be better if
additional EBRT if PgR
negative
HER2 status Any Any Any
Positive margins Not allowed Not allowed Additional EBRT
Positive nodes Not Allowed Not allowed Additional EBRT, particularly
if multiple positive nodes
Extensive lymphovascular
invasion
Not allowed Not allowed Additional EBRT
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Chapter 8 Conclusions
Using a large multicentre randomised trial design, we have falsified the hypothesis that omission ofradiation to the whole breast will significantly increase local breast cancer recurrence in quadrants
away from the original cancer. We found that a risk-adapted approach using TARGIT delivered as a single
dose during lumpectomy, and focused to the tissues immediately surrounding a small breast cancer, was
non-inferior to several weeks of conventional whole-breast EBRT in controlling breast cancer recurrence or
breast cancer death. We also found that with such focused irradiation that avoids other organs there is
also some reduction in mortality from causes other than breast cancer.
Although welcomed by patients and many clinicians, the results of this trial have been subjected to a storm
of criticism, which some have suggested144 could arise from an undeclared but readily available conflict of
interest. We have responded to and refuted these challenges to the interpretation of our data.64 The
details of this response as well as several additional analyses are included in Chapter 11. Even if we take
the worst case scenario based on a misunderstanding of the non-inferiority metric, then we are left with
a 1–2%, non-significant excess of local recurrences in the experimental arm of the study, with no
concomitant increase in cause-specific or all-cause mortality. We suggest that given a choice women
happily opt for TARGIT to avoid several weeks of daily attendance at the radiotherapy centre or, in
resource-poor parts of the world, the threat of a mastectomy.22,100,101,103,104,114,115
From a patient’s perspective, the most important benefit of TARGIT for a woman with breast cancer is that
it allows her to complete her entire local treatment (lumpectomy and radiation therapy) at the time of her
operation, with lower toxicity. Therefore, the use of TARGIT in relatively mobile patients in the most
developed and well-resourced communities would avoid the inconvenience and cost of this prolonged
daily radiation course whereas others, who may have been obliged to choose a mastectomy, can avail
themselves of breast-conserving therapy. Furthermore, the survival benefit by avoiding non-breast-cancer
deaths in such patients with relatively good prognosis breast cancer has been confirmed in a recent
meta-analysis.112
From a health economic perspective, in the base-case analysis TARGIT was less costly than EBRT (mean
incremental cost –£685) and produced slightly more QALYs than EBRT (mean QALYs gained 0.034).
TARGIT had a positive incremental net monetary benefit that was borderline statistically significantly
different from zero and had a probability of > 90% of being cost-effective. If TARGIT were given instead
of EBRT in suitable patients, it might potentially reduce costs to health-care providers by £8–9.1 million
each year. This does not include environmental, patient and societal costs. Taking into account the
travel cost alone increases the total saving to the UK national economy to between £18.1 million and
£20.9 million each year.
If our risk-adapted, pragmatic approach tested in the TARGIT-A trial is to be applied in the real world,
patient selection will be of importance – those who are aged ≥ 45 years with a small (≤ 3.5 cm) invasive
ductal carcinoma, bearing in mind that the addition of one positive tumour factor (PgR- or ER-positive
status) appears to predict local control with TARGIT during lumpectomy that is nearly identical to that seen
with conventional whole-breast EBRT. The patients who do not fulfil these criteria or for whom clinicians
feel that TARGIT alone is not suitable would usually fulfil the eligibility criteria for participation in the
HTA-funded TARGIT-B randomised trial, which is evaluating whether or not TARGIT boost is superior to
EBRT boost when given in addition to whole-breast radiation.
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Chapter 9 Implication for health care and practice
Over 250 breast cancer teams worldwide now use TARGIT, including 60 in the USA (e.g. ClevelandClinic, OH; University of California San Francisco and University of Southern California; Cornell
University, NY; Georgetown University, Washington, DC; Advocate Health Care hospitals in Chicago, IL;
Moffitt Cancer Center, FL; Cancer Treatment Centers of America), about two-thirds of breast cancer
centres in Germany (n = 60) and several centres in the rest of Europe. The busiest centre has treated
> 500 cases.
Worldwide adoption: a survey of 125 of the 250 centres using the TARGIT IORT technique has reported
that 11,740 patients have been treated until October 2015.145 Thus, an estimate of more than 20,000
patients have already undergone this treatment in centres of excellence in the world.146 It is considered as
a standard option in several countries with advanced health-care systems, such as Germany (60 centres),
Italy and the USA (60 centres).
In Australia, the Medical Services Advisory Committee, a body similar to NICE, has approved TARGIT for
NHS funding based on the published evidence and the treatment made available from September 2015.
Thus, this idea and resulting research have revolutionised the treatment paradigm from radical
radiotherapy to localised radiotherapy.
Impact on patients and their families: improvement in length and quality
of life at a reduced cost
Many women are obliged to choose a mastectomy when they are not able to take the prolonged
postoperative course of radiotherapy because of geography, time or money constraints. Many receive
suboptimal treatment. With TARGIT, such women can have a lumpectomy and preserve their breast.
Even among those who have a lumpectomy, TARGIT causes less pain, higher levels of patient satisfaction
and higher quality-of-life scores than conventional radiotherapy.107 There is a significant improvement in a
woman’s cancer journey when the whole of local treatment is completed at the time of the cancer
operation, rather than having a daily 3- to 6-week commute to the cancer hospital. TARGIT patients also
have half the risk of dying from heart disease or other cancers than those undergoing EBRT. From the
numbers in the trial (13 fewer deaths among 1140 patients who were randomised to receive TARGIT at
the time of lumpectomy), one can extrapolate that, of 20,000 patients, 228 such deaths have already been
prevented. In communities in which patients have to pay for their treatment, TARGIT is a fraction of the
cost of conventional radiotherapy, leading to more equitable availability of treatment.
Impact on routine treatment guidelines/recommendations for patients
in the community
The TARGIT-A trial was the first proof of principle of ‘partial breast irradiation’ and other methods of giving
PBI have proliferated. TARGIT, either as a tumour bed boost or as definitive treatment, as well as other
methods of PBI are now included in guidelines issued by the European Society of Breast Cancer
Specialists147 and the European Society of Medical Oncology (which are also endorsed by the Japanese
Society of Medical Oncology)148 and in German national guidelines.149
In March 2011, at the biennial international St Gallen Consensus Conference, 52 world experts voted
in favour of using intraoperative radiation in selected patients. At this time, the only level 1 randomised
evidence was from the TARGIT-A trial.150 In December 2012, the newsletter at the largest breast cancer
conference at St Gallen featured our late-breaking paper.151 Our research has also attracted significant
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media attention both in scientific periodicals and in the lay press (copies of articles without URLs are
available on request).152–167
National Institute for Health and Care Excellence is currently consulting on the use of TARGIT in routine
practice and gave a provisional recommendation for its funding in the NHS in July 2014 [see www.nice.
org.uk/guidance/GID-TAG353/documents/breast-cancer-early-intrabeam-radiotherapy-system-appraisal-
consultation-document (accessed 6 July 2016)]. Since then they have requested further information, which
has been supplied (see details in Chapter 11).168 The Marmot committee on screening has suggested that,
in patients whose cancers are found only on mammographic screening, if TARGIT is used rather than EBRT
this would minimise side effects because of the overdiagnosis and overtreatment that is known to occur
with mammographic screening.169 We have also demonstrated that TARGIT is a method for avoiding the
cardiac toxicity of EBRT.170
Impact on health-care delivery and budget
Breast cancer constitutes one-third of the workload of a typical radiotherapy department and in many
areas there can be long waiting lists. When a significant proportion of this time is freed up by using
TARGIT in the operating theatre, it can be used to treat other cancers in a timely manner. A recently
published paper originating from several centres in France98 concluded that > 50% of patients with early
breast cancer would be suitable for TARGIT.
One estimate is that the 20,000 patients who had TARGIT during their lumpectomy would have required
20,000 × 20 = 400,000 radiotherapy sessions rather than the single session in the operating theatre if they
were to have lumpectomy and conventional radiotherapy. Assuming that TARGIT takes the time equivalent
of four routine radiotherapy sessions, this is a saving of 400,000 – 80,000 = 320,000 radiotherapy sessions
to date. Assuming that each session costs a conservative £200, the saving of 320,000 sessions has already
saved £64 million worldwide. It is estimated that adoption of TARGIT in the UK will potentially save
£8–9.1 million per year. A North American model has predicted this amount to be US$280 million in
the USA.171
IMPLICATION FOR HEALTH CARE AND PRACTICE
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Chapter 10 Recommendations for research
This large international randomised clinical trial has challenged the existing dogma and has opened adoor to a new way of thinking about adjuvant radiotherapy, particularly for breast cancer.
Future research should focus on assessing the biological mechanisms of action of this type of radiation
given in this manner, to the fresh tumour bed. Of particular interest is the way in which it appears to alter
the tumour microenvironment.
Addition of EBRT to TARGIT appears to have interesting effects. These need to be studied in further detail
and we hope that the clinical data from the TARGIT-B trial will be helpful in this regard. Funding for
translational research would allow for biological pathways to be discovered and may even lead to the
development of drugs that could replace the need for radiation.
The effect that we have observed on non-breast-cancer mortality is interesting and needs to be
investigated further with an open mind; if the mechanism is not simply the avoidance of EBRT toxicity,
it may well open several new doors.
For the health economic analyses, further research is required to measure directly the impact of TARGIT
on patient utility values. In addition, future analyses should take a wider (e.g. societal) perspective when
measuring costs.
With regard to further work on the TARGIT-A trial population, including continuing to collect follow-up
information for 10 years on every patient, details are provided in Appendix 4.
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Chapter 11 Further analysis as requested by the
National Institute for Health and Care Excellence
Introduction
National Institute for Health and Care Excellence is currently appraising the TARGIT technique for adoption
in the NHS.
On 27 July 2014, NICE issued a press release and published draft guidance on the use of INTRABEAM
radiotherapy, giving a draft recommendation for the use of TARGIT in the NHS (see Appendix 5).
Following this announcement widespread positive media attention was given to the research and its results
and how it could improve the care of patients with breast cancer. However, there was an unprecedented
level of opposition to the recommendations, mainly from a small group of individuals in the radiation
oncology community. This led to a prolonged delay in the final recommendations, which were due to be
announced in August 2014.
From July 2014, the TARGIT investigators, as part of the response to NICE, collaborated with various
departments in the Department of Health to create tables that show how the use of TARGIT in the NHS
would be coded. The detailed tables of these codes, prepared in collaboration with the national cancer
registries and the national coding teams, are provided in Appendix 6.
In the course of communications with NICE, NICE requested further analysis. It requested that we should
use the dataset that was used for the recent Lancet publications without re-unblinding of the data.
Such analysis was performed and submitted to NICE in March 2015. The TARGIT investigators also offered
to provide the raw data but were told that NICE were satisfied with the analysis and did not wish to see
the raw data.
This chapter provides the details of this new analysis.
Further information requested by the National Institute for Health and
Care Excellence
National Institute for Health and Care Excellence requested further information from the authors in
August 2014. These were initially supplied in a meeting in December 2014 and the following further
information was supplied on 10 March 2015 in a face-to-face meeting. At this meeting it was clarified that
we had initially supplied the integrated difference between the Kaplan–Meier curves but that NICE had
requested that we also supply the difference in the values for the 5-year Kaplan–Meier estimates as well as
the 95% CIs. It was agreed that the NICE committee recognised that:
l The right-hand end of the Kaplan–Meier curve is the one with the most uncertainty and with the widest CIs.
l In the presence of censoring the Kaplan–Meier point estimate at a particular time point, for example
5 years are not a simple binomial proportions, and treating them as a binomial proportion introduces
a bias resulting in a wider CI. Therefore, it is inappropriate to apply the simple formula normally used
to calculate the SE (and CI) of a difference between binomial proportions, namely
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SE12 + SE22
p
to
calculate differences between such point estimates.
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l These values, that is, 5-year point estimates, should not be used to calculate the CI of the difference or
for testing non-inferiority.
l These values are being requested by NICE mainly for completion and will not be wrongly used to assess
non-inferiority.
The rest of this chapter includes all of the graphs and statistics requested by the committee, as of the data
lock on 25 June 2012, in addition to the blinded analysis including new events until 1 October 2014.
In response to the recommendation in the draft recommendation, we have also included a diagram to help
patients make a shared decision along with their consultant.
Executive summary of the analysis provided to the National Institute for Health and
Care Excellence
1. This document provides all of the additional analyses requested by NICE. Following the initial request,
NICE and the TARGIT-A trial investigators met on 9 December 2014. The TARGIT-A investigators gave
a response on 18 December. NICE responded on 16 February 2015, which was followed by a meeting
on 3 March to discuss and confirm that all of the required analyses had been included.
2. It is well established that the peak hazard of recurrence is in the first 2–3 years. Most importantly, the
effect of radiotherapy on local recurrence is limited to the first 5 years, with most of the radiotherapy
effect being seen in the first 2–3 years.
3. The results in the TARGIT-A trial were obtained despite the fact that the eligibility criteria and cases in
the trial were not limited to very-low-risk cases (between 450 and 550 patients had a grade 3 tumour
or a tumour size > 2 cm or node-positive disease).
4. With over 1200 patients with a median follow-up of 5 years, there were very few events for local
recurrence (n = 34), suggesting that both treatments work very well; on the other hand, the number
of events for local recurrence-free survival was substantial (n = 120) and similar with TARGIT and EBRT,
giving sufficient data to change clinical practice.
5. The Kaplan–Meier curves for local recurrence, survival without local recurrence, overall survival, breast
cancer survival and disease-free survival all demonstrated that the lines representing TARGIT and EBRT
with their 95% CI overlap each other.
6. On the other hand, the 95% CIs for the TARGIT and EBRT curves for non-breast-cancer survival do not
overlap, demonstrating the previously published statistically significant difference.
7. Absolute difference between Kaplan–Meier curves:
i. the appropriate method of calculating the difference between Kaplan–Meier curves was by using
the integrated difference of the two survival functions to quantify the difference between the
Kaplan–Meier curves
ii. for the primary outcome of local recurrence, the difference between the Kaplan–Meier curves for
TARGIT and EBRT from 0 to 5 years was as follows:
¢ for the whole trial 0.62% (95% CI 0.007% to 1.24%)
¢ for the prepathology stratum 0.3% (95% CI –0.4% to 1.03%).
8. Data from further follow up: as of October 2014, the number of patients with a minimum follow-up
of 5 years in the whole trial was 1116. For the prepathology stratum this number was 776, with
15 new events of local recurrence in addition to the previous 16. We were told that unplanned
unblinding for new analysis was not necessary. Therefore, we have remained blind to the apportioning
of the new events and have provided a blinded analysis. In the most plausible hypothetical scenario,
weighted against TARGIT the new local recurrences might be distributed as TARGIT 10, EBRT 5. In this
case, the difference between the binomial proportions of the two arms would be 0.83 (90% CI 0.0 to
1.6, 95% CI –0.1 to 1.8; Pnon-inferiority = 0.00038) and TARGIT would remain non-inferior to EBRT.
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9. There was no significant difference between TARGIT during lumpectomy and EBRT by conventional
log-rank test (p = 0.31) and TARGIT was non-inferior to EBRT using the standard test for non-
inferiority (Pnon-inferiority < 0.00001) and the 5-year survival without local recurrence was 93.9% (95% CI
90.9% to 95.9%) for TARGIT and 92.5% (95% CI 89.7% to 94.6%) for EBRT (p = 0.35).
10. Mortality cannot be ignored when a difference is generated within a randomised trial (TARGIT 29 vs.
EBRT 42 deaths), particularly when the number of events is several times higher than the number of
local recurrence (71 deaths vs. 16 local recurrences) and death is clearly an important outcome. If a
statistically significant difference is found at the time of analysis initial ‘power’ calculations are
not relevant.
11. Cosmetic outcome and quality of life have been shown to be better with TARGIT than with EBRT as
per the published randomised data from the TARGIT-A trial.
12. In conclusion, using three quite separate statistical methodologies, the risk-adapted approach using
single-dose TARGIT IORT given during lumpectomy is found to provide breast cancer control that is
not inferior to that seen with several weeks of conventional radiotherapy; it also provides a more
cost-effective treatment that is more convenient for patients.
13. Figure 37 provides a pictogram to help patients and doctors make a shared well-informed decision.
What happened to women with early breast cancer,
treated with TARGIT during lumpectomy compared with those treated with EBRT,
over the first 5 years?
There was no statistically significant difference in survival without local recurrence
1 dot = 1 woman
TARGIT-A international multicentre trial included 3451 women randomised to receive TARGIT or EBRT.
These figures are created by applying 5-year Kaplan–Meier estimates of survival without local recurrence to 
1000 women having breast-conserving therapy in the two trial arms. Distant or regional disease not shown:
there was no difference seen between TARGIT and EBRT
939 women alive without local recurrence
20 women alive after treatment of local recurrence
1 woman died after local recurrence
40 women died
1000 women randomised to TARGIT
925 women alive without local recurrence
10 women alive after treatment of local recurrence
1 woman died after local recurrence
64 women died
1000 women randomised to EBRT
FIGURE 37 A pictogram to help patients and doctors to make a shared, well-informed decision.
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Important considerations about the use of radiotherapy for breast cancer
Breast cancer surgery has evolved from being very radical (e.g. radical mastectomy and axillary clearance)
to being more individualised and precise (lumpectomy and sentinel node biopsy).
Even though randomised evidence supported less radical treatment, there was strong initial opposition to
its adoption only a few decades ago. The TARGIT-A trial has provided evidence that radiotherapy also does
not need to be radical and should be more precisely and individually optimised. The opposition to its
adoption appears to be similar to that shown by strong proponents of radical mastectomy towards those
who wanted to spare women this mutilating operation. Some important and relevant points about the
natural history of breast cancer have been elucidated via the results of several randomised controlled trials:
1. The peak hazard of recurrence is in the first 2–3 years and, more importantly, the effect of radiotherapy
on local recurrence is limited to the first 5 years, with most of the radiotherapy effect being seen in the
first 2–3 years.4,119,121,122 This is clearly seen from the figures below. Thus, local recurrence occurring
between 5 and 25 years is no more frequent in non-irradiated patients than in those who have
received radiotherapy.4,119,121,122
[Parts of Figures 33 and Figures 34 that were included in the correspondence are reproduced here for
ease of reading.] These figures demonstrate how the reduction in local recurrence by radiotherapy
occurs only in the first 5 years, with most of the effect already seen in the first 2–3 years. Figure 33b
(top figure) is the Kaplan–Meier plot from the landmark NSABP B06 trial by Fisher et al.119 of
radiotherapy compared with no radiotherapy after lumpectomy. Figure 34a (middle figure) is the
Kaplan–Meier plot taken from the Swedish trial by Wickberg et al.121 of radiotherapy compared with no
radiotherapy after lumpectomy with a 25-year follow-up. Figures 34b and c (bottom figures) are also
based on the data from the same Swedish trial by Wickberg et al.122
Therefore, the available follow-up in the TARGIT-A trial provides enough information to enable its use
in clinical practice.
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2. When the reduction in local recurrence because of radiotherapy is < 10%, there is no discernible
benefit for survival from breast cancer.
3. The detrimental effect of conventional whole-breast radiotherapy on non-breast-cancer deaths
(e.g. from cardiac disease/other cancers) becomes more important when deaths from breast cancer are
few and this effect starts in the first few years.
4. It has been suggested that TARGIT treatment is as good as ‘no radiotherapy’. Table 20 provides the
results of randomised controlled trials testing the effect of completely omitting radiotherapy. As can be
seen clearly in the table, one in every 17–25 of even the most stringently selected low-risk patients
would have a local recurrence if radiotherapy were omitted.11,106,129 On the other hand, when TARGIT is
given during lumpectomy local recurrence is rare – one in 48, which reduces to one in 71 when just a
single selection criterion (ER positive) is applied.
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5. Importantly, TARGIT-A trial eligibility was not limited to ‘good prognosis’ cases. In fact, 85% of patients
in the TARGIT-A trial were aged < 70 years and there were a large number of patients in each of the
adverse prognostic groups such as node positive (n = 502), ER or PgR negative (n = 554), grade 3
(n = 459) or tumour size > 2 cm (n = 397); > 60% of cases in the TARGIT-A trial would be considered
‘unsuitable’ or ‘cautionary’ by the ASTRO criteria for PBI;172 and only 17.5% of patients in the TARGIT-A
trial prepathology stratum would have been eligible for the PRIME II trial – all others (82.5%) had
‘worse’ prognosis cancers. The results in the trial were obtained despite the fact that the eligibility
criteria and cases in the TARGIT-A trial were not limited to very-low-risk cases.
6. In a non-inferiority trial, if the difference between the treatments being tested (and its upper confidence
limit) is less than a preset non-inferiority margin the treatments are considered non-inferior, even if the
difference is ‘statistically significant’ using a log-rank test. The pre-specified non-inferiority boundary of
a 2.5% absolute difference in local recurrence is very conservative and has been validated in patient
preference studies.101,103,104 At this boundary, TARGIT is non-inferior to EBRT (Pnon-inferiority < 0.00001)
(Figure 38). Furthermore, we have recommended that TARGIT should be used during the initial
lumpectomy, as in the prepathology stratum (note that this is a stratum not a subgroup), when the
difference between the two treatments was undoubtedly not statistically significant (p = 0.31).
TABLE 20 The results of randomised trials of radiotherapy vs. no radiotherapy compared with the TARGIT-A
trial results
CALGB11 BASO II129 PRIME II106 TARGIT-A prepathology
Number of trial participants 636 1135 1326 2298 (1625 ER and PgR positive)
Age (years) ≥ 70 ≥ 65 ≥ 65 ≥ 45
Tumour size ≤ 2 cm ≤ 2 cm ≤ 2 cm Small T2, preferably ≤ 3.5 cm
Grade Grade 1 Grade 1 or
grade 2
No restriction
Nodes Negative Negative Negative No restriction
Lymphovascular invasion Negative Negative No restriction
ER status Positive Positive Positive No restriction
5-year local recurrence (LR) 4% vs. 1% 6% vs. 2% 4.1% vs. 1.3% 2.1% vs. 1.1% overall
Statistically
significant
Statistically
significant
Statistically
significant
1.5% vs. 1.1% if ER positivea
Both not statistically significant
5-year LR in experimental arm 1 in 25 1 in 17 1 in 25 1 in 48 overall
1 in 71 if ER positive
BASO, British Association of Surgical Oncology.
a ER-positive prepathology, n= 1751; TARGIT 1.5% (five events, 95% CI 0.6% to 3.8%) vs. EBRT 1.1% (five events,
95% CI 0.5% to 2.6%); p = 0.95.
Blue font distinguishes TARGIT-A results from others and green font shows the results of the trials.
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Whole-study population: local recurrence
(a) Local recurrence:
i. The absolute number of local recurrence events (n) (Table 21).
ii. A Kaplan–Meier analysis including all patients from TARGIT-A for each treatment group showing
the cumulative risk of local recurrence over time using the latest available follow-up data.
The requested figures for this survival analysis are given below, with or without censor lines
and 95% CI curves (Figures 39–43). Figure 44 shows the 5-year survival without local recurrence.
The numbers of patients at risk of local recurrence in each treatment group at yearly intervals are
reported below the plot.
iii. The absolute difference in the Kaplan–Meier estimate of the 5-year risk of local recurrence
between treatment groups and the 95% CI around that difference.
¢ In the paper,2 we reported the 90% CI of the difference in binomial proportions, not of the
difference in Kaplan–Meier estimates (for non-inferiority testing the convention is to use the
90% CI rather than the 95% CI105,173–175). The difference between the binomial proportions of
local recurrence for TARGIT and EBRT was 0.72% (90% CI 0.15% to 1.30%) (95% CI 0.05%
to 1.40%).
¢ In the presence of censoring, the Kaplan–Meier point estimate at a particular time point, for
example 5 years, is not a simple binomial proportion. Therefore, it is inappropriate to apply the
simple formula normally used to calculate the SE (and CI) of a difference between binomial
proportions, namely
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SE12 + SE22
p
, to calculate differences between such point estimates.
¢ Furthermore, when looking at Kaplan–Meier curves, the right-hand end of the curve is the one
with the most uncertainty and with the widest CIs. These values, that is, 5-year point
estimates, should not be used to calculate the CI of the difference or for testing non-inferiority.
National Institute for Health and Care Excellence agreed that the differences in 5-year Kaplan–Meier
estimates are not to be used for assessing non-inferiority, but are provided for completion. For local
recurrence the difference is 2% (95% CI –0.14% to 4.14%) (90% CI 0.18% to 3.82%). For survival
without local recurrence the difference is 0.64% (95% CI –2.09% to 3.37%) (90% CI –1.69% to 2.97%).
The appropriate method for calculating the difference between Kaplan–Meier curves is by using the
integrated difference of the two survival functions to quantify the difference between the Kaplan–Meier
curves.176 The difference between the Kaplan–Meier curves for TARGIT and EBRT from 0 to 5 years is
0.62% (95% CI 0.007% to 1.24%).
TABLE 21 The absolute number of local recurrence events (n), whole trial
Whole-study population TARGIT EBRT
Number of local recurrence events 23 11
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FIGURE 39 Whole-trial: Kaplan–Meier curves of cumulative risk of local recurrence over time for each treatment,
with tick marks indicating censoring and 95% CIs around the curve for each treatment group. (a) Local recurrence
in the conserved breast (all patients) with 95% CIs and censor lines: magnified y-axis; and (b) local recurrence in the
conserved breast (all patients) with 95% CIs and censor lines: full y-axis. Light green lines, 95% CI of TARGIT;
light blue lines, 95% CI of EBRT. Censoring ticks: small black vertical lines at the point of last follow up, withdrawal
or death.
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FIGURE 40 Whole-trial: Kaplan–Meier curves of cumulative risk of local recurrence over time for each treatment,
without tick marks indicating censoring but with 95% CIs around the curve for each treatment group. (a) Local
recurrence in the conserved breast (all patients) with 95% CIs: magnified y-axis; and (b) local recurrence in the
conserved breast (all patients) with 95% CIs: full y-axis. Light green lines, 95% CI of TARGIT; light blue lines, 95% CI
of EBRT.
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FIGURE 41 Whole-trial: Kaplan–Meier curves of cumulative risk of local recurrence over time for each treatment,
with tick marks indicating censoring but without 95% CIs around the curve for each treatment group. (a) Local
recurrence in the conserved breast (all patients) with censor lines: magnified y-axis; and (b) local recurrence in the
conserved breast (all patients) with censor lines: full y-axis. Censoring ticks: small black vertical lines at the point of
last follow up, withdrawal or death.
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FIGURE 42 Whole-trial: Kaplan–Meier curves of cumulative risk of local recurrence over time for each treatment,
without tick marks indicating censoring or 95% CIs around the curve for each treatment group. (a) Local
recurrence in the conserved breast (all patients): magnified y-axis; and (b) local recurrence in the conserved breast
(all patients): full y-axis. Part (a) reproduced with permission from Vaidya et al.2 Copyright © Vaidya et al.
Open Access article distributed under the terms of CC BY-NC-ND.
FURTHER ANALYSIS AS REQUESTED BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
118
TARGIT
EBRT
100%
(a)
95%
Su
rv
iv
al
 w
it
h
o
u
t 
lo
ca
l 
re
cu
rr
en
ce
90%
0 1 2
Years
Survival without local recurrence
All patients
3 4 5
1679
1696
Number at risk
TARGIT
EBRT
1251
1244
963
956
679
674
491
479
290
296
TARGIT
EBRT
100%
(b)
90%
80%
70%
60%
50%
Su
rv
iv
al
 w
it
h
o
u
t 
lo
ca
l 
re
cu
rr
en
ce
40%
30%
20%
10%
0%
0 1 2
Years
Survival without local recurrence
All patients
3 4 5
1679
1696
Number at risk
TARGIT
EBRT
1251
1244
963
956
679
674
491
479
290
296
FIGURE 43 Whole-trial: Kaplan–Meier curves of cumulative survival without local recurrence. (a) Survival without
local recurrence (all patients): magnified y-axis; and (b) survival without local recurrence (all patients): full y-axis.
This Kaplan–Meier plot is the true representation of how patients with breast cancer would fare in the first 5 years
of their life following treatment with TARGIT or EBRT with respect to local control. Censoring is carried out at the
point of last follow-up or withdrawal.62,63 For any patient her chance of being alive without local recurrence can be
read off this plot. Five-year survival without local recurrence: TARGIT 93.1% (95% CI 90.8% to 94.9%); EBRT 93.8%
(95% CI 91.7% to 95.4%) (p= 0.81).
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Whole-study population: survival
(b) Survival (whole trial).
i. The absolute number of deaths (n) (Table 22).
ii. The number of patients with different causes of death (n) (Table 23).
iii. Kaplan–Meier analysis of mortality:
A Kaplan–Meier analysis including all patients from TARGIT-A for each treatment group showing the
cumulative risk of death over time using the latest available follow-up data. The two requested figures
for this survival analysis are given below, with or without 95% CI curves (Figures 44 and 45).
iv. The absolute difference in the Kaplan–Meier estimate of the 5-year risk of overall mortality between
treatment groups (TARGIT and EBRT) in the whole-study population and the 95% CI around that
difference. Note that the caveats mentioned in Whole-study population: local recurrence about using
5-year estimates to calculate the difference between treatments and its CI should be read before using
these figures. The difference between 5-year Kaplan–Meier estimates is –1.38% (95% CI –3.67% to
0.91%) (90% CI –3.3% to 0.57%). Using the integrated difference of the two survival functions to
quantify the difference between the Kaplan–Meier curves,176 the difference between the Kaplan–Meier
curves for TARGIT and EBRT from 0 to 5 years is –0.85% (95% CI –1.75% to 0.04%).
TABLE 23 The number of patients with different causes of death (n), whole trial
Whole-study population, causes of death TARGIT EBRT
Breast cancer 20 16
Other cancer 8 16
Cardiac 2 8
Other vascular 0 3
Other 7 8
TABLE 22 The absolute number of deaths (n), whole trial
Whole-study population TARGIT EBRT
Number of deaths 37 51
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FIGURE 44 Whole-trial: Kaplan–Meier curves (including all patients) for each treatment group showing the
cumulative risk of overall mortality including the 95% CIs around each curve for each treatment group. Light green
lines, 95% CI of TARGIT; light blue lines, 95% CI of EBRT.
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(c) Breast cancer mortality (whole trial).
i. The absolute number of breast cancer deaths (n) (Table 24).
ii. Kaplan–Meier analysis of breast cancer deaths.
A Kaplan–Meier analysis including all patients from TARGIT-A for each treatment group showing
the cumulative risk of breast-cancer death over time using the latest available follow-up data.
The two requested figures for this survival analysis are given below, with or without 95% CI curves
(Figures 46 and 47).
iii. The absolute difference in the Kaplan–Meier estimate of the 5-year risk of breast cancer mortality
between treatment groups (TARGIT and EBRT) in the whole-study population and the 95% CI
around that difference. Note that the caveats mentioned in Whole-study population: local
recurrence about using 5-year estimates to calculate the difference between treatments and its CI
should be read before using these figures. The difference between 5-year Kaplan–Meier estimates
is 0.67% (95% CI –1.01% to 2.35%) (90% CI –0.76% to 2.10%). Using the integrated difference
of the two survival functions to quantify the difference between the Kaplan–Meier curves,176 the
difference between the Kaplan–Meier curves for TARGIT and EBRT from 0 to 5 years is 0.15%
(95% CI –0.71% to 0.42%).
TABLE 24 The absolute number of breast cancer deaths (n), whole trial
Whole-study population TARGIT EBRT
Number of breast cancer deaths 20 16
TARGIT
EBRT
10%
5%
D
ea
th
0%
0 1 2
Years
Death
All patients
3 4 5
1721
1730
Number at risk
TARGIT
EBRT
1285
1272
997
978
706
693
514
496
309
302
FIGURE 45 Whole-trial: Kaplan–Meier curves (including all patients) for each treatment group showing the
cumulative risk of overall mortality not including the 95% CIs around each curve for each treatment group.
Reproduced with permission from Vaidya et al.2 Copyright © Vaidya et al. Open Access article distributed under the
terms of CC BY-NC-ND.
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FIGURE 46 Whole-trial: Kaplan–Meier curves (including all patients) for each treatment group showing the
cumulative risk of breast cancer death including the 95% CIs around each curve for each treatment group.
Light green lines, 95% CI of TARGIT; light blue lines, 95% CI of EBRT.
TARGIT
EBRT
10%
5%
B
re
as
t 
ca
n
ce
r 
d
ea
th
0%
0 1 2
Years
Breast cancer death
All patients with 95% CI
3 4 5
1721
1730
Number at risk
TARGIT
EBRT
1285
1272
997
978
706
693
514
496
309
302
FIGURE 47 Whole-trial: Kaplan–Meier curves (including all patients) for each treatment group showing the
cumulative risk of breast cancer death not including 95% CIs. Reproduced with permission from Vaidya et al.2
Copyright © Vaidya et al. Open Access article distributed under the terms of CC BY-NC-ND.
FURTHER ANALYSIS AS REQUESTED BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
122
(d) Non-breast-cancer mortality (whole trial).
i. The absolute number of non-breast-cancer deaths (n) (Table 25).
ii. Kaplan–Meier analysis of non-breast-cancer mortality:
A Kaplan–Meier analysis including all patients from TARGIT-A for each treatment group showing
the cumulative risk of non-breast-cancer death over time using the latest available follow-up data.
The two requested figures for this survival analysis are given below, with or without 95% CI curves
(Figures 48 and 49).
iii. The absolute difference in the Kaplan–Meier estimate of the 5-year risk of non-breast-cancer
mortality between treatment groups (TARGIT and EBRT) in the whole-study population and the
95% CI around that difference. Note that the caveats mentioned in Whole-study population: local
recurrence about using 5-year estimates to calculate the difference between treatments and its CI
should be read before using these figures. The difference between 5-year Kaplan–Meier estimates is
–2.08% (95% CI –3.70% to –0.46%) (90% CI –3.46% to –0.70%). Using the integrated difference
of the two survival functions to quantify the difference between the Kaplan–Meier curves,176 the
difference between the Kaplan–Meier curves for TARGIT and EBRT from 0 to 5 years is –0.72
(95% CI –1.42 to –0.02).
(e) Tabulation of the number of patients with at least 5 years of follow-up data (Table 26).
TABLE 25 The absolute number of non-breast-cancer deaths (n), whole trial
Whole-study population TARGIT EBRT
Number of non-breast-cancer deaths 17 35
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FIGURE 48 Whole-trial: Kaplan–Meier curves (including all patients) for each treatment group showing the
cumulative risk of non-breast-cancer death including the 95% CIs around each curve for each treatment group.
Light green lines, 95% CI of TARGIT; light blue lines, 95% CI of EBRT.
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Prepathology stratum: local recurrence
(a) Local recurrence.
i. The absolute number of local recurrence events (n) (Table 27).
ii. A Kaplan–Meier analysis including all patients in the prepathology stratum of the TARGIT-A trial for
each treatment group showing the cumulative risk of local recurrence over time using the latest
available follow-up data. The requested figures for this survival analysis are given below, with or
without censor lines and 95% CI curves (Figures 50–53). Figure 54 shows the 5-year survival
without local recurrence. The numbers of patients at risk of local recurrence in each treatment
group at yearly intervals are reported below the plot.
iii. The absolute difference in the Kaplan–Meier estimate of the 5-year risk of local recurrence
between treatment groups and the 95% CI around that difference.
¢ In the paper,2 we reported the 90% CI of the difference in binomial proportions, not of the
difference in Kaplan–Meier estimates (for non-inferiority testing the convention is to use
the 90% CI rather than the 95% CI105,173–175).
¢ The difference between binomial proportions of local recurrence for TARGIT and EBRT was
0.37% (90% CI –0.23% to 0.97%) (95% CI –0.33% to 1.07%).
¢ In the presence of censoring, the Kaplan–Meier point estimate at a particular time point, for
example 5 years, is not a simple binomial proportion. Therefore, it is inappropriate to apply the
simple formula normally used to calculate the SE (and CI) of a difference between binomial
proportions, namely
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SE12 + SE22
p
, to calculate differences between such point estimates.
¢ Furthermore, when looking at Kaplan–Meier curves, the right-hand end of the curve is the one
with the most uncertainty and with the widest CIs. These values, that is, 5-year point
estimates, should not be used to calculate the CI of the difference or for testing non-inferiority.
TABLE 26 The number of patients with at least 5 years of follow-up data, whole trial
Whole-study population TARGIT EBRT Total
Number of patients with at least 5 years
of follow-up data (as of 25 June 2012)
309 302 611
Number of patients with at least 5 years
of follow-up data (as of 1 October 2014)
1116
Detailed new analysis below (see p. 135)
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FIGURE 49 Whole-trial: Kaplan–Meier curves (including all patients) for each treatment group showing the cumulative
risk of non-breast-cancer death not including the 95% CIs around each curve for each treatment group. Reproduced with
permission from Vaidya et al.2 Copyright © Vaidya et al. Open Access article distributed under the terms of CC BY-NC-ND.
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FIGURE 50 Prepathology stratum: Kaplan–Meier curves of cumulative risk of local recurrence over time for each
treatment, with tick marks indicating censoring and 95% CIs around the curve for each treatment group. (a) Local
recurrence in the conserved breast (prepathology) with 95% CIs and censor lines: magnified y-axis; and (b) local
recurrence in the conserved breast (prepathology) with 95% CIs and censor lines: full y-axis. Light green lines,
95% CI of TARGIT; light blue lines, 95% CI of EBRT. Censoring ticks: small black vertical lines at the point of last
follow up, withdrawal or death.
TABLE 27 The absolute number of local recurrence events (n), prepathology
Prepathology group TARGIT EBRT
Number of local recurrence events 10 6
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FIGURE 51 Prepathology stratum: Kaplan–Meier curves of cumulative risk of local recurrence over time for each
treatment, without tick marks indicating censoring but with 95% CIs around the curve for each treatment group.
(a) Local recurrence in the conserved breast (prepathology) with 95% CIs: magnified y-axis; and (b) local recurrence
in the conserved breast (prepathology) with 95% CIs: full y-axis. Light green lines, 95% CI of TARGIT; light blue
lines, 95% CI of EBRT.
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FIGURE 52 Prepathology stratum: Kaplan–Meier curves of cumulative risk of local recurrence over time for each
treatment, with tick marks indicating censoring but without 95% CIs around the curve for each treatment group.
(a) Local recurrence in the conserved breast (prepathology) with censor lines: magnified y-axis; and (b) local
recurrence in the conserved breast (prepathology) with censor lines: full y-axis. Censoring ticks: small black vertical
lines at the point of last follow up, withdrawal or death.
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FIGURE 53 Prepathology stratum: Kaplan–Meier curves of cumulative risk of local recurrence over time for each
treatment, without tick marks indicating censoring or 95% CIs around the curve for each treatment group.
(a) Local recurrence in the conserved breast (prepathology) with censor lines: magnified y-axis; and (b) local
recurrence in the conserved breast (prepathology) with censor lines: full y-axis. Part (a) reproduced with permission
from Vaidya et al.2 Copyright © Vaidya et al. Open Access article distributed under the terms of CC BY-NC-ND.
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FIGURE 54 Prepathology stratum: Kaplan–Meier curves of cumulative survival without local recurrence. (a) Survival
without local recurrence (prepathology): magnified y-axis; and (b) survival without local recurrence (prepathology):
full y-axis. This Kaplan–Meier plot is the true representation of how patients with breast cancer would fare in the
first 5 years of their life following treatment with TARGIT during lumpectomy or EBRT with respect to local control.
Censoring is carried out at the point of last follow-up or withdrawal.62,63 For any patient her chance of being alive
without local recurrence can be read off this graph. Five-year survival without local recurrence: TARGIT 93.9%
(95% CI 90.9% to 95.9%); EBRT 92.5% (95% CI 89.7% to 94.6%) (p= 0.35).
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National Institute for Health and Care Excellence agreed that the differences in 5-year Kaplan–Meier
estimates are not to be used for assessing non-inferiority, but are provided for completion. For local
recurrence the difference is 1% (95% CI –0.68% to 2.68%) (90% CI –0.43% to 2.43%). For survival
without local recurrence the difference is –1.32% (95% CI –4.74% to 2.10%) (90% CI –4.24% to 1.60%).
If the difference in Kaplan–Meier estimates is being used to assess the difference between treatments
(despite the concerns about using these), then although the upper confidence limit of the 95% CI of the
difference in local recurrence is 2.68%, the absolute difference in overall mortality between TARGIT and
EBRT is –2.33% (95% CI –5.48% to 0.82%), favouring TARGIT. The lower confidence limit of the 95% CI
for overall mortality is –5.48 and this is a very much larger value than for local recurrence and is in the
opposite direction – for a much more important outcome. It would mean that, although at worst the
difference in local recurrence might be 2.68% favouring EBRT, the difference in overall mortality might be
5.48% favouring TARGIT. One cannot consider one and ignore the other value.
In addition, while discussing the actual difference between recurrence rates (not for non-inferiority
determination), both the 95% confidence limits need to be looked at, not just one. If the upper 95%
confidence limit is considered, that is, 2.68%, as the worst-case scenario, then the lower 95% confidence
limit (–0.68%) should also be considered as it has exactly the same chance of occurring.
The chance of being alive without local recurrence is the most relevant statistic (there cannot really be a
local recurrence if the patient is no longer alive). For this statistic, the two treatments have very similar
outcomes; the number of events is also large and similar in the two arms [TARGIT 57 vs. EBRT 59 for the
whole trial (n = 3451) and TARGIT 36 vs. EBRT 45 for the prepathology stratum (n = 2298): the number of
events without excluding those who had a mastectomy were 120 (59 vs. 61) in the whole trial and 85
(TARGIT 38 vs. EBRT 47) in the prepathology stratum].
The appropriate method of calculating the difference between Kaplan–Meier curves is by using the
integrated difference of the two survival functions to quantify the difference between the Kaplan–Meier
curves.176 The difference between the Kaplan–Meier curves for TARGIT and EBRT from 0 to 5 years is 0.3%
(95% CI –0.4% to 1.03%).
Prepathology stratum: survival
i. The absolute number of deaths (n) (Table 28).
ii. The number of patients with different causes of death (n) (Table 29).
iii. Kaplan–Meier analysis of survival:
A Kaplan–Meier analysis including all patients in the prepathology stratum of the TARGIT-A trial for
each treatment group showing the cumulative risk of death over time using the latest available
follow-up data. The two requested figures for this survival analysis are given below, with or without
95% CI curves (Figures 55 and 56).
iv. The absolute difference in the Kaplan–Meier estimate of the 5-year risk of overall mortality between
treatment groups (TARGIT and EBRT) in the whole-study population and the 95% CI around that
difference. Note that the caveats mentioned in Whole-study population: local recurrence about using
5-year estimates to calculate the difference between treatments and its CI should be read before using
these figures. The difference between the 5-year Kaplan–Meier estimates is –2.33% (95% CI –5.48%
to 0.82%) (90% CI –5.02% to 0.36%). Using the integrated difference of the two survival functions to
quantify the difference between the Kaplan–Meier curves,176 we found that the difference between the
Kaplan–Meier curves for TARGIT and EBRT from 0 to 5 years is –1.43% (95% CI –2.66% to –0.2%).
TABLE 28 The absolute number of deaths (n), prepathology
Prepathology group TARGIT EBRT
Number of deaths 29 42
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TABLE 29 The number patients with different causes of death (n), prepathology
Prepathology group, causes of death TARGIT EBRT
Breast cancer 17 15
Other cancer 5 12
Cardiac 2 6
Other vascular 0 2
Other 5 7
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FIGURE 55 Prepathology stratum: Kaplan–Meier curves (including all patients in the prepathology group) for each
treatment group showing the cumulative risk of overall mortality including the 95% CIs around each curve for
each treatment group. Light green lines, 95% CI of TARGIT; light blue lines, 95% CI of EBRT.
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FIGURE 56 Prepathology stratum: Kaplan–Meier curves (including all patients in the prepathology group) for each
treatment group showing the cumulative risk of overall mortality not including the 95% CIs. Reproduced with permission
from Vaidya et al.2 Copyright © Vaidya et al. Open Access article distributed under the terms of CC BY-NC-ND.
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(b) Breast cancer mortality (prepathology stratum).
i. The absolute number of breast cancer deaths (n) (Table 30).
ii. Kaplan–Meier analysis of survival:
A Kaplan–Meier analysis including all patients in the prepathology stratum of the TARGIT-A trial for
each treatment group showing the cumulative risk of breast cancer death over time using the latest
available follow-up data. The two requested figures for this survival analysis are given below, with or
without 95% CI curves (Figures 57 and 58).
iii. The absolute difference in the Kaplan–Meier estimate of the 5-year risk of breast cancer mortality
between treatment groups (TARGIT and EBRT) in the whole-study population and the 95% CI
around that difference. Note that the caveats mentioned in Whole-study population: local recurrence
about using 5-year estimates to calculate the difference between treatments and its CI should be
read before using these figures. The difference between the 5-year Kaplan–Meier estimates is
0.66% (95% CI –1.72% to 3.04%) (90% CI –1.36% to 2.68%). Using the integrated difference of
the two survival functions to quantify the difference between the Kaplan–Meier curves,176 we found
that the difference between the Kaplan–Meier curves for TARGIT and EBRT from 0 to 5 years is
–0.34% (95% CI –1.17% to 0.49%).
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FIGURE 57 Prepathology stratum: Kaplan–Meier curves (including all patients in the prepathology group) for each
treatment group showing the cumulative risk of breast cancer death including the 95% CIs around each curve for
each treatment group. Light green lines, 95% CI of TARGIT; light blue lines, 95% CI of EBRT.
TABLE 30 The absolute number of breast cancer deaths (n), prepathology
Prepathology group Intrabeam EBRT
Number of breast cancer deaths 17 15
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(c) Non-breast-cancer mortality (prepathology stratum).
i. The absolute number of non-breast-cancer deaths (n) (Table 31).
ii. Kaplan–Meier analysis of survival:
A Kaplan–Meier analysis including all patients in the prepathology stratum of the TARGIT-A trial for
each treatment group showing the cumulative risk of non-breast-cancer death over time using the
latest available follow-up data. The two requested figures for this survival analysis are given below,
with or without 95% CI curves (Figures 59 and 60).
iii. The absolute difference in the Kaplan–Meier estimate of the 5-year risk of non-breast-cancer
mortality between treatment groups (TARGIT and EBRT) in the whole-study population and the 95%
CI around that difference. Note that the caveats mentioned in Whole-study population: local
recurrence about using 5-year estimates to calculate the difference between treatments and its CI
should be read before using these figures. The difference between the 5-year Kaplan–Meier
estimates is –3.07% (95% CI –5.25% to 0.89%) (90% CI –4.93% to 1.21%). Using the integrated
difference of the two survival functions to quantify the difference between the Kaplan–Meier
curves,176 we found that the difference between the Kaplan–Meier curves for TARGIT and EBRT from
0 to 5 years is –1.11% (95% CI –2.05% to –0.17%).
(d) Tabulation of the number of patients with at least 5 years of follow-up data (Table 32).
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FIGURE 58 Prepathology stratum: Kaplan–Meier curves (including all patients in the prepathology group) for each
treatment group showing the cumulative risk of breast cancer death not including the 95% CIs. Reproduced with
permission from Vaidya et al.2 Copyright © Vaidya et al. Open Access article distributed under the terms of CC
BY-NC-ND.
TABLE 31 The absolute number of non-breast-cancer deaths (n), prepathology
Prepathology group TARGIT EBRT
Number of non-breast-cancer deaths 12 27
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FIGURE 59 Prepathology stratum: Kaplan–Meier curves (including all patients in the prepathology group) for each
treatment group showing the cumulative risk of non-breast-cancer death including the 95% CIs around each curve
for each treatment group. Light green lines, 95% CI of TARGIT; light blue lines, 95% CI of EBRT.
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FIGURE 60 Prepathology stratum: Kaplan–Meier curves (including all patients in the prepathology group) for each
treatment group showing the cumulative risk of non-breast-cancer death not including the 95% CIs. Reproduced
with permission from Vaidya et al.2 Copyright © Vaidya et al. Open Access article distributed under the terms of CC
BY-NC-ND.
TABLE 32 The number of patients with at least 5 years of follow-up data, prepathology
Prepathology group Intrabeam EBRT Total
Number of patients with at least 5 years
of follow-up data (as of 25 June 2012)
199 204 403
Number of patients with at least 5 years
of follow-up data (as of 1 October 2014)
776
Detailed new analysis below (see p. 135)
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New analysis
1. During the meeting of 8 December 2014, we presented an additional analysis of the data published in
The Lancet,2 namely that the disease-free survival of the patients in the TARGIT and EBRT arms is
identical for the whole trial (p = 0.78) and for the prepathology stratum (p = 0.68), with the
Kaplan–Meier curves overlapping each other (Figure 61).
2. As it was made clear to us that the NICE committee did not expect us to unblind the trial at this
moment, we presented new updated data resulting from increased follow-up as of 1 October 2014,
using the total number of events without unblinding the trial.
3. Further follow up: at the time of this analysis, the median follow-up was 4 years, which means that a
very large number of patients (n = 1725) had at least 4 years of follow-up or longer. This number is
large compared with the majority of breast cancer trials.
4. New events: with additional follow-up since the last data lock in June 2012, there was a total of 15
new local recurrences in the prepathology stratum. This was in addition to the 16 already reported in
The Lancet,2 out of a total number of 2298 patients.
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FIGURE 61 Ten-year Kaplan–Meier estimates for disease-free survival for (a) all patients; and (b) the prepathology
stratum [TARGIT 91.6% (95% CI 88.7% to 93.8%) vs. EBRT 90.1% (95% CI 86.8% to 92.6%) at 5 years and TARGIT
81.3% (95% CI 71% to 88%) vs. EBRT 71.2% (95% CI 49% to 85%) at 10 years].
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5. Remaining blind to the randomisation arm, we presented two hypothetical scenarios – one worst-case
scenario and one less extreme but still weighted against TARGIT.
6. For the 15 total new events of local recurrence, rather than an even split of seven compared with eight
or eight compared with seven, remaining blind to the randomisation arm we modelled the events as in
Tables 33 and 34.
7. For death, the secondary end point, there were 28 new events and these would need to have occurred
in a ratio of 20 in the TARGIT arm to 8 in the EBRT arm to equalise the total number of deaths
between the two treatments (Table 35). As the initial observation was 29 deaths in the TARGIT arm
and 42 in the EBRT arm, the probability of such a drastic reversal is low (p = 0.008) and so the
difference in deaths is likely to remain in favour of TARGIT.
Although NICE clarified that mortality was not the remit of this committee, we are compelled to
emphasise the fact to your attention because it arose during the discussion. It is important to recognise
that, when a study actually finds a difference, the question of power is not relevant any more. Then,
the probability of observing the difference favouring TARGIT that was observed, if there was no real
difference between the two groups is given by the p-value, which in the case of the TARGIT-A trial
was 0.099 for all deaths and 0.0086 for deaths from causes other than breast cancer. We believe we
cannot ignore these randomised data, particularly when deaths were more frequent than recurrences
(n = 88 vs. n = 34) and non-breast-cancer deaths (n = 52) were more frequent than breast cancer
deaths (n = 36) or local recurrences (n = 34).
TABLE 33 A worst-case hypothetical scenario in which the new local recurrences might be distributed as TARGIT 12,
EBRT 3
TARGIT (n= 1107) EBRT (n= 1127)
Actual local recurrences published (5-year risk) 10 (2.2%) 6 (1.2%)
Hypothetical theoretical split of new events – a
worst-case scenario
12 3
Hypothetical new total local recurrences (rate) 22 (1.99%) 9 (0.8%)
Difference 1.19% (90% CI 0.4% to 2.0%)
(95% CI 0.2% to 2.2%)
Pnon-inferiority 0.0041
TARGIT remains non-inferior to EBRT even in the worst-case
Even in this case, the difference between the binomial proportions of the two arms is only 1.19% (90% CI 0.4% to 2.0%)
(95% CI 0.2% to 2.2%) (Pnon-inferiority= 0.0041). Therefore, even in this worst-case scenario, TARGIT remains non-inferior to EBRT.
TABLE 34 A less extreme hypothetical scenario, still weighted against TARGIT might be that the new local
recurrences are distributed as TARGIT 10, EBRT 5
TARGIT (n= 1107) EBRT (n= 1127)
Actual local recurrences published (5-year risk) 10 (2.2%) 6 (1.2%)
Hypothetical theoretical split of new events – a less
extreme scenario, still weighted against TARGIT
10 5
Hypothetical new total local recurrences (rate) 20 (1.8%) 11 (0.97%)
Difference 0.83% (90% CI 0.0% to 1.6%)
(95% CI –0.1% to 1.8%)
Pnon-inferiority 0.00038
TARGIT remains non-inferior to EBRT
In this case, the difference between the binomial proportions of the two arms is 0.83% (90% CI 0.0% to 1.6%) (95% CI
–0.1% to 1.8%) (Pnon-inferiority = 0.00038) and TARGIT remains non-inferior to EBRT.
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8. We were asked by the NICE committee whether or not we would offer INTRABEAM to patients in the
control arm of the TARGIT-A trial who have already received EBRT if NICE gives a positive response. In
fact, the surgery and radiation treatment of patients in the TARGIT-A trial (whether INTRABEAM or
whole-breast radiotherapy) has already been long completed (the trial closed in June 2012). Therefore,
all those who received EBRT in the TARGIT-A trial cannot and will not be offered an operation to
reopen their wound and give INTRABEAM.
9. Please note that, as published in The Lancet,2 there is no significant difference between TARGIT and
EBRT by conventional log-rank test (p = 0.31) and TARGIT was non-inferior to EBRT using the standard
test for non-inferiority (Pnon-inferiority < 0.00001).
The TARGIT-A trial investigators offered to supply the raw data as long as all of the governance, consent,
custody, data access and security issues were looked after appropriately. NICE declined, saying that it was
not necessary to supply the raw data because all of the analysis requested by the committee had been
satisfactorily supplied.
Table 36 shows the results of the four different methods of analyses and the raw numbers, which
essentially show very similar results.
In conclusion, using four quite separate statistical methodologies, the TARGIT-A trial has demonstrated
that the risk-adapted approach using single-dose TARGIT IORT given during lumpectomy provides breast
cancer control that is not inferior to several weeks of conventional radiotherapy.
Acknowledgement
We thank Dr Hajime Uno PhD (Department of Biostatistics, Harvard University, Boston, MA, USA) for
providing the software code and for independently verifying our results and our interpretation.
TABLE 35 A model for the additional deaths
TARGIT (n= 1107) EBRT (n= 1127)
Number of deaths as of June 20122 29 42
Hypothetical theoretical split of new events – a worst-case scenario 20a 8a
Hypothetical new total deaths 49 50
a The probability of observing such a reversal of numbers if there is no real difference is very low (p = 0.008) and it is
therefore more likely that there are fewer deaths in the TARGIT arm than in the EBRT arm.
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Appendix 1 International Steering Committee and
Data Monitoring Committee
TABLE 37 Dates and venues of ISC meetings
Meeting Date Venue
01 March 2002 Barcelona
02 November 2002 Frankfurt
03 March 2003 St Gallen
04 December 2003 San Antonio
05 March 2004 Hamburg
06 June 2004 New Orleans
07 December 2004 San Antonio
08 January 2005 St Gallen
09 May 2005 Orlando
10 October 2005 Paris
11 March 2006 Nice
12 November 2006 Venice
13 March 2007 St Gallen
14 November 2007 Frankfurt
15 April 2008 Berlin
16 September 2008 London
17 March 2009 St Gallen
18 September 2009 Berlin
19 December 2009 Teleconference
20 March 2010 Barcelona
21 November 2010 London
22 March 2011 St Gallen
23 September 2011 Frankfurt
24 March 2012 Vienna
25 July 2012 London
26 September 2012 London
27 March 2014 London
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International Steering Committee members
Jayant S Vaidya, Frederik Wenz, Max Bulsara, Jeffrey S Tobias, David J Joseph (co-chairperson),
Mohammed Keshtgar, Henrik L Flyger, Samuele Massarut, Michael Alvarado, Christobel Saunders,
Wolfgang Eiermann, Marinos Metaxas, Elena Sperk, Marc Sütterlin, Laura Esserman, Alastair Thompson,
John A Dewar, Mary Falzon, Eleanor Harris, Frank Melchert, Albert Schmidt, Olive Murphy, Joan Houghton,
Oscar Streeter, Michael Osborne, Chuck Vecoli, Uta Kraus-Tiefenbacher, April Matthews, Tammy Corica,
Norman R Williams and Michael Baum (co-chairperson).
Data Monitoring Committee members
Jack Cuzick, Hazel Thornton and Alan Rodger.
Contrary to the statement by Jack Cuzick published in the correspondence columns of The Lancet on
17 May 2014, he did not resign. This was corrected on the Lancet website on 10 April 2015.
The remit of the DMC was completed when the trial finished recruitment in June 2012. The committee
was thanked and dissolved on 24 May 2013.
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Appendix 2 Accrual
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FIGURE 65 Accrual in the UK for the TARGIT trial. GST, Guy’s and St Thomas’ Hospital; HJE, Hospital of St Johns
and St Elizabeth; RFH, Royal Free Hospital.
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Appendix 3 List of presentations
The TARGIT website [see www.targit.org.uk (accessed 7 July 2016)] has a wealth of information aboutthe TARGIT technique and the TARGIT trials.
Date Invited presentation title and meeting
2 March 1997 Multicentricity of breast cancer: new findings and their clinical and biological implications
(15 minutes)
1st Annual Meeting of the Indian Breast Group at Tata Memorial Hospital, Mumbai, India
2 March 1998 Local recurrence has nothing to do with residual disease (20 minutes)
Biennial Presidential Conference of the British Oncological Association, Royal Society of Medicine,
London, UK
19 September 1998 Radiosurgery: a novel method of treatment of early breast cancer (15 minutes)
International Meeting on Whole-Body Stereotactic Radiotherapy, Edinburgh, UK
13 November 1998 Radiosurgery: a novel method of treatment of early breast cancer (15 minutes)
North London Cancer Network Breast Cancer Tumour Board Away Day, Royal Society of Arts,
London, UK
18 February 1999 Novel radiotherapy techniques at the Middlesex hospital (45 minutes)
Meyerstein Institute of Oncology Seminar, London, UK
22 June 1999 Radiosurgery: an innovative approach to management of early breast cancer (45 minutes)
Surgical Forum, Department of Surgery, Norfolk and Norwich University Hospital, Norwich, UK
7 September 1999 Radiosurgery: an innovative approach to local treatment of breast cancer (1 hour)
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
8 September 1999 Radiosurgery: an innovative approach to local treatment of breast cancer (1 hour)
Cleveland Clinic, Cleveland, OH, USA
13 September 1999 Radiosurgery: an innovative approach to local treatment of breast cancer (1 hour)
Our Lady of Mercy Medical School, New York, NY, USA
18 February 2000 Breast conservative therapy – novel approaches – targeted Intraoperative radiotherapy
(20 minutes)
Breast Cancer in the New Millennium, Nagpur, India
1–2 December 2000 Rethinking cancer research – discussion
‘Blue-Skying’ the Future of Cancer Research, Cambridge, UK
9 December 2000 TARGIT – a novel approach to local treatment of breast cancer (30 minutes)
23rd Annual San Antonio Breast Cancer Conference (Satellite Symposium), San Antonio, TX, USA
31 January 2001 Targeted intraoperative radiotherapy for breast cancer – a randomised trial (20 minutes)
International Conference of Radiation Oncology (ICRO) (Satellite Symposium), Melbourne, VIC
Australia
27 February 2002 Intraoperative radiotherapy for breast cancer (20 minutes)
Breakthrough Breast Cancer, London, UK
8 March 2002 Intraoperative radiotherapy for breast cancer – the UK experience
8th Annual Clinical Oncology Symposium: Current Concepts and Developments in Intraoperative
Radiation Oncology, New York, NY, USA
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Date Invited presentation title and meeting
20 March 2002 Targeted intraoperative radiotherapy – rationale, technique and results (30 minutes)
3rd European Breast Cancer Conference, Barcelona, Spain
17 May 2002 Targeted Intraoperative radiotherapy – rationale, technique and results
Congress of the Portuguese Society of Radiology and Radiotherapy, Algarve, Portugal
22 May 2002 Targeted intraoperative radiotherapy for early breast cancer – a randomised trial
American Brachytherapy Society meeting, Orlando, FL, USA
5 June 2002 Targeted intraoperative radiotherapy – a randomised trial (30 minutes)
4th Milan Breast Cancer Conference, Milan, Italy
17 June 2002 TARGIT
5th meeting of UK clinical triallists, Birmingham, UK
25 September 2002 Supervision of first two cases of intraoperative radiotherapy for breast cancer using INTRABEAM
and lecture (1 hour)
CRO (National Cancer Institute), Aviano, Italy
5 November 2002 Intraoperative radiotherapy for breast cancer
Symposium on Novel Treatments for Breast Cancer, Empoli, Italy
13 March 2003 Update on cosmetic outcome of TARGIT
8th International Conference: Primary Therapy of Early Breast Cancer (Satellite Symposium on
Intraoperative Radiotherapy), St Gallen, Switzerland
6 June 2003 TARGIT – targeted Intraoperative radiotherapy for breast cancer (30 minutes)
5th Milan Breast Cancer Conference, Milan, Italy
19 August 2003 Targeted intraoperative radiotherapy, its rationale, technique and trials (45 minutes)
MD Anderson Cancer Center, Houston, TX, USA
4 December 2003 Intraoperative radiotherapy for breast cancer (TARGIT) (30 minutes) – webcast [PowerPoint®
(Microsoft Corporation, Redmond, WA, USA)]
26th Annual Breast Cancer Conference, San Antonio, TX, USA
9 December 2003 The novel approach of targeted intraoperative radiotherapy for breast cancer (45 minutes)
Memorial Sloan Kettering Cancer Center, New York, NY, USA
9 December 2003 The novel approach of targeted intraoperative radiotherapy for breast cancer (45 minutes)
New York Presbyterian Hospital, Cornell Institute, New York, NY, USA
3 February 2004 Intraoperative radiotherapy for breast cancer (TARGIT)
Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
18 Jun 2004 Updated results of TARGIT (15 minutes)
6th Milan Breast Cancer Conference, Milan, Italy
19 November 2004 Intraoperative radiotherapy for breast cancer
Annual Meeting of the Scottish Radiological Society, Dundee, UK
26 November 2004 Intraoperative radiotherapy for breast cancer
Focus on Innovative and Locoregional Treatments – VII Congresso Nazionale SITILO (Societa’
Italiana di Terapie Integrate Locoregionali in Oncologia), Florence, Italy
7 December 2004 TARGIT meeting with surgeons and radiation oncologists
New Orleans, LA, USA
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
170
Date Invited presentation title and meeting
21 December 2004 The international TARGIT trial
1st Workshop on the Health Technology Assessment Programme for Italy (Programma Ricerca e
Innovazione Emilia-Romagna – 1° Workshop – La radiotherapia intraoperatoria nel tumore della
mammella), Bologna, Italy
25 February 2005 Targeted intraoperative radiotherapy trial
Scottish Cancer Triallists Meeting, St Andrews, UK
1 November 2005 Debate on partial breast irradiation in selected patients and accurate targeting of boost in others:
rationale for partial breast irradiation in selected patients (15 minutes)
13th European Cancer Conference (ECCO-13), Paris, France
17 December 2005 Intraoperative radiotherapy for breast cancer (20 minutes)
3rd European Conference on Plastic and Reconstructive Surgery of the Breast, Milan, Italy
10 March 2006 Targeted intraoperative radiotherapy trial
Breast Cancer Triallists Meeting, Dundee, UK
24 June 2006 The indications for TARGIT (20 minutes)
8th Milan Breast Cancer Conference, Milan, Italy
14 March 2007 Targeted intraoperative radiotherapy – rationale, technique and clinical trials (30 minutes)
10th International Conference on Primary Therapy of Early Breast Cancer (Satellite Symposium),
St Gallen, Switzerland
18 April 2007 Breast conserving surgery – TARGIT for the 21st century and related translational research
(40 minutes)
Cambridge International Conference on Breast Screening, Cambridge, UK
15 September 2007 Cutting edge techniques at the forefront of breast surgery (40 minutes)
Delegates: about 100 surgeons from 17 countries (14–16 September 2007), Conrad Dublin,
Dublin, Ireland
19 September 2007 The TARGIT trials – alone and as a boost (1 hour)
Nottingham International Breast Cancer Conference (Satellite Symposium), Nottingham, UK
6 December 2007 Round table discussion between cancer specialists in the UK along with the Minister for Health,
the Cancer Czar, Chairman of the National Cancer Research Network (NCRN) and the All Party
Chairman On Cancer Care
House of Commons, London, UK
20 December 2007 Breast conserving surgery – TARGIT for the 21st century (1 hour)
Goa Medical College Staff Society Meeting, Goa, India
12 April 2008 Individualised treatment for breast cancer: TARGIT for the 21st century
Indian Breast Cancer Initiative, New Delhi, India
12 April 2008 Demonstration of operative technique: targeted intraoperative radiotherapy for breast cancer
Indian Breast Cancer Initiative, New Delhi, India
29 May 2008 An update of the novel approach to local treatment of breast cancer using intraoperative
radiotherapy
Radiation Medicine Program, RMP Special Lecture, Radiation Physics Department, University
Health Network, Princess Margaret Hospital, Toronto, ON, Canada
2 June 2008 TARGIT Satellite Meeting (30 minutes)
ASCO Satellite, Chicago, IL, USA
27 June 2008 TARGIT German user group meeting (30 minutes)
University of Mannheim, Mannheim, Germany
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Date Invited presentation title and meeting
13 January 2009 The TARGIT trial
Institute Curie, Paris, France
16 January 2009 The TARGIT trial
Sheffield Cancer Network, Sheffield, UK
12 March 2009 Targeted intraoperative radiotherapy – update of the randomised trial (20 minutes)
11th International Conference on Primary Therapy of Early Breast Cancer (Satellite Symposium),
St Gallen, Switzerland
8 May 2009 Individualising breast cancer treatment – TARGIT for the 21st century
Lincoln, UK
11 June 2009 TARGIT trial – progress
UK Breast Intergroup, Birmingham, UK
3 September 2009 Targeted intraoperative radiotherapy – the clinical trials
Copenhagen, Denmark
23 October 2009 Targeted Intraoperative radiotherapy
All India Institute of Medical Sciences, Army Medical Referral and Research Centre, New Delhi,
India
29 October 2009 Targeted intraoperative radiotherapy
Tata Memorial Hospital, Mumbai, India
30 October 2009 Demonstration of two surgical operations with the TARGIT procedure
Indo-American Cancer Centre and Research Institute, Hyderabad, India
7 November 2009 Innovations and progress in breast cancer treatment (unable to take up)
Innaugural conference, Institute of Breast Cancer, Saifee Hospital, Mumbai India
25 March 2010 TARGIT trials: a 15-year evolution
TARGIT Satellite Meeting, European Breast Cancer Conference, Barcelona, Spain
30 April 2010 Intraoperative radiotherapy (TARGIT trials) (plenary)
American Brachytherapy Society Meeting, Atlanta, GA, USA
6 June 2010 First results of the TARGIT-A trial: safety and efficacy of targeted intraoperative radiotherapy vs.
external beam radiotherapy results with a 10-year maximum follow up
TARGIT Symposium at the ASCO Meeting, Chicago, IL, USA
9 June 2010 First results of the TARGIT-A trial: safety and efficacy of targeted intraoperative radiotherapy vs.
external beam radiotherapy results with a 10-year maximum follow up
University of Louisville, KY, USA and University of Indianapolis, IN, USA
10 June 2010 First results of the TARGIT-A trial: safety and efficacy of targeted intraoperative radiotherapy vs.
external beam radiotherapy results with a 10-year maximum follow up
Cleveland Clinic, Cleveland, OH, USA
18 June 2010 First results of the TARGIT-A trial: safety and efficacy of targeted intraoperative radiotherapy vs.
external beam radiotherapy results with a 10-year maximum follow up
TARGIT Symposium, Milan Breast Cancer Conference, Milan, Italy
16 September 2010 Targit-A trial: the results at the end of 10 years maximum follow up and TARGIT-B trial: targeted
intra-operative radiotherapy boost – a randomised trial for young and high risk patients including
those after post-neoadjuvant systemic therapy lumpectomy (30 minutes)
European Society of Surgical Oncology, Bordeaux, France
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Date Invited presentation title and meeting
16 September 2010 Targit-A trial- the results at the end of 10 years maximum follow up (15 minutes) [plenary – given
via Skype™ (Microsoft Corporation, Redmond, WA, USA)]
British Breast Cancer Research Conference, Nottingham, UK
16 September 2010 Workshop on New Technologies – Intraoperative Radiotherapy (30 minutes) (could not take up)
British Breast Cancer Research Conference, Nottingham, UK
22 September 2010 TARGIT for the 21st century (30 minutes)
Annual South West England breast screening education day, Taunton Racecourse, Taunton, Exeter
23 September 2010 TARGIT-A trial results
Weekly meetings of the Institute of Womens’ Health, University College London, London, UK
7 October 2010 TARGIT-A trial results – lecture followed by panel discussion (25 minutes)
University College London Partners and North London Cancer Network Breast Cancer Away Day,
RIBA, London, UK
12 November 2010 TARGIT-A trial results, TARGIT-Boost trial and implications for India
Tata Memorial Hospital, Mumbai, India, and Raheja Hospital, Mumbai, India
13 November 2010 Plenary: TARGIT-A trial and TARGIT-Boost trial and implications for India; Panel discussion:
screening for breast cancer in India
New India Cancer Charity Initiative Brinker Awardee Symposium, New Delhi, India
14 November 2010 TARGIT-A trial results, TARGIT-Boost trial and implications for India
Apollo Hospital, New Delhi, India
26 February 2011 The evolution of TARGIT
National Undergraduate Medical Students Conference, University College London, London, UK
17 March 2011 TARGIT-A trial – 1 year on
St Gallen Breast Cancer Conference (Satellite Symposium), Switzerland
29 April 2011 Intraoperative radiotherapy (plenary)
American Society of Breast Surgeons, Washington, DC, USA
7 May 2011 Oxford style debate on intraoperative radiotherapy as a boost (plenary debate)
International Society of Intraoperative Radiotherapy (ISIORT) and ESTRO, London
12/13 May 2011 Demonstration of technique of TARGIT; TARGIT-A trial results and TARGIT-B trial
University of Padua Medical School, Padua, Italy
17 June 2011 TARGIT-A and TARGIT-Boost trials and implications for India
Medicity Hospital, New Delhi, India
18 June 2011 TARGIT-A and TARGIT-Boost trials and implications for India
Association of Radiation Oncologists in India (AROI) (Tamilnadu and Pondicherry Chapter),
Chennai, India
19 June 2011 TARGIT-A and TARGIT-Boost trials and implications for India
Bangalore Oncology Group Meeting, Bangalore, India
30 June 2011 TARGIT-A trial results
2nd UK National Breast Cancer Meeting, King’s Fund, London, UK
1 July 2011 TARGIT trials and training day
User group and training meeting, University of Mannheim, Mannheim, Germany
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Date Invited presentation title and meeting
28 August 2011 Main speaker, Swedish Surgical Society’s Annual Surgical Week
Karolinska Institute, Sweden
3 September 2011 Keynote address (30 minutes): Original research: evolution of TARGIT; Screening, MRI, and skin
sparing mastectomy (15 minutes)
Breast Cancer CME and Symposium, 1st West Zone CME Programme, Association of Breast
Surgeons of India, Pune, India
7 November 2011 Targeted intraoperative radiotherapy for breast cancer (TARGIT) (plenary)
British Association of Surgical Oncology – Association of Cancer Surgeons (BASO-ACS) Scientific
Conference, Royal College of Surgeons of England, London [see www.baso.org/conferences/
past-conferences/baso-∼-acs-scientific-conference-nov-2011.aspx (accessed 18 July 2016)]
29 December 2011 Keynote address: TARGIT – intraoperative radiotherapy to the breast (unable to take up)
71st Annual Conference of the Association of Surgeons of India (ASICON), Kochi, India
23 February 2012 New models of radiotherapy. Cutting-edge cancer treatments: expense and expectation?
An Independent Cancer Patients’ Voice workshop, CRUK London Research Institute, London, UK
27 February 2012 TARGIT trials update
Breast Tumour Away Day, North London Cancer Network, London, UK
15 March 2012 Intraoperative radiotherapy vs. whole breast radiotherapy (plenary – given via Skype)
9th Annual Miami Breast Cancer Conference, Miami, FL, USA
18 May 2012 IORT – who, when and how: TARGIT for India (plenary – remotely with audience participation)
1st Annual Conference of the Association of Breast Surgeons of India International Congress,
Hyderabad, India
9 June 2012 Update on targeted radiotherapy
9th Düsseldorf Breast Cancer Conference, Düsseldorf, Germany
13 June 2012 Expert advisor, Medical Technologies Advisory Committee meeting
NICE, London, UK
29 June 2012 TARGIT trials – surgical aspects and trial update
University of Mannheim, Mannheim, Germany
12 August 2012 Felicitation and lifetime achievement award lecture
Centenary Celebrations of the Gomant Vidya Niketan, Goa, India
13 September 2012 Invited speaker: intraoperative radiotherapy: results from the randomised trial
ASCO Breast Symposium, San Francisco, CA, USA
10/11 October 2012 Visiting Professorship, Morris Deutsch Memorial Lectureship Dinner and Grand Rounds
Johns Hopkins Hospital, Baltimore, MD, USA
19 October 2012 TARGIT-A and TARGIT-B trials
Master’s course – seminar on intraoperative radiotherapy, Madrid, Spain
30 November 2012,
will present Remotely
Surgery in breast cancer: does ‘less mean more?’
Patient First – Joint International Conference, Sri Balaji Vidhyapeeth, Pondicherry, India, and the
Royal College of Physicians and Surgeons, Glasgow, UK
2 February 2013 Main speaker: TARGIT trials in breast cancer
New York Metropolitan Breast Cancer Group (NYMBCG) 40th Annual Symposium, New York
Academy of Medicine, NY, USA
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Date Invited presentation title and meeting
13/14 April 2013 Guest plenary lecture: Breast conservation: emerging trends and future directions
Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
13 June 2013 TARGIT – update *Highlight*
7th INTRABEAM user meeting, Mannheim, Germany
19 September 2013 TARGIT trials
Clinicians from University of Miami, Miami, FL, USA
20 September 2013 TARGIT trials
Ashikari Breast Center, Dobbs Ferry, NY, USA
21 September 2013 TARGIT trials
Satellite meeting at ASTRO and Emory University, Atlanta, GA, USA
2 October 2013 Controversies in management of breast cancer: the evolution of the TARGIT treatment
Divisional Away Day, University College London, London, UK
4 October 2013 TARGIT trials
Journées Franco-Brésiliennes de Cancérologie Mammaire: Mise à Jour sur le Cancer du Sein –
Updating on Breast Cancer, Strasbourg, France
24 October 2013 Intraoperative technique – one stop shopping – what could be better? (25 minutes)
American Brachytherapy Society School of Breast Brachytherapy, Las Vegas, NV, USA
25 October 2013 Debate – IORT vs. APBI (1 hour)
American Brachytherapy Society School of Breast Brachytherapy, Las Vegas, NV, USA
9 January 2014 Developing evidence for new devices in clinical practice with randomised trials
UCL French Embassy Science and Technology Workshop, Nanomaterials for Biomedical
Applications, London, UK
7 February 2014 Results of the TARGIT-A trial
4th International Breast Disease Centres Congress, Paris, France
6 May 2014 The TARGIT-A and TARGIT-B trials (45 minutes)
Sírio Libanês Hospital, São Paulo, Brazil
7 May 2014 The TARGIT-A and TARGIT-B trials (30 minutes)
Brazilian National Cancer Hospital, with remote connection to the Cancer Hospital in Fortaleza
and Oswaldo Cruz Hospital in Recife, Brazil
8 May 2014 The TARGIT-A and TARGIT-B trials (30 minutes, plenary)
2nd International Breast Symposium, Salvador, Brazil
11 October 2014 The TARGIT-A and TARGIT-B trials
International Conference on Advances in Breast Cancer, Goa, India
31 October 2014 The TARGIT-A and TARGIT-B trials
ESSO-34 European Society of Surgical Oncology and British Association of Surgical Oncology Joint
Conference, Liverpool UK
12 November 2014 The TARGIT-A and TARGIT-B trials
Breast Educational Day, Oxford, UK
9 December 2014 The TARGIT-A trial results
NICE, London, UK
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Date Invited presentation title and meeting
10 February 2015 Oxford-style debate: the TARGIT-A trial results
Royal College of Radiologists, London, UK
27 April 2015 The TARGIT-A trial results – it is safe to not irradiate rest of the breast
ESTRO Forum, Barcelona, Spain
7 May 2015 The TARGIT-A and TARGIT-B trials
Mount Carmel Hospital West, Columbus OH, USA
7 May 2015 The TARGIT-A and TARGIT-B trials
William Beaumont Hospital, Michigan OH, USA
9 May 2015 The TARGIT-A and TARGIT-B trials
Advances in Brachytherapy Symposium, Weill Cornell Medical Center, New York, NY, USA
16 May 2015 The TARGIT-A and TARGIT-B trials [via FaceTime (Apple Inc., Cupertino, CA, USA)]
4th MAYMET SENATURK Meeting on Value Based Quality in Breast Care, Kusadasi, Aydin, Turkey
9–10 July 2015 Keynote lecture on the TARGIT trials, chairing of sessions
9th Intrabeam System User Meeting, Manheimm, Germany
26 August 2015 Expert opinion (no presentation)
INTRABEAM appraisal by NICE, London, UK
APBI, Accelerated Partial Breast Irradiation; CME, Continuing Medical Education.
Late-breaking proffered papers
Date Presentation title and meeting
1 November 2010 Targeted intraoperative radiotherapy (TARGIT) vs. whole breast external beam radiotherapy (EBRT)
by ASTRO risk categories: late-breaking abstract (oral presentation in the plenary hall)
52nd Annual meeting of ASTRO, San Diego, CA, USA
6 December 2012 Targeted intraoperative radiotherapy for early breast cancer: TARGIT-A trial – updated analysis of
local recurrence and first analysis of survival (oral presentation in the plenary hall)
35th San Antonio Breast Cancer Symposium, San Antonio, TX, USA
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Appendix 4 Future work
The grant applicants believe that there is much further work required and are in the process of applyingfor funding to carry out some or all of the following:
l work package 1: continue to gather efficacy and safety data to year 10, all centres
l work package 2: gather death and new primary cancer data from UK patients through the Office for
National Statistics
l work package 3: lymphoedema
l work package 4: health economics
l work package 5: patient preference
l work package 6: quality of life
l work package 7: cardiopulmonary effects.
Work package 1: continue to gather efficacy, safety and
follow-up data to year 10, all centres, using the current case
report forms as per protocol
Aim and rationale
The latest analysis of the TARGIT-A trial includes a very large number of patients (n = 1222) with a median
follow-up of 5 years and our analysis suggests that the results remain stable for cohorts of patients with
increasing periods of follow-up up to 5 years. However, for the whole trial, the median follow-up is
2.6 years and one of the barriers to widespread adaptations of the new treatment appears to be the
perception that we should undertake 5-year follow-up of all of the patients in the trial. This will mean that
a substantial number will also have 10-year follow-up, a milestone that is now considered essential in
many trials. Importantly, follow-up up to 10 years was stipulated in the original protocol.
Work package 1 will deliver this.
Primary and secondary objectives
To evaluate in the longer term the primary outcome of local recurrence in the conserved breast and
secondary outcomes of the main trial, including complications/side effects and breast cancer and
non-breast-cancer survival.
Work package 2: collect death and new primary cancer data
from UK patients through the Office for National Statistics
Collection of death and new primary cancer data from UK patients through the Office for National
Statistics will help improve the completeness of the data and will support work package 1.
Work Package 3: lymphoedema [Joint Evaluation With
Emphasis on Lymphoedema and Shoulder (JEWELS)]
This work package addresses the Joint Evaluation With Emphasis on Lymphoedema and Shoulder (JEWELS)
of TARGIT and EBRT post treatment. It will involve a postal questionnaire assessment of quality of life and
shoulder and arm morbidity in patients randomised within the TARGIT trial, which compares intraoperative
and conventional EBRT as part of the treatment of women with early breast cancer.
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Aim and rationale
This work package is designed to investigate whether the two methods of radiotherapy utilised in the
TARGIT trial are associated with a longer-term difference in quality of life, shoulder and arm function
or lymphoedema.
Primary and secondary objectives
To evaluate the longer-term side effects (particularly arm and shoulder function and lymphoedema) and
quality of life in patients randomised within the TARGIT trial to one of two methods of radiotherapy after
surgical treatment of early breast cancer.
Work package 4: health economics
This work package will be a longitudinal cross-sectional study addressing the health economics aspects of
a randomised controlled trial to compare TARGIT with conventional postoperative radiotherapy after breast
conservative surgery for women with early-stage breast cancer.
Primary and secondary objectives
To evaluate the costs and benefits experienced by patients in the trial using the following tools:
l European Quality of Life-5 Dimensions five-level questionnaire (EQ-5D 5L)
l cost data:
¢ capital costs associated with the TARGIT equipment (completed)
¢ NHS contacts for receipt of radiotherapy (completed)
¢ NHS contacts for treating the side effects of radiotherapy
¢ costs incurred by patients and families.
Work package 5: patient preferences for adjuvant radiotherapy
in early breast cancer (TARGIT-A trial)
Detailed description
This will be a cross-sectional analytical study to determine what increased risk of local recurrence women
who have completed postoperative radiotherapy for early breast cancer are prepared to accept in return
for the increased convenience and altered toxicity profile of TARGIT and the factors that influence these
preferences, to guide women and their doctors in making choices about radiotherapy after surgery for
early breast cancer.
This work package is based on a study successfully run in Sir Charles Gairdner Hospital, Perth, WA,
Australia. It will address the patient preference subprotocol of TARGIT-A.
Aim and rationale
Patient preferences for adjuvant radiotherapy in early breast cancer, a substudy of the TARGIT-A trial.
Work package 6: quality of life
The aim of this package is to assess the impact of IORT compared with conventional radiotherapy on
early-stage breast cancer patients’ quality of life, psychosocial well-being and satisfaction with treatment.
In addition, the role of moderating/mediating variables such as treatment cognitions and treatment effects
will be examined according to the model developed by Leventhal et al.178
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In this work package the primary end point will be quality of life and the secondary end points will be
treatment satisfaction, mood, symptoms, fatigue and treatment impact.
Work package 7: cardiopulmonary effects
Aim and rationale
The conventional treatment of early breast cancer involves surgical excision of the tumour, surgery to the
axillary lymph nodes and EBRT to the conserved breast tissue. Although this is an effective treatment with
a low rate of local recurrence of cancer, recent developments have explored alternatives to EBRT.
The TARGIT trial studied the use of single-dose IORT compared with conventional radiotherapy. The trial
has demonstrated equivalence with both study arms having a low local recurrence rate and acceptable
acute toxicity.
This work package is designed to investigate whether the two methods of radiotherapy utilised in the
TARGIT trial have adversely affected the heart.
Primary and secondary objectives
To evaluate the cardiac and respiratory outcomes in patients randomised within the TARGIT trial to one of
two methods of radiotherapy after surgical treatment of early breast cancer.
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Appendix 5 National Institute for Health and
Care Excellence draft recommendation and adoption
National Institute for Health and Care Excellence is currently appraising the TARGIT technique foradoption in the NHS. The status of this appraisal is available at www.nice.org.uk/guidance/
indevelopment/gid-tag353 (accessed 7 July 2016).
National Institute for Health and Care Excellence press release
On 27 July 2014, NICE issued the following press release. This text has been reproduced with permission
from NICE from www.nice.org.uk/news/press-and-media/nice-to-recommend-new-breast-cancer-
radiotherapy-treatment-alongside-further-research.168
NICE to recommend new breast cancer radiotherapy treatment alongside
further research
An innovative new type of radiotherapy for breast cancer is set to be
recommended for NHS patients in England under carefully
controlled circumstances.
National Institute for Health and Care Excellence has published draft guidance on the use of intrabeam
radiotherapy as a treatment option for people with early breast cancer [see Explanation of terms point 1].
It says that the radiotherapy treatment should be recommended for NHS funding provided patients are
properly informed about its pros and cons and that further data are collected.
Professor Carole Longson, director of health technology evaluation at NICE, said the treatment has
the potential to be a much more efficient form of radiotherapy:’ Unlike regular radiotherapy, with the
Intrabeam Radiotherapy System only one dose is required.
‘This single dose is given at the same time as surgery, eliminating the need for numerous hospital visits.
Regular radiotherapy typically requires numerous doses over a 3 week period – although some people may
receive it for longer – and is performed weeks or months after surgery or chemotherapy.
‘The Appraisal Committee concluded that whilst current evidence was not extensive, this type of
radiotherapy was more convenient for patients and can improve a person’s quality of life.’
Just over 41,500 women and 300 men in England are diagnosed with breast cancer every year [see
Explanation of terms point 2]. Figures suggest that about 86% of them – 35,970 people each year – will
potentially have early breast cancer [see Explanation of terms point 3].
The draft guidance, published for consultation, says that intrabeam radiotherapy should be offered to NHS
patients as long as doctors:
l explain the full range of treatment options available to patients, and their associated risks and benefits.
This is to allow patients to make an informed decision about whether to choose Intrabeam or
conventional radiotherapy.
l enter details about all of their breast cancer patients having treatment with the Intrabeam Radiotherapy
System onto a national register [see Explanation of terms point 4].
¢ audit, review and document clinical outcomes locally and consider the relationship between
outcomes and patients’ characteristics.
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‘It’s still a new treatment,’ Professor Longson explained.’ So far, only 6 centres in the UK have used the
Intrabeam Radiotherapy System to treat early breast cancer.
‘Because it is still relatively new it is only right to recommend its use in a carefully controlled way. This will
ensure patients are fully aware of the risks and benefits before choosing which treatment to have and
allow doctors to gather more information about the treatment.’
The institute’s public consultation runs until Friday 15 August 2014. Final guidance is expected to be
published in November 2014. Until then, local NHS bodies are expected to make their own funding
decisions for new treatments.
Explanation of terms
1. Early stage breast cancer is when the tumour is confined to the breast area and has not spread beyond
the lymph nodes to other parts of the body.
2. These data were provided to Cancer Research UK by the Office for National Statistics on request,
July 2013. Further information can be found on the CRUK website: http://www.cancerresearchuk.org/
cancer-info/cancerstats/types/breast/.
3. Early invasive breast cancer is defined as cancer that is confined to the breast and ipsilateral axillary
lymph nodes. This is usually classified as stage I and II breast cancer. Data on around 17,800 women
diagnosed with breast cancer in the East of England in 2006–2009 shows that, of the 92% of cancers
for which a stage was recorded, 41% were stage I, 45% stage II, 9% stage III and 5% stage IV.
Source: Lyratzopoulos G, Abel GA, Barbiere JM, et al. Variation in advanced stage at diagnosis of lung
and female breast cancer in an English region 2006–2009. Br J Cancer 2012. 106(6):1068–75:
http://www.ncbi.nlm.nih.gov/pubmed/22382691. For more information about the stages of breast
cancer, please see: http://www.cancerresearchuk.org/cancer-help/type/breast-cancer/treatment/
number-stages-of-breast-cancer.
4. The data and clinical outcomes to be entered into the national register include:
i. histology of the cancer and patients’ characteristics (including type, size, side of tumour, grade,
lymph node status, oestrogen receptor status, progesterone receptor status, human epidermal
growth factor receptor 2 status and age of the patient)
ii. local recurrence
– treatment received after local recurrence
– development of metastatic disease
– disease-free survival
– overall survival
– adverse effects of treatment
iii. health-related quality of life (including EQ-5D)
About the guidance
l The draft guidance for Intrabeam (IORT) for early breast cancer will be available from the NICE website
at http://www.nice.org.uk/Guidance/InDevelopment/GID-TAG353 from Friday 25 July 2014. Embargoed
copies of the draft guidance are available from the NICE press office on request.
l The Appraisal Committee concluded that the evidence did not conclusively show that intrabeam
radiotherapy is as effective as conventional radiotherapy (called External Beam Radiotherapy – EBRT) at
preventing local breast cancer recurrence (when the cancer returns to the same breast). However, the
committee acknowledged that the recurrence rates reported in the clinical trial could be considered low
in absolute terms. Based on the evidence available so far, it agreed that these were not out of line
compared with current recurrence rates with EBRT in the NHS.
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
182
l The committee also acknowledged that for some people, the benefits of avoiding the need for
post-surgical radiotherapy would outweigh the consideration that much less is known about the long
term outcomes of Intrabeam treatment compared with conventional radiotherapy.
l The independent Appraisal Committee considered that it was not possible to declare a most plausible
incremental cost-effectiveness ratio (ICER) for intrabeam compared with EBRT. This was because of a
high degree of uncertainty in the cost-effectiveness analysis. However, the committee concluded that
intrabeam was associated with slightly lower costs and fewer QALYs (Quality-adjusted Life-years)
than EBRT.
The committee noted that there were also several benefits highlighted by the patient expert and clinical
specialists in terms length of treatment and improving patients’ quality of life, which could not be captured
in the QALY calculation.
l According to the manufacturer, the cost of an intrabeam radiotherapy machine is £435,000 (excluding
VAT). The manufacturer estimated that device maintenance and servicing costs per year are in the
region of £35,000.
l When published, this guidance will apply to England only.
Draft guidance
On 25 July 2014 the UK NICE issued draft guidance recommending that TARGIT with Intrabeam should be
made available in the NHS for suitable patients. ‘The Intrabeam Radiotherapy System is recommended as
an option for adjuvant treatment of early invasive breast cancer during breast conserving surgical removal
of the tumour, only if clinicians:
l fully explain the treatment options available to patients, including their associated risks and benefits,
so that patients can make an informed choice about their treatment. Clinicians should ensure that
patients understand that less is known about the long-term outcomes of treatment with the Intrabeam
Radiotherapy System than with conventional external beam radiotherapy and that the rate of local
recurrence with Intrabeam could be higher than with external beam radiotherapy and
l enter details about all patients having treatment with the Intrabeam Radiotherapy System for adjuvant
treatment of early invasive breast cancer onto a national register. They should audit, review and
document clinical outcomes (see section 6) locally and consider the relationship between outcomes and
patients’ characteristics.
There were two further NICE appraisal public meetings in August 2014 following which NICE requested
further information from the investigators and these were supplied (as per Chapter 11).
The last meeting of NICE was held in August 2015 and the November 2015 statement is as follows:
the Committee decided that further work by the Institute would be required before it could issue a
recommendation to the NHS. The Committee appreciated the advantages of Intrabeam, especially for
people who are keen to avoid having external beam radiotherapy, but was also concerned about the
remaining uncertainties in the evidence, and the difficulties these present for both patients and clinicians in
making an informed choice about the best treatment. The technology appraisals team is exploring options
for evidence development that could be used to support the use of Intrabeam intraoperative radiotherapy in
the NHS. Consequently, the timeline for the development of the provisional guidance has been extended.
NICE have also stated that ‘While this NICE appraisal is ongoing, intrabeam radiotherapy can continue to
be offered to NHS patients who need it. Until NICE publishes its final guidance, decisions on whether or
not to fund specific treatments are the responsibility of local NHS bodies’.58
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Appendix 6 Method of data collection for
patients treated with TARGIT using the INTRABEAM
device as per National Institute for Health and Care
Excellence draft guidance
This appendix provides details about how data from patients treated with TARGIT using the INTRABEAMdevice are entered onto the existing national cancer registry (National Cancer Registration Service;
NCRS) and how slight modifications will ensure that these data could simply and easily be collected
without any additional costs. This method was sent to NICE shortly after the draft guidance appeared.
The method was compiled and sent to NICE by Professor Jayant S Vaidya in collaboration with:
l the clinical coding team at UCLH (Robert Gray, Clinical Coding Auditor, UCLH NHS Foundation Trust,
Moorfields NHS FT, Base: UCLH Clinical Coding Department, London, UK).
l the NCRS, Public Health England (Claire Beattie, Registration Manager; Sally Vernon, Head of Quality
and Analysis, Eastern Office, Public Health England, Cambridge, UK).
l the Knowledge and Intelligence Team, Public Health England [John Broggio, West Midlands, Senior
Public Health Cancer Analyst (Cancer); Catherine Lagord, Breast Cancer Audit Project Manager].
l the National Cancer Intelligence Network, Public Health England (Sean McPhail, Senior Information
Analyst, Wellington House, London, UK).
From the National Cancer Registration Service
The NCRS collects data on all invasive, in situ and uncertain malignancies in England (and also benign
tumours of the brain). This includes both invasive and in situ breast cancer data.
The NCRS aims to collect all Cancer Outcomes and Services Dataset (COSD) data items [see www.ncin.org.uk/
collecting_and_using_data/data_collection/cancer_outcomes_and_services_dataset_cosd_latest_downloads
(accessed 7 July 2016)]. However, COSD was introduced only in 2013 and data completeness is not
guaranteed from all trusts yet.
The NCRS does not explicitly collect data on TARGIT treatment. However, such treatment is simple to
identify by selecting cases that have both surgery and radiotherapy coded (see From the coding team)
on the same date or by looking in the National Radiotherapy Dataset (RTDS).
Of the data items on your list, the NCRS historically collects and has good data completeness on NHS
number, histology, size, side, grade, stage (including lymph node status) and age of the patient. The NCRS
also collects ER, PR and HER2 receptor status. The NCRS receives feeds from the Office for National
Statistics and so has good data on time of overall survival.
The Cancer Outcomes and Services Dataset mandates that data items should allow the measurement of
local recurrence, metastatic disease and disease-free survival. However, these data have not been collected
well historically and there would be more data quality issues around them.
The NCRS does not directly collect adverse effects of treatment. However, we do get linked hospital
admission data, which may show reasons for admission that are an adverse effect of treatment.
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The NCRS does not directly collect health-related quality of life (including EQ-5D) data for all patients.
When these data have been collected as part of another NHS survey (such as the Cancer Patient
Experience Survey or Patient Reported Outcomes Measures), they may be held by the cancer registry.
These data could also be collected as part of local audit by individual trusts.
As a test, the Public Health England Knowledge and Intelligence Team searched for patients with both
breast surgery and radiotherapy treatment on the same day. They found that 146 patients had the specific
combination of codes representing the TARGIT procedure. This number is very similar to the number
expected in the trial for that period. This gives reassurance that the current coding system works. Further
standardisation as detailed below would make the process even more robust.
I can confirm that the codes that you have agreed with your clinical coders for capturing IORT should
enable cancer registry staff to recognise and record this treatment. We would ensure that our staff were
aware of this.
From the coding team
Currently, this procedure is being coded in the major centres as the following:
l X65.2 – Preparation for intracavitary radiotherapy
l X68.2 – Delivery of a fraction of intracavitary radiotherapy
l Y35.4 – Introduction of radioactive substance for brachytherapy
l Z15 – Breast.
In this manner all cases treated with TARGIT will be captured as a matter of routine.
We would like to ensure that it is coded uniformly, capturing all stages, and this document could be used
by NICE to advise all hospitals treating such patients as the standard operating procedure.
The procedure is broken down into three sections as follows.
1. Radiotherapy preparation for targeted intraoperative radiotherapy using
the INTRABEAM device
l X68.2 – Preparation for intracavitary brachytherapy (as currently used).
This is because the treatment involves irradiation of tissues immediately next to the applicator within a
surgically prepared cavity (tumour bed) following wide local excision of breast cancer. The correct size of
the applicator is chosen by measuring the size of the cavity.
As there is no specific code in the book at present, this code is chosen because it best approximates the
TARGIT procedure. However, the cavity that is prepared is different from the physiological cavities that this
code is usually meant for (e.g. thoracic, abdominal, pelvic, oral cavity).
In the next edition of OPCS-4, it would be preferable to describe this new surgical technique with a new
code, for example X68.4 – Preparation for giving targeted intraoperative radiotherapy using INTRABEAM.
Until then, X68.2 should be used.
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2. Surgical preparation for targeted intraoperative radiotherapy using the
INTRABEAM device (including insertion of the applicator)
The codes that we would suggest would be:
l B37.8 – Other specified other operations on breast, plus
l Y258 – Other specified suture of organ not otherwise classified (NOC), plus
l Y02.8 – Other specified placement of prosthesis in organ NOC.
This is because, after wide local excision of breast cancer, the tumour bed needs to be prepared. First,
complete haemostasis needs to be achieved as small amounts of oozing blood can affect the treatment.
Then, a carefully placed purse-string suture that is taken in such a manner that the tissues closely appose
the spherical applicator without bringing the dermis/skin or the ribs too close to the applicator surface.
The applicator is attached to the X-ray source, which is covered with a sterile drape, and is then placed
within the tumour bed. The purse string is then tightened. After delivery of the radiation is complete, the
purse string is cut and the applicator is removed and the tumour bed inspected. The breast is then closed
in the usual manner.
In the next edition of the OPCS-4, it would be preferable to describe this new surgical technique with
new codes:
l B37.6 – Preparation of tumour bed for giving targeted intraoperative radiotherapy (TARGIT) with
INTRABEAM, plus
l Y02.3 – Placement of INTRABEAM applicator for giving targeted intraoperative radiotherapy (TARGIT).
Until then, B37.8 plus Y25.8 plus Y02.8 should be used.
3. Delivery of targeted intraoperative radiotherapy using the
INTRABEAM device
The codes should be:
l X65.2 – Delivery of a fraction of intracavitary radiotherapy (as currently used), plus
l Y35.8 – Other specified introduction of removable radioactive material into organ NOC, plus
l Y89.8 – Other specified brachytherapy, plus
l Z15.– – Breast (as currently used).
This is because, after the applicator is placed in the tumour bed, single-dose radiation is delivered to the
tumour bed. This takes between 15 and 35 minutes depending on the size of the applicator/tumour bed.
The radiation source is X-rays, which are emitted only after the radiation is switched on. Once the radiation
has been delivered, the radiation is switched off.
First, the word ‘fraction’ in X65.2 might imply that this treatment is part of a course of several fractions
(5–15); however, TARGIT using INTRABEAM is always given as a single dose and therefore, ideally, a new
code should be introduced in the next edition of the coding manual, for example X69.1 – Delivery of
single dose of targeted intraoperative radiotherapy (TARGIT) using INTRABEAM.
Second, this is not strictly a ‘radioactive material’ as specified in Y35.8; however, as there is no code to
describe the introduction of a X-ray source into an organ and, in reality, the source does emit radiation
when switched on, this code should be used until a new code is introduced in the next edition of the
OPCS-4 to describe the procedure. This could be achieved by removing the word ‘radioactive’ from
the three category heading at Y35, for example Y35.5 – Introduction of low-energy/low-dose rate X-ray
source – INTRABEAM – into breast.
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Third, the additional code of Y89.8 should be used to specify that this is a brachytherapy (internal
radiotherapy) that is neither high dose nor pulsed dose until a new code is introduced in the update of the
OPCS-4, for example Y89.3 – Single low-dose brachytherapy treatment with INTRABEAM.
Until then the X65.2 plus Y35.8 plus Y89.8 plus Z15.– codes should be used.
Ideally, there should be a single new code for the procedure of ‘Wide local excision of breast
cancer + TARGIT-IORT’ because the latter cannot be given without initially removing the tumour. This will
allow easier coding the classification.
Codes for targeted intraoperative radiotherapy
TABLE 38 Codes from the current edition of OPCS-4 to be used should be all of the followinga
Current code Description (explanation)
X68.2 Preparation for intracavitary brachytherapy (radiotherapy preparation)
B37.8 Other specified other operations on breast (surgical preparation of the tumour bed)
Y25.8 Other specified suture of organ NOC (insertion of the purse-string suture)
Y02.8 Other specified placement of prosthesis in organ NOC (insertion of INTRABEAM applicator)
X65.2 Delivery of a fraction of intracavitary radiotherapy (delivery of TARGIT IORT with INTRABEAM)
Y35.8 Other specified introduction of removable radioactive material into organ NOC (insertion of
INTRABEAM X-ray source in the applicator)
Y89.8 Other specified brachytherapy (single rather than multiple brachytherapy treatments)
Z15.– Breast (to indicate that this is a breast operation)
a This should be conveyed to the coding team of every trust that uses TARGIT IORT with INTRABEAM.
TABLE 39 Recommended codes for inclusion in the next edition of the OPCS-4
New code Description (explanation)
X68.4 Preparation for giving targeted intraoperative radiotherapy using INTRABEAM
B37.6 Preparation of tumour bed for giving targeted intraoperative radiotherapy (TARGIT) with INTRABEAM
Y02.3 Placement of INTRABEAM applicator for giving targeted intraoperative radiotherapy (TARGIT)
X69.1 Delivery of single dose of targeted intraoperative radiotherapy (TARGIT) using INTRABEAM
Y35.5 Introduction of low-energy/low-dose rate X-ray source – INTRABEAM – into breast
Y89.3 Single low-dose brachytherapy treatment with INTRABEAM
Z15.– Breast (to indicate that this is a breast operation)
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